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Abstract 
Polycystic ovary syndrome (PCOS) is a chronic illness that affects approximately five 
million premenopausal women in the United States and is associated with significant cosmetic, 
reproductive, metabolic, and psychological consequences.  Despite its prevalence, few studies 
have explored the lived experiences and illness perceptions of women living with PCOS.  
Identifying illness perceptions of women living with (WLW) PCOS is important, because 
mounting research suggests that a person’s perceptions of their chronic illness and its 
management determine that person’s coping behaviors (e.g., adherence, self-management) and, 
consequently, illness outcomes. 
In this dissertation, the Common Sense Model (CSM) is used as a framework to identify 
the illness perceptions of PCOS held by WLW the syndrome.  As such, this dissertation is the 
first to test the ecological validity of the CSM in a population of women diagnosed with PCOS. 
In addition, the relationship between illness perceptions and (1) infertility, a common symptom 
of the syndrome, and (2) health-related quality of life (HRQoL) is explored.  Lastly, this study 
makes a novel contribution to the literature by describing one of the first samples of WLW 
PCOS recruited through a social networking site.  This includes a discussion of the participant’s 
demographic information, fertility experiences, and HRQoL. 
This is a two-phase mixed methods study. Phase one consisted of an online quantitative 
survey capturing data on 376 participants’ demographic information and medical history. Data 
were also collected on each participant’s HRQoL using the SF-36, a generic, well-validated 
measure of the phenomenon.  Of the 376 survey participants, 34 were interviewed via phone or 
 ix 
 
video chat in the fall 2013 and spring 2014 semesters.  Quantitative data were downloaded from 
Qualtrics® and analyzed using SAS statistical software version 9.3.  In this analysis, descriptive 
statistics were generated to describe sample characteristics and SF-36 domain scores were 
calculated for each participant.  In the qualitative analysis, data were analyzed through a series of 
sorting techniques and transcripts were imported into NVivo 10 and subjected to content 
analysis.   
The mean age of  survey participants was 31.8 years (SD=5.8).  Respondents were 
primarily non-Hispanic (92.5%), white (88.3%), straight (94.4%), and married (73.4%) with a 
college education (64.1%).  On average, participants reported living with PCOS for 7.6 years 
(SD=6.1).  Approximately half of the sample reported having biological children (47.9%) and 
currently trying to conceive (42.1%), and most participants reported a history of infertility 
(70.7%).  In addition, almost half of the total sample reported heights and weights that placed 
them in the morbidly obese category (BMI>35).  Lastly, a history of depression (63.6%) and 
anxiety (68.6%) was common among participants. 
Few survey participants reported their general health as being excellent (2.6%) or very 
good (27.4%).  Similarly, women reported the lowest levels of functioning on the dimension of 
vitality, meaning that, in general, women reported feeling tired and being low in energy.  
Conversely, women reported the highest scores on the dimensions of physical functioning and 
role limitations due to physical health, meaning that, in general, women did not report that their 
health limited their physical abilities or caused problems with work or other daily activities.  
 Interview findings suggest that WLW PCOS generally have illness perceptions of the 
syndrome that are consistent with the domains identified in the CSM.   In addition, it was found 
that, in relation to their illness cognitions, WLW PCOS described the extent to which they felt 
 x 
 
they had a comprehensive understanding of the syndrome, a phenomenon labeled illness 
coherence.  Similarly, participants identified PCOS as a common condition (i.e. labeled 
perceived prevalence).  Lastly, a number of relationships were identified between illness 
perceptions and (1) infertility status and (2) HRQoL scores. 
Overall, this dissertation identifies a number of implications for patient education, 
provider education, clinical practice, and policy improvements.  Examples include addressing (1) 
unmet information needs, (2) significant psychological morbidity and unmet mental health 
needs, (3) breastfeeding challenges and need for breastfeeding support, (4) poor quality of care 
and low patient satisfaction, and (5) limited access to care – all among women living with PCOS.
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Chapter 1:  Introduction 
Polycystic ovary syndrome (PCOS) is a common hormone disorder that affects 
approximately five million premenopausal women in the United States (Leventhal, Brisette, & 
Leventhal, 2003; National Institutes of Health, 2012).  It is a chronic condition characterized by 
clinical and/or biochemical signs of androgen excess, ovulatory dysfunction, and polycystic 
ovaries (Azziz et al., 2006).  As such, common manifestations of PCOS include hirsutism, acne, 
and alopecia, due to androgen excess, and signs of ovulatory dysfunction, including menstrual 
irregularities and infertility (Teede et al., 2010).  These symptoms can be a major source of 
psychological morbidity and are associated with a significant reduction in health-related quality 
of life (HRQoL) (Barry, Kuczmierczyk, & Hardiman, 2011; Jones, Hall, Balen, & Ledger, 
2007).  Moreover, women living with (WLW) PCOS are typically insulin resistant, and, 
consequently, the syndrome is a risk factor for the metabolic syndrome (MetS) and associated 
sequelae, including cardiovascular disease (CVD) and type 2 diabetes mellitus (T2D) 
(Tomlinson, Millward, Stenhouse, & Pinkney, 2010).  Because HRQoL is identified as a national 
health standard and because T2D and CVD are national health priority areas (U.S. Department of 
Health and Human Services), PCOS is identified as a “major public health issue for women”  
(National Institutes of Health, 2012). 
Like other syndromes,
a
 the clinical spectrum of PCOS varies widely (Balen et al., 1995).  
At one end of the spectrum are women who are largely asymptomatic, and, at the other are  
 Defined as a group of symptoms that together are characteristic of a specific disorder, disease, or the like. 
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women who present with most manifestations of the syndrome.  While the presence of a woman 
on the spectrum is likely predetermined by genetic factors (Givens, 1988; Govind, Obhrai, & 
Clayton, 1999; Kashar-Miller, Nixon, Boots, Go, & Azziz, 2001; Prapas et al., 2009; Wilroy et 
al., 1975),  her position on the spectrum is likely related to lifestyle factors, particularly degree of 
obesity (Gambineri, Pelusi, Vicennati, Pagotto, & Pasquail, 2002; Glueck et al., 2005; Lord & 
Norman, 2006; McCook, 2002; Nestler, Clore, & Blackard, 1989; Pasquail, Gambineri, & 
Pagotto, 2006).  That is, obese WLW PCOS typically present with more manifestations of the 
syndrome (Acién et al., 1999; Balen et al., 1995; Kiddy et al., 1990; Rachon & Teede, 2010).   
Because there is no cure for PCOS and because body weight has an important bearing on 
the phenotype of the syndrome, a woman’s ability to achieve and maintain a normal body weight 
is critical to improving her health, including her HRQoL, and preventing long-term 
complications of PCOS  (Panidis et al., 2013; R. Thomson et al., 2010).  As such, lifestyle 
changes, including diet modifications and increased physical activity, are advocated as the first-
line therapeutic approach (Teede et al., 2010). Also, pharmacological interventions may be 
appropriate and are dependent on the presenting symptoms of the woman and her preferences 
(Benjamins & Barratt, 2009).  In these cases, successful PCOS management is not only 
determined by a woman’s ability to achieve and maintain a healthy body weight but also by her 
adherence to a medical regimen.  In short, the management of PCOS, like other chronic 
conditions, requires considerable self-care efforts by WLW the syndrome. 
Statement of Need 
 Although self-care is emphasized in PCOS management, little attention has been paid to 
why some women readily engage in PCOS self-care behaviors while others do not. At the same 
time, there is an abundance of literature on self-care among other illness populations, including 
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those living with PCOS-related conditions such as T2D and CVD.  In this literature, many 
factors that influence self-care behaviors have been identified, and much attention has been given 
to the perceptual and cognitive factors that underlie individuals’ motivations or intentions to 
adopt self-care behaviors (Ory & DeFriese, 1998).  In this field of inquiry, illness perceptions 
have emerged as a significant factor influencing self-care behaviors and, consequently, illness 
outcomes (Leventhal, Leventhal, & Robitaille, 1998).   
Theoretical Framework 
Illness perceptions are an individual’s beliefs and expectations about an illness and have 
predominantly been described as part of the common-sense model (CSM) of self-regulation of 
health and illness developed by Leventhal and colleagues (Leventhal, Meyer, & Nerenz, 1980; 
Leventhal, Nerenz, & Steele, 1984).  They maintain that individuals are active problem solvers 
who construct complex cognitive and emotional representations of illness, termed illness 
perceptions, when confronted with threats to their health.  According to the model, illness 
perceptions give rise to self-regulation efforts or coping strategies, which are evaluated in terms 
of their success in reaching a desired goal.  The result of the evaluation may be a change in 
perceptions about the illness and/or a change in the coping strategy.  In short, the CSM presents a 
mediational model in which coping mediates the effects of illness perceptions on health 
outcomes. 
Although cognitions and emotions are equally emphasized in the CSM, cognitions 
receive more attention in the literature.  Leventhal et al. (2003) identifies five related, but 
conceptually and empirically distinct, core dimensions of cognitive representations of illness: 
identity (perceptions of symptoms and illness labels), consequences (beliefs about illness 
outcomes: physical, social, and behavioral), timeline (expectations about the duration of illness 
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and persistence of symptoms),cause (beliefs about the cause of the illness: biological, emotional, 
environmental, or psychological), and cure/control (beliefs about controllability and curability of 
illness or symptoms) (see Table 1 for PCOS example).  These cognitive representations are 
processed in parallel to emotional representations, which create feeling states such as anger, 
depression, and anxiety (Leventhal, Diefenbach, & Leventhal, 1992).   
Table 1. Cognitive Representations of Illness: A PCOS Example 
Identity Label/name women give to PCOS and the symptoms women associate with the 
syndrome 
Consequences Impact of PCOS and its symptoms on women’s well being 
Timeline Women’s expectations about the duration of  PCOS and persistence of its 
symptoms  
Cause Perceived cause of PCOS 
Cure/Control Women’s beliefs that PCOS is either curable and/or controllable 
 
The assumptions of the CSM are supported by cross-sectional and longitudinal data from 
studies of individual’s with a range of medical conditions, including myocardial infarction 
(French, Cooper, & Weinman, 2006), diabetes (Mc Sharry, Moss-Morris, & Kendrick, 2011), 
rheumatoid arthritis (Graves, Scott, Lempp, & Weinman, 2009), asthma (Kaptein, Klok, Moss-
Morris, & Brand, 2010), chronic fatigue syndrome (Knoop, Prins, Moss-Morris, & Bleijenberg, 
2010), and Crohn’s disease (Knowles, Wilson, Connell, & Kamm, 2011).  Studies centering on 
mental health conditions such as schizophrenia (Lobban, Barrowclough, & Jones, 2005) and 
depression (Lynch, Moore, Moss-Morris, & Kendrick, 2011) also support the assumptions of the 
CSM.  Likewise, a number of reviews and meta-analyses report a relationship among illness 
perceptions, coping strategies, and health outcomes (Hagger & Orbell, 2003a; Hoving, van der 
Meer, Volkova, & Frings-Dresen, 2010; Kaptein et al., 2008; Kucukarslan, 2012; Petrie, Jago, & 
Devcich, 2007).   
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Purpose of the Dissertation 
Because little is known about factors that influence self-care behaviors of WLW PCOS 
and because illness perceptions have emerged as an important antecedent of self-care, the 
primary purpose of this dissertation is to identify the illness perceptions of PCOS held by 
WLW the syndrome.  In this investigation, the relationship between illness perceptions and 
infertility, a common symptom of the syndrome is also explored.  Infertility is emphasized for 
two reasons.  First, the CSM posits that emotional responses to an illness (and its symptoms) are 
antecedents of illness perceptions.  The literature suggests that WLW PCOS have strong 
emotional responses to infertility (Jones et al., 2007; Y. Li et al., 2011; Shi, Zhang, Fu, & Li, 
2011).  Therefore, the experience of infertility may influence the illness perceptions of WLW 
PCOS.  Second, the CSM suggests that individuals construct illness perceptions according to the 
concrete and abstract sources of information available to them (Leventhal et al., 2003).  Because 
WLW PCOS who experience infertility typically require additional medical interventions 
(Brassard, AinMelk, & Baillargeon, 2008) and because medical interventions, by nature, require 
more interactions with healthcare providers (who are potential sources of information), WLW 
PCOS who experience infertility may have additional and unique opportunities to obtain 
information.   
The relationship between illness perceptions and HRQoL is also explored in this study.  
Although the literature clearly indicates that PCOS has a significant impact on HRQoL (Jones et 
al., 2007; Trent, Rich, Austin, & Gordon, 2002), few factors that contribute to this have been 
explored (Barnard et al., 2007).  All but one study has focused on clinical features of the 
syndrome and their management.  These few studies suggest (1) that symptoms associated with 
the syndrome (i.e. ovulatory dysfunction, hirsutism, obesity, and infertility) contribute 
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significantly to the reduction of HRQoL and (2) that successful management of these symptoms 
improve HRQoL (Jones et al., 2007).  Given these findings, an expectation may exist for a direct 
relationship between clinical severity of PCOS and HRQoL.  However, Trent and colleagues 
(Trent et al., 2002) report that perception of PCOS severity, not actual severity, correlates 
directly with HRQoL.  This finding emphasizes the need for further investigations into the 
perceptual factors related to HRQoL.  Because illness perceptions of PCOS may be a promising 
determinant of HRQoL among WLW the syndrome, an exploration of the relationship between 
illness perceptions and HRQoL compliments the primary aim of this dissertation. 
Like other research studies, an important task is to describe the sample of women 
recruited for the study.  Because accessing a clinical population of WLW PCOS is not feasibly in 
the current study, WLW PCOS were recruited from a social networking site (SNS).  This study 
makes a novel contribution to the literature by describing one of the first samples of WLW 
PCOS recruited through a SNS.  This includes a discussion of the participant’s demographic 
information, fertility experiences, and HRQoL. 
Specific Aims and Research Questions 
 The specific aims and research questions of the dissertation are listed in Table 2. 
Table 2. Specific Aims and Research Questions of the Dissertation 
Specific Aims and sub-aims Research Questions 
1. To identify the illness perceptions of 
PCOS held by WLW the syndrome. 
 
 1. What illness perceptions do women 
hold about their PCOS? How do these 
relate to the CSM? How do they differ? 
 
 a. To explore the relationship between 
infertility and illness perceptions of 
PCOS held by WLW the syndrome 
 
2. Does the experience of infertility 
impact the illness perceptions that 
women hold about their PCOS? 
 b. To explore the relationship between 
HRQoL and illness perceptions of 
PCOS held by WLW the syndrome 
 
3. Is there a relationship between 
women’s HRQoL and the illness 
perceptions they have about PCOS? 
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Table 2 (Cont) 
Specific Aims and sub-aims Research Questions 
2. To identify the illness perceptions of 
PCOS held by WLW the syndrome. 
 
 4. What illness perceptions do women 
hold about their PCOS? How do these 
relate to the CSM? How do they differ? 
 
 c. To explore the relationship between 
infertility and illness perceptions of 
PCOS held by WLW the syndrome 
 
5. Does the experience of infertility 
impact the illness perceptions that 
women hold about their PCOS? 
 d. To explore the relationship between 
HRQoL and illness perceptions of 
PCOS held by WLW the syndrome 
 
6. Is there a relationship between 
women’s HRQoL and the illness 
perceptions they have about PCOS? 
 
Significance of the Dissertation  
The present study identifying the illness perceptions of PCOS held by WLW PCOS is 
novel in a number of ways.  Most importantly, this study is the first to identify the illness 
perceptions of WLW PCOS and informs future studies exploring the mediating role of illness 
perceptions on PCOS outcomes.  If this role is significant, addressing illness perceptions could 
be an effective strategy in promoting self-care behaviors among WLW PCOS and preventing 
PCOS-related illness.   
This study also is the first to test the ecological validity of the CSM in a population of 
women diagnosed with PCOS.  That is, it is the first to explore to what extent the dimensions of 
the CSM conform to the illness perceptions of WLW PCOS.   In the field of health education and 
promotion, an important goal is to test health behavior theories iteratively in the real world 
(Rosenstock, 1990).  While the CSM has been used as a guiding framework in studies of acute 
and chronic conditions, both physical and mental, no PCOS-related studies have adopted the 
CSM.   
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In addition, this study is the first to explore the relationship between illness perceptions 
of WLW PCOS and their HRQoL.  If specific illness perceptions are associated with HRQoL, 
addressing these illness perceptions could be an effective strategy in increasing HRQoL among 
WLW the syndrome.  This is important, because HRQoL is identified as a national health 
standard (U.S. Department of Health and Human Services).  Lastly, this study will be the first to 
describe a sample of WLW PCOS recruited through a SNS.   
Definition of Key Terms 
1. Health-related quality of life (HRQoL) is a “multi-dimensional concept that includes 
domains related to physical, mental, emotional and social functioning.  It goes beyond 
direct measures of population health, life expectancy and causes of death, and focuses on 
the impact health status has on quality of life” (U.S. Department of Health and Human 
Services). 
2. Illness perceptionsa are a person’s beliefs and expectations about illness.  According to 
the CSM, cognitive and emotional representations of illness shape a person’s illness 
perceptions (Leventhal et al., 2003). 
3. Polycystic ovary syndrome (PCOS)b is a chronic condition characterized by a set of 
symptoms that result from a hormonal imbalance in the female body (The Rotterdam 
ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004b).  Although the 
diagnostic criteria for PCOS remains debated, all proposed criteria center around the  
a
 Some authors use the terms cognitive representations of illness and illness perception s interchangeably. Depending on the 
author and/or the purpose of the text, a discussion of emotional representations of illness may or may not be included.  For this 
dissertation, the term illness perceptions is used in the context of the CSM and is distinct from cognitive representations of 
illness. 
b Polycystic ovary syndrome is also known as polycystic ovarian syndrome, hyperandrogenic chronic anovulation, functional 
ovarian hyperandrogenism, and Stein-Leventhal syndrome.  These terms are used interchangeably typically depending on author 
or organization preferences and date of publication.  For this dissertation, the term polycystic ovary syndrome is used throughout 
for consistency. 
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following key features: (1) excess androgen, (2) ovulatory dysfunction, and (3) polycystic 
ovaries. 
4.  Self-care is defined as the activities individuals “undertake with the intention of 
enhancing health, preventing disease, limiting illness, and restoring health” (World 
Health Organization, 1983). 
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Chapter 2: Review of the Literature 
Using the most conservative prevalence estimates (5%) of polycystic ovary syndrome 
(PCOS), it can be said that at least 5 million American women of reproductive age live with the 
syndrome (The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 
2012).  While some women living with (WLW) PCOS will remain largely asymptomatic 
throughout their lives, others may experience numerous dermatologic, reproductive, metabolic, 
and psychological issues (Teede et al., 2010).  Either way, the lived experience WLW PCOS 
may begin with a number of seemingly unrelated health issues, continue with difficulties in 
obtaining services that may not be covered by health insurance, and, even if receiving treatment, 
result in reduced health-related quality of life (HRQoL).  Each step of this journey will be 
characterized by interactions among (1) physical and social environments, (2) the biology and 
behavior of the individual, and (3) the healthcare system.  “On a population scale, these 
interactions create patterns of disease, utilization of services, and outcomes” that have major 
public health implications (Macaluso et al., 2010). 
For this reason, a public health approach to PCOS is adopted in this dissertation.  
Because PCOS is not preventable, primary prevention efforts may not be directed at the 
condition itself (Tweedy, 2000).  However, secondary prevention efforts can be directed at 
identifying women with PCOS early so that prompt and appropriate management can be initiated 
(Stankiewicz & Norman, 2006).  Also, tertiary prevention efforts targeting weight reduction in 
obese WLW PCOS and prevention of excess weight gain in all WLW PCOS are recommended 
to improve PCOS-related outcomes and is the focus of this dissertation. 
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The following literature review is organized into three main sections.  The first section 
provides a brief overview of PCOS.  Specifically, the definitions, prevalence estimates, and 
manifestations are described.  The pathophysiology and therapeutic approaches to PCOS are also 
outlined to facilitate understanding of the syndrome.  In the second section, PCOS research and 
clinical practices related to PCOS are summarized to illustrate the need for the dissertation.  
Lastly, an overview of the theoretical framework on which this study is based is provided. 
Polycystic Ovary Syndrome (PCOS) 
Pathophysiology.  In brief, an underlying hormonal imbalance created by a combination 
of elevated androgen (i.e. hyperandrogenism) and insulin levels (i.e. hyperinsulinemia leading to 
insulin resistance) underpin PCOS (Balen et al., 1995; Kiddy et al., 1990).  While it is well 
accepted that genetic and environmental factors contribute to this imbalance (Gambineri et al., 
2002; Givens, 1988; Govind et al., 1999; Kashar-Miller et al., 2001; Nestler et al., 1989; Prapas 
et al., 2009; Wilroy et al., 1975),  a better understanding of these pathophysiological contributors 
has been hampered by a lack of ideal methods to assess both hyperandrogenism and insulin 
resistance (IR) (Azziz, 2004; Barth, Yasmin, & Balen, 2007).  It has been estimated that up to 
70% of WLW the syndrome have elevated androgen levels, and the other 30% are in the high-
normal range (Marx & Metha, 2003).  Likewise, it has been suggested that all women with the 
syndrome have IR, although IR has only been described in 50-80% of populations of WLW 
PCOS(Dunaif, 1997, 2003).  Again, methods used to measure IR have been cited for this 
discrepancy.  Because hyperandrogenism and hyperinsulinemia coexist in PCOS, it is unclear if 
one causes the other.  However, it has been established that they reinforce one another and 
disrupt ovarian follicular development (Pfeifer & Kives, 2009).  The consequent follicular arrest 
is responsible for the polycystic ovarian morphology commonly described in WLW PCOS and is 
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often accompanied by oligo- and/or anovulation (defined as infrequent ovulation or absence of 
ovulation)(Brassard et al., 2008; Carmina & Lobo, 1999; Teede et al., 2010). 
Definition. Currently, there is no international consensus on the definition of PCOS.  
Agreement has only been reached that PCOS is indeed a syndrome (i.e. a heterogeneous 
condition with unknown etiology) and is a diagnosis of exclusion
a
 (The Rotterdam 
ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004a).  Various diagnostic 
criteria have been proposed, generally centered on the features of hyperandrogenism, oligo- 
and/or anovulation, and polycystic ovarian morphology (see Table 3) (The Rotterdam 
ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004a).  Although four main 
phenotypes have been identified, many experts argue that only two are justifiable (e.g. 
Phenotypes A and B; see Table 3) (Azziz et al., 2006).  The issue that is debated most 
contentiously is whether the diagnosis should require confirmation of polycystic ovaries (PCO) 
(Azziz, 2006; Balen & Michelmore, 2002; Franks, 2006).  Thus, the term polycystic ovary 
syndrome adds to the confusion surrounding its diagnosis (Balen & Michelmore, 2002). 
Inclusion of PCO in diagnostic criteria is debated for two main reasons: (1) there is no 
universally agreed upon PCO ultrasound criteria for the diagnosis of PCOS and (2) the long-term 
health risks of PCOS phenotypes including PCO are poorly understood (Balen & Michelmore, 
2002).  The latter is important, because syndromes are largely defined by their long-term health 
risks (Azziz et al., 2006).  In the case of PCOS, the increased risk of developing type 2 diabetes 
mellitus (T2D) is most often used as the phenotypic anchor against which to measure each 
phenotype.  This does not imply, however, that all WLW PCOS will develop T2D, but that a 
phenotypic group collectively will be at higher risk.   
 Disorders which mimic PCOS phenotypes should first be excluded before diagnosis. These may include congenital adrenal 
hyperplasia, Cushing’s syndrome, androgen-secreting tumors, 21-hydroxylase-deficient non-classic adrenal hyperplasia, thyroid 
dysfunction, hyperprolactemia, and androgen/anabolic drug use or abuse. 
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Table 3. Phenotypes of PCOS according to the 1990 NIH criteria, 2003 Rotterdam  criteria, 
and 2006 AES criteria 
a 
Features Phenotypes 
 A B C D 
Oligo- and/or anovulation  
Clinical and/or biochemical signs of hyperandrogenism 
Polycystic ovaries 
 
1990 NIH PCOS Diagnostic Criteria 
2003 Rotterdam Diagnostic Criteria 
2006 AES Diagnostic Criteria 
X 
X 
X 
 
✓ 
✓ 
✓ 
X 
X 
 
 
✓ 
✓ 
✓ 
X 
 
X 
 
 
✓ 
 
 
X 
X 
 
 
✓ 
✓ 
X, Features included in phenotypes; ✓, phenotype included in definition 
NIH= National Institutes of Health; AES=Androgen Excess Society 
a
 Assuming exclusion of other androgen excess or related disorders  
 
While it is well established that phenotypes A and B are associated with an increased risk 
of T2D, there is less evidence to support an association with phenotypes C (i.e. “non-
hyperandrogenic PCOS”) and D (i.e. “ovulatory PCOS”) (Ehrmann, Kasza, Azziz, Legro, & 
Ghazzi, 2005).  However, research does suggests that women with PCO have a higher 
prevalence of androgen excess and IR (Azziz, 2004; Polson, Adams, Wadsworth, & Franks, 
1988).  According to NIH criteria, these women cannot be diagnosed with PCOS unless they also 
present with ovulatory dysfunction.  Because women are able to move between ovulatory and 
anovulatory cycles as a result of changes in body weight, lifestyle choices, and age; a diagnosis 
of “ovulatory PCOS” is less debated than a diagnosis of “non-hyperandrogenic PCOS” (Azziz, 
2006; Elting, Korsen, Rekers-Mombarg, & Shoemaker, 2000).  However, more research is 
needed to determine the long-term health consequences of phenotypes C and D. 
Prevalence. Prevalence estimates of PCOS are dependent on the criteria used to define 
the syndrome.  In U.S. populations, researchers using the narrowest definition of PCOS, the NIH 
criteria, have consistently estimated that  5-10% of reproductive-age women have the syndrome, 
making it the most common endocrinopathy in this population (Speroff & Fritz, 2005).  In a few 
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of these studies, researchers have reported that, if the broadest definition of PCOS  (i.e. the 
Rotterdam criteria) were used, the overall prevalence of PCOS would increase approximately 
21% (Trivax & Azziz, 2007).  These figures are consistent with research findings in other 
countries, where studies using the Rotterdam criteria suggests a PCOS prevalence of 26% in 
women of reproductive age (Michelmore, Balen, Dungar, & Vessey, 1999).  However, more 
research is needed to clarify the prevalence of PCOS phenotypes in both pre-menopausal and 
post-menopausal American women. 
Also, prevalence estimates for different ethnic groups in the U.S. are difficult to compare, 
because different recruitment strategies and PCOS definitions are used.  A few studies, however, 
have compared prevalence rates between ethnic groups in a single population.  In a prevalence 
group of 400 Alabama women receiving pre-employment physicals, statistically similar 
prevalence rates were reported in white (4.8%) and black (8%) women using NIH criteria (Azziz 
et al., 2004).  In another study, Lo et al. searched an automated health plan ambulatory visit 
database to identify WLW PCOS (Lo et al., 2006).  Only 2.6% of women age 15-45 years had 
received such a diagnosis [International Classification of Diseases, Ninth Revision (ICD-9) code 
256.4] - the smallest prevalence ever reported.  Of the 11,035 women identified, 34.2% were 
white, 12% were Hispanic, 10.1% were Asian, and 5% were black (Note: 38.6% of the 
race/ethnicity data were missing.).  The limitations of these studies are many, and highlight the 
need for additional large-scale studies to clarify the prevalence of PCOS across different 
ethnic/racial groups.  Specifically, the proportion of PCOS phenotypes among ethnic/racial 
groups should be determined. 
Manifestations of PCOS.  Despite their limitations, prevalence studies have led to a 
greater understanding of PCOS, and it is now recognized that there is a continuum of clinical 
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presentations (Balen et al., 1995).  At one end of the continuum are women who are largely 
asymptomatic, and, at the other, are women who present with dermatologic, reproductive, 
metabolic, and psychological manifestations of the syndrome.  While the presence of a woman 
on the continuum is likely predetermined by genetic factors (Givens, 1988; Govind et al., 1999; 
Kashar-Miller et al., 2001; Prapas et al., 2009; Wilroy et al., 1975),  her position on the 
continuum is likely related to lifestyle factors, particularly degree of obesity (Gambineri et al., 
2002; Glueck et al., 2005; Lord & Norman, 2006; McCook, 2002; Nestler et al., 1989; Pasquail 
et al., 2006).  Obesity plays a central role in the phenotypic expression of PCOS by increasing 
insulin and androgen levels, leading to greater hormonal disturbances which are associated with 
more severe phenotypes (Gambineri et al., 2002; Nestler et al., 1989).  For this reason, obese 
WLW PCOS present with more clinical manifestations of the syndrome, which are described 
below (Acién et al., 1999; Balen et al., 1995; Kiddy et al., 1990; Rachon & Teede, 2010). 
Depending on the population studied, 20-76% of WLW PCOS are obese (Rachon & 
Teede, 2010; The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop 
Group, 2012).  However, the highest prevalence of obesity is reported in studies conducted in 
Australia and the U.S (61-76%) (Rachon & Teede, 2010; The Amsterdam ESHRE/ASRM-
Sponsored 3rd PCOS Consensus Workshop Group, 2012).  These prevalence studies support 
other research findings which suggest that American WLW PCOS have more severe clinical 
manifestations of the syndrome than their counterparts in other countries (Carmina, Legro, 
Stamets, Lowell, & Lobo, 2003).These studies also highlight the public health significance of 
PCOS in the United States.  For a summary of the etiology, hormonal, and clinical features of 
PCOS, see Figure 1. 
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Dermatologic Manifestations. Dermatologic manifestations of PCOS result from 
hyperandrogenism.  Clinical signs of hyperandrogenism include hirsutism, acne vulgaris, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Etiological, Hormonal, and Clinical Features of Polycystic Ovary Syndrome 
 
Adapted from Teede et al. (2010) 
 
alopecia, and/or other skin problems (i.e. oily skin and dandruff) (Teede et al., 2010).  However, 
hirsutism is considered the best marker of hyperandrogenism (The Amsterdam ESHRE/ASRM-
Sponsored 3rd PCOS Consensus Workshop Group, 2012).  Hirsutism is the excessive growth of 
terminal hair (defined as coarse, long, and dark hair) on androgen-sensitive areas of the body, 
which include the inner thighs, buttocks, abdomen, chest, back, and face (Goolsby, 2001).  In 
general, hirsutism is present in approximately 70% of WLW PCOS(The Amsterdam 
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ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 2012).  However, there is 
widespread variability in the prevalence of hirsutism in PCOS populations across different 
countries.  The proportion of WLW PCOS who are hirsute ranges from 20% in Japan to 80% in 
the United States (The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop 
Group, 2012).  Ethnic differences and systemic factors, mainly obesity, are cited for these 
differences. 
Reproductive Manifestations.  Menstrual irregularities are the most common 
reproductive manifestations of PCOS and have consistently been documented in 70-80% of 
WLW the syndrome (Teede et al., 2010).  Usually, menstrual irregularities manifest as oligo- 
and/or amenorrhea (defined as infrequent menstruation or absence of menstruation) resulting 
from chronic oligo- and/or anovulation.  Chronic anovulation can lead to infertility, and PCOS is 
recognized as the most common cause of anovulatory infertility in women.  However, most 
women with the syndrome (60%) are fertile (defined as the ability to conceive within 12 
months), although the time it takes to conceive is often longer (Brassard et al., 2008).  
Importantly, of the women diagnosed with PCOS and infertility, approximately 90% are 
overweight.  
There is also increasing evidence suggesting a negative effect of PCOS on pregnancy 
outcomes.  In a meta-analysis including 15 studies comparing WLW PCOS (n=720) to women 
living without PCOS (n=4,505), WLW the syndrome demonstrated a higher risk of developing 
gestational diabetes (OR 2.94; 95% CI: 1.70–5.08), pregnancy-induced hypertension (OR 3.67; 
95% CI: 1.98–6.81), pre-eclampsia (OR 3.47; 95% CI: 1.95–6.17) and preterm birth (OR 1.75; 
95% CI: 1.16–2.62) (Boomsma et al., 2006).  In addition, babies of WLW PCOS had a 
significantly higher risk of admission to a neonatal intensive care unit (OR 2.31; 95% CI: 1.25–
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4.26) and a higher perinatal mortality (OR 3.07; 95% CI: 1.03–9.21), unrelated to multiple births.  
To limit the possible confounding factor of obesity on this analysis, the authors only included 
studies in which BMI did not differ between study groups.  However, to fully determine if PCOS 
is an independent risk factor for obstetrical morbidities, future studies should carefully match for 
BMI or analyze whether BMI is an independent predictor of outcomes.  Findings from these 
studies will have important implications for antenatal monitoring, including earlier screening for 
gestational diabetes among WLW PCOS (The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS 
Consensus Workshop Group, 2012). 
Psychological Manifestations.  Research also suggests that WLW PCOS are an at-risk 
group for mental illness and reduced health-related quality of life (HRQoL) (defined as a 
multidimensional concept that includes the physical, psychological, and social domains 
associated with a health condition or its treatment) (Himelein & Thatcher, 2006; Jones et al., 
2007).   However, studies in this area have been hampered by the existence of only one validated 
condition-specific questionnaire, the Polycystic Ovary Syndrome Questionnaire (PCOSQ).  This 
measures the HRQoL in adult WLW PCOS and includes 5 domains believed to be importance to 
WLW the syndrome: (1) body hair, (2) emotions, (3) weight problems, (4) menstrual problems, 
and (5) infertility(Cronin et al., 1998).  Studies applying the PCOSQ observe that the most 
adversely affected domain is weight, followed by infertility (Guyatt, Weaver, Cronin, Dooley, & 
Azziz, 2004; Jones et al., 2004; McCook, Reame, & Thatcher, 2005).  Conversely, studies using 
validated generic measures of mental health report that hirsutism and obesity are the major 
sources of psychological morbidity among WLW PCOS (Himelein & Thatcher, 2006).  In these 
studies, PCOS has been associated with several mental health issues, including anxiety and 
depression, body dissatisfaction and eating disorders, and diminished sexual satisfaction.   
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Metabolic Manifestations.  Varying degrees of metabolic dysfunction are demonstrated 
in PCOS and may include dyslipidemia, hypertension, metabolic syndrome (MetS), and impaired 
glucose tolerance (IGT), – all of which are highly predictive of T2D and cardiovascular disease 
(CVD)(Essah, Wickham, & Nestler, 2007; Tomlinson et al., 2010).  Because these features are 
usually present independent of obesity, lean WLW PCOS are considered a clinically significant 
population (The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 
2012).  However, it should be emphasized that these features are magnified by obesity (The 
Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 2012). 
A recent meta-analysis and systematic review of the literature supports a greater 
prevalence of T2D in WLW PCOS compared to women living without PCOS (OR 4.43; 95% CI: 
4.06-4.82; BMI-matched studies OR 4.00; 95% CI: 1.97-8.10), independent of obesity (Moran, 
Misso, Wild, & Norman, 2010).  Likewise, compared to age- and BMI-matched controls, WLW 
PCOS present with more subclinical atherosclerosis in multiple arterial locations including the 
carotid, femoral, and coronary arteries (Christian et al., 2003; Guzick et al., 1996; Talbott et al., 
2000; Vural, Caliskan, Turkoz, Kilic, & Demirci, 2005).  Based on this risk profile, Dahlgren et 
al. have predicted that WLW PCOS should have a 7-fold increased risk of myocardial infarction 
when compared to age-matched non-PCOS controls (Dahlgren, Janson, Johansson, Lapidus, & 
Odén, 1992).  However, evidence for increased CVD morbidity and mortality in WLW PCOS 
remains inconclusive (The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus 
Workshop Group, 2012; Tomlinson et al., 2010).  Long-term prospective studies are needed to 
define metabolic outcomes and CVD risk among WLW PCOS.  Specifically, outcomes based on 
PCOS phenotype should be clarified.   
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Management.  There is no cure for PCOS.  However, lifestyle changes, including diet 
modifications and increased physical activity, are advocated as the first-line therapeutic approach 
in PCOS management (Teede et al., 2010).  Because IR and obesity play an important role in the 
phenotypic expression of the syndrome, prevention of weight gain is important across the 
lifespan for all WLW PCOS (Teede et al., 2011),  and weight reduction is important for WLW 
the syndrome who are already overweight or obese (Thomson, Buckley, & Brinkworth, 2010).  
Even modest weight loss (5-14%) achieved through lifestyle changes has been shown to improve 
reproductive features (i.e. menstrual cyclicity, ovulation rates and fertility) (Clark et al., 1995; 
Clark, Thornley, Tomlinson, Galletley, & Norman, 1998; Huber-Buchholz, Carey, & Norman, 
1999), metabolic features (i.e. dyslipidemia, IR, and risk factors for CVD and DM) (Holte, 
Bergh, Berne, Wide, & Lithell, 1995; Kiddy et al., 1992; Moran, Noakes, Clifton, Tomlinson, & 
Norman, 2003), and psychological features (i.e. depression, poor body image, reduced HRQoL) 
among overweight WLW PCOS (R. L. Thomson et al., 2010).  Importantly, to promote healthy 
behaviors in WLW POS, it has been suggested that psychological features should be addressed 
to optimize self-efficacy, readiness to change, and sustainability of lifestyle interventions (Teede 
et al., 2011). 
In addition, pharmacological interventions may be appropriate and are dependent on the 
presenting symptoms of the patient and the patient’s preferences (Benjamins & Barratt, 2009).  
For example, hormonal contraceptives are beneficial to WLW PCOS who do not desire 
pregnancy.  Not only can they establish regular menstrual cycles in WLW the syndrome, but also  
they can help control the physical signs of hyperandrogenism (i.e. hirsutism and acne) (Azziz, 
2003).  Some WLW PCOS will further benefit from a combination of a hormonal contraceptive 
and an antiandrogen, which reduces hirsutism at the level of the hair follicle by blocking the 
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androgen receptors from “seeing” the androgens (Marx & Metha, 2003).  However, 
antiandrogens should not be prescribed for women desiring pregnancy, because these 
medications have teratogenic potential.  Instead, women desiring pregnancy who also have 
unwanted hair may choose nonsystemic hair removal treatments, such as bleaching, plucking, 
waxing, or shaving problem areas (Marx & Metha, 2003).  Women may also opt for electrolysis 
or laser therapy to permanently remove hair,  although the latter has limited efficacy in treating 
dark-skinned individuals, as laser therapies are best suited for persons with light skin and dark 
hair (Benjamins & Barratt, 2009).  In addition, insulin sensitizers, such as Metformin®, are 
commonly prescribed to WLW PCOS with hirsutism, IR, IGT, MetS, T2D, and/or ovulation 
dysfunction to improve insulin sensitivity, and, consequently, hyperandrogenism (Moll, van der 
Veen, & van Wely, 2007). 
 For infertile WLW PCOS who desire pregnancy, clomiphene citrate is the first-line 
medical treatment for ovulation induction (Atay, Cam, Muhcu, Cam, & Karateke, 2006; 
Dehbashi, Vafaei, Parsanezhad, & Alborzi, 2006).  Because women with a high BMI and/or high 
androgen levels may be unresponsive to this medication,  Metformin® is often used in 
conjunction with it (Radosh, 2009).  If clomiphene citrate therapy is unsuccessful, gonadotropins 
are traditionally the next line of treatment (Wei & Pritts, 2003).  Although gonadotropins are 
more likely to induce ovulation, they are associated with serious sequelae, including ovarian 
hyperstimulation syndrome and multiple gestation (Norman, Wu, & Stankiewicz, 2004).  
However, this approach is preferable over more invasive procedures, such as laparoscopic 
surgery or in-vitro fertilization (Speroff & Fritz, 2005).  Laparoscopic ovarian drilling is the most 
common surgical procedure performed on WLW PCOS to correct anovulation (Pfeifer & Kives, 
2009).  In a review of the literature, Seow et al. (2008) reports that 50-100% of patients resume 
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ovulation after undergoing this procedure.  However, if this treatment option fails, WLW PCOS 
may choose to utilize assisted reproductive technologies (ART), such as in-vitro fertilization 
(IVF).  These technologies are expensive, time consuming, and usually not covered by health 
insurance (The Boston Women's Health Book Collective, 2005).  Because infertility-related 
healthcare costs are often borne by individuals, significant economic and racial disparities are 
created (Macaluso et al., 2010).  There are also many risks involved in IVF associated with egg 
retrieval and embryo transfer.  Risks include infection, needle injury, adverse reactions to 
anesthesia, and reduced uterine receptivity owing to a thinner endometrium.  Lastly, multiple 
gestation is also common, which is associated with increased risk for maternal complications 
(Senat, Ancel, Bouvier-Colle, & Breart, 1998; The ESHRE Capri Workshop Group, 2000).  
Multiple-birth infants are also at increased risk for preterm delivery, low birth weight, infant 
death, and disability (Dhont, De Sutter, Ruyssinck, Martens, & Bekaert, 1999; Kiely, 1998; 
Pharoah, 2006; Senat et al., 1998; The ESHRE Capri Workshop Group, 2000).  It is notable that 
ART-conceived singletons are also at increased risk for fetal growth restriction, preterm delivery, 
low birth weight, and very low birth weight (Schieve et al., 2004; Schieve et al., 2002). 
For WLW infertility, adoption, surrogacy, and child-free living are also important 
alternatives to infertility treatments. However, “the risks, benefits, and costs associated with 
these alternatives are not immediately clear, and decision-making involves serious emotional 
responses” (Macaluso et al., 2010).  Furthermore, it is difficult to find objective information on 
these options, and the same racial and social disparities that affect access to infertility treatments 
also affect access to information on alternatives to treatment.  However, it should be reiterated 
here that most WLW PCOS (60%) are fertile and can conceive without medical intervention 
(Brassard et al., 2008). 
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Overall, management should address both the short- and long-term manifestations of the 
syndrome.  Because the mainstay of treatment is “diet and exercise,” research programs 
identifying self-care behaviors among WLW PCOS are needed.  However, none exists, which is 
the primary justification for the dissertation.  In the next section of the review, PCOS research 
and clinical practices related to PCOS are summarized to explain the dearth of PCOS-related 
behavioral studies and to emphasize the need for the dissertation.  To conclude this section, the 
economic burden of PCOS is highlighted. 
Economic Burden.  Because of its high prevalence and association with menstrual 
irregularities, infertility, hirsutism, and T2D, PCOS represents a significant financial burden to 
the U.S. healthcare system (Azziz, Marin, Badamgarav, & Song, 2005).  In the U.S., the 
estimated costs of evaluating women for PCOS and its associated morbidities and treating those 
morbidities exceed $4 billion annually (in 2004 US dollars).  This estimate, however, is 
considered relatively conservative for many reasons.  First, PCOS prevalence figures used in this 
calculation are derived using the narrowest definition of the syndrome, the NIH criteria (Azziz et 
al., 2005).   The estimated economic burden of PCOS could significantly increase if a broader 
definition of PCOS was used, such as the Rotterdam criteria.  Second, this estimate only includes 
conditions that are well established as being associated with PCOS, excluding other conditions 
for which data are highly suggestive but not conclusive (Azziz et al., 2005).  These include 
obstetrical morbidities, gynecologic cancers, hypertension, and mental illness.  Lastly, this  
estimate only accounts for the evaluation and treatment of WLW PCOS in their reproductive 
years (Azziz, 2007).  Many of the long-term, PCOS morbidities, such as CVD and T2D, will 
develop in the post-reproductive years.  Thus, the total economic burden of PCOS across the 
lifespan has yet to be estimated. 
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 The economic burden of T2D in PCOS represents approximately 40% of the overall cost 
estimated (Azziz et al., 2005).  The management of menstrual irregularities and hirsutism 
accounts for another 31% and 14% of the costs, respectively, and the provision of infertility 
services accounts for 12% of the costs.  The cost of the diagnostic evaluation for PCOS 
represents only 2% of the economic burden.   
PCOS: Research and Practice 
Although PCOS is the most common endocrine disorder among reproductive-age women 
(Speroff & Fritz, 2005), much remains unknown about the syndrome and the women who 
experience it.  Indeed, many biomedical studies have been conducted to further our 
understanding of the syndrome, and a few studies within the social sciences have been conducted 
to explore the lived experiences of WLW PCOS (Crete & Adamshick, 2011; Kitzinger & 
Willmont, 2002; Snyder, 2006; Weiss & Bulmer, 2011).  These studies have produced 
substantial knowledge about PCOS.  However, no behavioral studies have been conducted to 
identify strategies to promote health and prevent PCOS-related illness among WLW the 
syndrome.  To better understand the existence of this gap in the literature, and, in general, the 
current state of PCOS research and practice in the U.S., it is important to first understand the 
history of women’s health and the social transformation of American medicine, as this has 
largely impacted the way in which PCOS has been addressed. 
Women’s Health & American Medicine: Historical Context.  Traditionally, women’s 
health has been framed in terms of reproductive health (Mitchinson, 1998).  “This focus is a 
legacy of the medical conception of women’s health that emerged in the second half of the 19th 
century, when ideas about biological determinism and fundamental differences between the 
sexes were becoming prominent” (Weisman, 1997).  During this era, the study of women’s 
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health focused on female reproductive processes and the impact these processes were assumed to 
have on women’s mental and overall health – processes that made women “naturally” weak 
(Mitchinson, 1998).  At the same time, the prevailing gender ideology, which defined 
motherhood as women’s moral function and primary social purpose, gave legitimacy to the 
medical focus on reproduction (Weisman, 1997).   In the 1920s, the discovery of sex hormones 
further contributed to the medicalization of women’s health (Kuh & Hardy, 2003),  and, in 
1930s, the American medical profession reinforced the reproductive focus in women’s health by 
establishing a specialty board on obstetrics and gynecology (Weisman, 1997).  It was within this 
context that PCOS was first clearly described by two American gynecologists, Drs. Stein and 
Leventhal, in a paper presented at the 1935 Central Association of Obstetricians and 
Gynecologists conference (Farquar, 2007).  In their manuscript, the physicians described a small 
patient population of seven infertile women who presented with amenorrhea and bilateral 
polycystic ovaries.  Drs. Stein and Leventhal found that, after undergoing ovarian wedge 
resection, all seven patients returned to regular menstruation and two conceived.  Soon after this 
conference, laparotomy (i.e. abdominal surgery) and ovarian wedge biopsy – procedures 
primarily performed by obstetricians - became the mainstay for PCOS diagnosis and treatment.   
Over the next half century, PCOS was viewed as a reproductive issue.  The few PCOS 
research studies that were conducted at this time focused on the biology of the syndrome, and 
clinical management centered on fertility restoration.  Consequently, women experiencing PCOS 
without fertility concerns remained largely undiagnosed, and WLW the syndrome remained an 
unrecognized segment of the population at increased risk for metabolic dysfunction.   
It was also during this time that the role of OB/GYNs in the provision of well women’s 
care expanded with the introduction of the Pap smear and first oral contraceptive and the 
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legalization of abortion (Weisman, 1997).  As a consequence, women born after World War II 
(WWII) came into earlier and more continuous care by OB/GYNs than in previous generations.  
In terms of medical research, little attention was paid to conditions specific to women or risk 
factors unique to women (Baird, 2009).  Moreover, women were grossly underrepresented and 
often excluded in clinical trials exploring non-reproductive health issues.  Researchers argued 
that the menstrual cycle introduced a potential confounding variable, and ethicists expressed 
concern that experimental drug treatments would affect women’s reproductive capacity and 
expose fetuses to unknown risks (Sen & Ostlin, 2008).  It was also assumed that men and women 
would respond similarly to drug treatments.  However, the medical profession’s views of 
women’s health and the exclusion of women in medical research would soon be challenged. 
By the 1960s, the post-WWII baby-boom generation of women was college-aged, a 
culture of “free love” was emerging, and women were more inclined to view maternity as a 
peripheral component of their lives (Allyn, 2000; Weisman, 1997).  Women also began to 
challenge the medical profession’s authority to control women’s reproduction lives by regulating 
access to contraceptives and abortion (Weisman, 1997).  By the late 1960s, women were 
organizing for change and the Women’s Health Movement (WHM) was gaining momentum.  In 
the beginning, the WHM largely focused on reproductive rights and women’s limited access to 
health information.  Specifically, women’s health advocates challenged patriarchy in medicine 
by educating women about their bodies and by promoting patient involvement in the decision 
making process.  Arguably, the publication of Our Bodies, Ourselves in 1970 was the most 
iconic achievement of this period.  However, editions of this text failed to mention PCOS until 
the mid-90s, when the Boston Women’s Health Book Collaborative published the 25th 
anniversary edition of the text (The Boston Women's Health Book Collective, 1998). 
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By the 1980s, women’s health advocates realized that the lack of medical research 
focusing on women’s health issues had compromised not only the quality of health information 
available to women but also the health care they received (Baird, 2009).  They argued for a 
broader definition of women’s health and increased participation of women in research studies.  
In response, the U.S. Public Health Service commissioned a task force on women’s health, which 
later recommended that biomedical and behavioral research be expanded to ensure emphasis on 
diseases or conditions that (1) are unique to, or more prevalent, in women, (2) have risk factors 
and adverse health outcomes specific to women, and/or (3) require interventions unique to 
women(Public Health Service Task Force on Women's Health Issues, 1985).  Although this 1985 
report received little attention and most recommendations were never addressed, the NIH did 
establish an advisory committee on Women’s Health Issues (Baird, 2009).  Also, in 1986, the 
NIH announced a new policy that “urged grant applicants to consider inclusion of women in 
study populations of all clinical research efforts” (United States General Acounting Office, 
2000).   However, a few years later, the U.S. General Accounting Office (GAO) found that the 
NIH had been slow to implement this policy.  In response to criticism regarding the lack of 
progress in women’s health research, the NIH established the Office of Research on Women’s 
Health (ORWH) in 1990. 
It is no coincidence that, also in 1990, the first international conference on PCOS was 
sponsored by the NIH in Bethesda, MD (The Rotterdam ESHRE/ASRM-Sponsored PCOS 
consensus workshop group, 2004b).  Here, the first set of PCOS diagnostic criteria were  
recommended based on majority expert opinion, which was an important first step in 
standardizing diagnosis.  The establishment of these criteria also led to a number of landmark 
randomized multi-center clinical trials in PCOS (Azziz et al., 2001; Nestler et al., 1991).   Still 
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today, the syndrome remains one of the most poorly defined endocrinopathies and continues to 
produce considerable scientific debate (Farquar, 2007).  Also, evidence of the increasing interest 
in this syndrome is not difficult to find (see Figure 2).  An electronic search on PubMed using 
the medical subject heading (MeSH) term “polycystic ovary syndrome” (performed February 20, 
  Figure 2. PCOS Publications on PubMEd 
2012) produced 8,786 citations; 1,589 were review articles and 971 were clinical trials; the 
majority (74%) of publications occurred after 1990.  Arguably, the most critical issue in PCOS 
research and subsequent practice is the lack of uniformity in diagnostic criteria.  Without a  
universally agreed upon definition of the syndrome, women are being diagnosed based on 
provider preference (of PCOS diagnostic criteria) rather than evidence-based guidelines.  
Furthermore, research into the genetics, etiology, clinical associations, treatment, and long-term 
consequences of the syndrome continues to challenge researchers (Balen & Michelmore, 2002).  
Likewise, comparisons of research studies on PCOS have proved difficult as different diagnostic 
criteria have been used for study entry (Cussons, Stuckey, Walsh, Burke, & Norman, 2005). 
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Contemporary Approaches to PCOS Practice in the U.S.  It appears that many women 
experiencing PCOS continue to receive insufficient care (Weisman, 1997).  One reason is the 
fragmentation of healthcare (defined, in terms of women’s health, as the separate delivery of 
reproductive and non-reproductive services without provisions of coordinated care) (Weisman, 
1997).  Although this is not an issue unique to WLW PCOS, it does present a challenge to WLW 
the syndrome, because they may have dermatologic, reproductive, metabolic, and/or 
psychological concerns - all of which are traditionally addressed by different medical specialists.  
Coordination of care, however, is not the only issue.  Many medical societies believe that PCOS 
awareness is low among physicians, and PCOS experts have expressed concern that millions of 
WLW T2D and CVD may be receiving inadequate treatment, because their providers do not 
recognize these symptoms as indications of PCOS (Christopher, 2004).  Hence, more research is 
needed to explore the PCOS knowledge of American physicians.   
For now, women’s stories of their PCOS clinical experiences provide the only insight 
into the current state of PCOS practice.  In studies exploring the lived experience of WLW the 
syndrome, women initially talk about the frustration they felt about delays in their diagnosis 
(Crete & Adamshick, 2011; Kitzinger & Willmont, 2002; Snyder, 2006; Weiss & Bulmer, 2011).  
Women often report seeing multiple specialists before receiving a diagnosis, and younger 
women in particular feel that providers are reluctant to conclude that they are observing 
something outside of normal pubertal development (Weiss & Bulmer, 2011).  Some women even 
report that, after searching their symptoms online, they diagnosed themselves and later 
confirmed their diagnosis with their provider (Crete & Adamshick, 2011; Snyder, 2006). 
During the diagnostic visit, women feel that their provider did not give them enough 
information about the syndrome and that the information given to them was confusing (Crete & 
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Adamshick, 2011; Kitzinger & Willmont, 2002; Snyder, 2006; Weiss & Bulmer, 2011).  In 
response to feeling frustrated and confused, many women engage in information seeking  
activities (Crete & Adamshick, 2011; Kitzinger & Willmont, 2002; Snyder, 2006; Weiss & 
Bulmer, 2011).  Many describe these activities as helpful and report gaining a sense of control 
over symptoms through self-education and treatment (Crete & Adamshick, 2011).  Likewise, 
those who feel alienated by their diagnosis often find comfort in reading other’s stories (Weiss & 
Bulmer, 2011).  However, others say these activities heighten their anxiety, and a few report 
feeling overwhelmed to the point of tears (Crete & Adamshick, 2011).  Interestingly, subgroups 
of WLW PCOS, including those who are lean and/or lesbian, report having trouble finding 
useable information.  Their main complaints, respectively, are that PCOS information focuses on 
dieting and fertility (Weiss & Bulmer, 2011). 
As women come to understand their diagnosis better, some develop feelings of anger 
and/or mistrust towards their providers for not describing the full implications of PCOS (Crete & 
Adamshick, 2011).  Feelings of mistrust also develop for some women after different providers 
give them different advice and information (Crete & Adamshick, 2011).  Many women also 
believe that they are more knowledgeable about PCOS than their provider, which often leads to a  
problem in the patient-provider relationship (Kitzinger & Willmont, 2002; Weiss & Bulmer, 
2011).  Specifically, providers make women feel like they have acted inappropriately by being 
assertive and asking for specific treatments.   
Lastly, women express frustration over how their PCOS has been managed.  Many feel 
that their providers are too focused on fertility and ignore other PCOS-related problems (Weiss 
& Bulmer, 2011).  Some women even report that, after years of treatment, there have been no 
significant improvements in their PCOS symptoms (Crete & Adamshick, 2011).  Consequently, 
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these women expressed a lack of confidence in their providers.  Many also perceive their care as 
being symptom-based, rather than comprehensive, and feel that their providers are looking for a 
“quick fix” (Crete & Adamshick, 2011).  Overall, women feel a sense of inattentiveness from 
their providers, and some even described their care as insensitive (Crete & Adamshick, 2011; 
Kitzinger & Willmont, 2002; Weiss & Bulmer, 2011).  In order to gain control over the 
syndrome, many report visiting several doctor but rarely reported total management (Crete & 
Adamshick, 2011). 
Contemporary Approaches to PCOS Research.  As a result of the medicalization of 
women’s health, most PCOS research has focused on reproductive aspects of the syndrome.a 
However, a few studies in the fields of public health, sociology, and nursing have explored the 
psychological consequences of the syndrome and the lived experiences of women with PCOS.  
Although the findings of these studies have already been described, it is important to note their 
limitations.  First, almost all women included in these studies were white, straight, 
premenopausal women. Because PCOS affects women across the lifespan, research is needed in 
populations of all ages.  Likewise, researchers should consider purposively sampling minority 
women, both in terms of race/ethnicity and sexual orientation, to explore difference among 
subpopulations of WLW PCOS.  Second, PCOS diagnosis was defined differently in all samples.  
While participants in some studies were not asked to provide documented proof of their 
diagnosis, participants in other studies were only considered eligible after specific diagnostic 
criteria were confirmed.  Third, all studies were retrospective and, consequently, there was 
potential for recall bias.  For example, in one study, participants diagnosed more than 20 year  
 
NOTE: Although certain aspects of women’s health were negatively impacted by the medicalization of women's health, others 
were significantly improved.  For example, during this time, MCH outcomes, such as infant and maternal mortality, were reduced 
(Centers for Disease Control and Prevention, 1999). 
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ago were asked to reflect on their diagnostic visit.  However, it is arguable that the data obtained 
still proved advantageous in achieving the overall purpose of these studies.  Fourth, in regards to 
the qualitative studies, the data were very rich, but no findings were explored in depth.  Instead 
of broadly exploring women’s lived experiences of PCOS, future studies should explore specific 
findings.  For example, many women report changing their lifestyles (as is recommended) after 
diagnosis, but no studies identify specific behaviors or the factors that promote or impede 
behavior change. The dissertation is the first to explore antecedents of behavior change among 
WLW PCOS. 
Call to Action. The complexity of PCOS necessitates a multidisciplinary approach to 
research, practice, and policy.  Currently, providers are not caring for women in a collaborative 
manner, and this traditional approach places women experiencing the syndrome at greater risk 
for PCOS-related conditions.  The difficulty of receiving medical care from multiple providers 
who may not be in contact and/or acting collaboratively is not unique, but a paradigm shift is 
required to holistically care for women experiencing PCOS.  In terms of clinical management, 
the emerging diabetes centers in the United States may provide a model for the needed 
collaborative approach. Likewise, the recent influx of announcements for center grants through 
the NIH are encouraging and may provide a funding source in which to research the best 
approaches to preventing, diagnosing, and managing PCOS.  Specifically, research programs 
should be established to identify factors that impact self-care among WLW PCOS, as lifestyle 
changes are recommended as the first line therapeutic approach.  The purpose of the dissertation 
is to establish such a program. 
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Theoretical Framework 
It is well-established that health promotion efforts are most effective when they are 
theory-based (Crosby, Kegler, & DiClemente, 2009). For this reason, theories and models are 
used to guide public health research and intervention development. As a set of interrelated 
concepts, definitions, and propositions that present a systematic view of phenomena, theories 
enable researchers and practitioners to explain observed health behavior (ex. self-care among 
WLW PCOS) and to predict behavior change (Glanz, Rimer, & Lewis, 2002).  Therefore, a well-
defined theoretical approach is necessary to study self-care among WLW PCOS if the goal of the 
research program is to identify and test health-promotion strategies centering on this population. 
Behavioral theories are organized by “levels of influence” (Crosby et al., 2009).  That is, 
health behaviors are viewed as being affected by or affecting (1) individual, (2) interpersonal, (3) 
community, and (4) societal factors.  Thus, health behaviors among WLW PCOS, including self-
care, can (and should) be studied from a variety of perspectives including that of the women 
themselves, their health care providers, community-based organizations that serve WLW PCOS 
(ex. online PCOS support groups), as well as through the examination of social institutions (ex., 
U.S. healthcare system).  
Importantly, the choice of a theoretical framework should begin with identifying the  
problem, goal, and units of practice, not with selecting a theory because it is intriguing or 
familiar (Glanz et al., 2002).  In this dissertation, PCOS is the public health problem of interest, 
and, more specifically, the dissertation begins to address the dearth of information on health 
behaviors among WLW the syndrome.  Accordingly, the unit of practice is women diagnosed 
with PCOS.  Because the purpose of the dissertation is to identify individual factors related to 
self-care among WLW PCOS and because little is known about the phenomenon, it is best to 
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consider research in related chronic conditions, such as T2D and CVD, which have identified 
individual factors related to self-care (Broadbent, Donkin, & Stroh, 2011; French et al., 2006; 
Mc Sharry et al., 2011; Searle, Norman, Thompson, & Vedhara, 2007).  In this field of inquiry, 
research suggests that, in response to illness, persons create their own models or representations 
of illness, known as illness perceptions, and that illness perceptions are antecedents of self-care 
behaviors (Weinmann, Petrie, Moss-Morris, & Horne, 1996).  Because illness perceptions are 
central to Leventhal and colleagues’ Common-Sense Model (CSM) of self-regulation of health 
and illness, it serves as the theoretical foundation of the dissertation.  What follows is a 
discussion of the CSM and related measurements. 
The Common-Sense Model (CSM).  In the early 1970s, Leventhal and colleagues 
(1979) studied the effect of fear messages on health behaviors, demonstrating that health 
behaviors or coping strategies were related not only to fear but also to the individual’s thinking 
related to the health threat.  Over the next decade, their work led to the development of the 
CSM(Leventhal et al., 1980; Leventhal et al., 1984), which, posits that  individuals develop 
complex cognitive and emotional representations of illness, termed illness perceptions, when 
confronted with an illness.  These perceptions are said to affect coping strategies and to be 
affected by appraisal of these strategies.  According to the model, this bidirectional process is an 
important pathway in explaining adjustment to illness and, consequently, illness outcomes.   
Basic Assumptions of the CSM.  Leventhal and colleagues(2003)identify three basic 
assumptions of the CSM: 
(1) Individuals are active problem solvers.  Here, “problem solving” suggests that most 
human actions are purposeful and goal-oriented.  In the context of health and illness, 
individuals are expected to first try to “make sense” of the illness, then to develop 
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coping strategies (based on their illness perceptions) in an effort to regain health and 
normal functioning.  Here, the process of illness adaptation is similar to problem 
solving. 
(2) Individuals adapt to illness based on their “common sense” beliefs.  Thus, coping 
strategies and health outcomes are based on how the individual understands his or her 
illness. 
(3) Objective, medical representations of illness are distinct from subjective, individual 
representations of illness.  This distinction is important, because individual 
representations, regardless of medical accuracy, shape the responses of individuals to 
illness.  Subjective representations may be constructed according to the abstract and 
concrete sources of information available to the individual, including healthcare 
providers, media, social networks, and previous experiences with the illness itself.   
Illness Perceptions.  According to the CSM, individuals develop coping strategies based 
on two types of illness representations: (1) cognitive representations or illness cognitions and (2) 
emotional representations (Leventhal et al., 2003).  Importantly, illness perceptions begin to form 
as soon as individuals experience their first symptom of an illness and typically change with 
illness progression, emergent symptoms, and treatment response. 
Extensive semi-structured interviews and open-ended questionnaire investigations have 
established that illness cognitions are multidimensional and have a common content across 
illnesses (Skelton & Croyle, 1991).  In their original work, Leventhal and colleagues (1980; 
1984)identified four related, but conceptually and empirically distinct, core dimensions of illness 
cognitions: (1) identity (i.e., illness label and perception of symptoms),(2) consequences (i.e., 
beliefs about illness outcomes: physical, social, and behavioral), (3)timeline (i.e., expectations 
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about the duration of illness and persistence of symptoms), and (4) cause (i.e., beliefs about the 
cause of the illness: biological, emotional, environmental, or psychological).  Later, a fifth 
dimension, cure/control (i.e., beliefs about controllability and curability of illness or symptoms), 
was added based on the findings of Lau and colleagues (Lau, Bernard, & Hartman, 1989).   
Emotions are also an integral component of the CSM and are processed in parallel to 
illness cognitions (Leventhal et al., 1992).  Emotional representations develop as a more 
subjective experience and create feeling states such as anger, depression, and anxiety.  These 
emotions can influence illness cognitions in a number of ways, including (1) affecting the onset 
and progression of illness, (2) increasing the difficulty of self-diagnosis and the decision to seek 
care, (3) altering attention to and interpretation of the physical state, and (4) affecting health 
behaviors in response to physical or somatic changes (Ory & DeFriese, 1998).  The latter is 
discussed more in the following section. 
Assessing Illness Perceptions.  In the 1990s, Weinman and colleagues (1996) designed a 
questionnaire to assess the five dimensions of illness cognitions, the Illness Perceptions 
Questionnaire (IPQ).  Later, attempts to revise this measure highlighted the importance of 
additional dimensions to understanding illness (Moss-Morris et al., 2002).  Today, the Illness 
Perceptions Questionnaire-Revised (IPQ-R) includes subscales assessing emotional 
representations of illness and illness coherence, the latter defined as a sense of having a 
comprehensive understanding of an illness.  Control has also been subdivided to differentiate 
between two components: (1) personal control and self-efficacy beliefs and (2) outcome 
expectancies (i.e. belief in the treatment or recommended advice).  Likewise, timeline has been 
subdivided to assess cyclical timeline beliefs in addition to acute/chronic timeline beliefs. 
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Coping Strategies.  The CSM posits that illness perceptions lead to the selection and 
implementation of coping strategies (Leventhal et al., 2003).  These are sometimes referred to as 
self-regulation efforts, as they function to manage or regulate the cognitive and/or emotional 
representations of illness.  Overall, coping strategies are aimed at decreasing emotional distress 
and reducing or eliminating illness threat.  If the emotional distress is overwhelming, coping will 
focus on emotional comfort and may include strategies such as denial and seeking emotional 
support.  If the emotional distress is not overwhelming, the individual is focus on specific health 
behaviors aimed at alleviating illness threat. 
Appraisal.  Lastly, the CSM postulates that individuals evaluate coping strategies in 
terms of their success in reaching desired goals (Leventhal et al., 2003).  If the strategy does not 
have the desired effect, individuals will modify their illness perceptions and/or coping strategies.  
Thus, the appraisal process functions as a feedback loop.  A graphical representation is provided 
(see Figure 3, pg. 37).  In summary, the CSM presents a mediational model in which coping 
mediates the effects of illness perceptions on health outcomes.  The focus of this dissertation is 
illness perceptions only.  This study lays the groundwork for future studies exploring the coping 
strategies and illness outcomes of WLW PCOS. 
CSM Research.  The assumptions of the CSM are supported by cross-sectional and 
longitudinal data from studies of individual’s with a range of medical (French et al., 2006; 
Graves et al., 2009; Kaptein et al., 2010; Knoop et al., 2010; Knowles et al., 2011; Mc Sharry et 
al., 2011; Sullivan et al., 2010) and mental health conditions (Lobban et al., 2005; Lynch et al., 
2011), both acute and chronic.  Likewise, a number of reviews and meta-analyses report a 
relationship among illness perceptions, coping strategies, and health outcomes (Hagger & Orbell, 
2003a; Hoving et al., 2010; Kaptein et al., 2008; Kucukarslan, 2012; Petrie et al., 2007).  
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Specifically, the literature suggests an association between illness perceptions and physical 
functioning, psychological distress, role functioning, social functioning, vitality, psychological 
well-being, and health-related quality of life.  Also, there is evidence that health outcomes and 
quality of care can be significantly improved when illness perceptions of patients are addressed 
in health care settings (Broadbent, Ellis, Thomas, Gamble, & Petrie, 2009; Moss-Morris, Sharon, 
Tobin, & Baldi, 2005) . 
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Chapter 3: Methods 
The long-term goal of this research is to establish theory-driven, evidence-based 
interventions that will improve self-care behaviors among women living with (WLW) polycystic 
ovary syndrome (PCOS), resulting in increased health-related quality of life (HRQoL) and 
decreased PCOS-related illness.  The primary aim of this dissertation is to identify the illness 
perceptions of PCOS held by WLW the syndrome.  This is important, because illness 
perceptions research suggests that individual differences in people’s perceptions of their 
condition influence self-care behaviors and illness outcomes, including HRQoL (French et al., 
2006; Hagger & Orbell, 2003a; Kucukarslan, 2012; Mc Sharry et al., 2011).   
Importantly, a sub-aim of this dissertation is to explore the relationship between illness 
perceptions and infertility, a common symptom of the syndrome.  Infertility is emphasized for 
two reasons.  First, the literature suggests that WLW PCOS have strong emotional responses to 
infertility (Jones et al., 2007; Y. Li et al., 2011; Shi et al., 2011).  According to the CSM, 
emotional responses to an illness (and its symptoms) are antecedents of illness perceptions.  
Second, WLW PCOS who experience infertility typically require additional medical intervention 
(Brassard et al., 2008).  More medical intervention, by nature, requires more interactions with 
healthcare providers, who are potential sources of information.  According to the CSM, 
individuals construct illness perceptions according to the concrete and abstract sources of 
information available to them (Leventhal et al., 2003).  Therefore, WLW PCOS who experience 
infertility may have additional and unique opportunities to obtain information.   
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A second sub-aim of the dissertation is to explore the relationship between illness 
perceptions and HRQoL.  Although the literature clearly indicates that PCOS has a significant 
impact on HRQoL (Jones et al., 2007; Trent et al., 2002) , few factors that contribute to this have 
been explored (Barnard et al., 2007).  All but one study has focused on clinical features of the 
syndrome and their management.  These few studies suggests (1) that symptoms associated with 
the syndrome (i.e. ovulatory dysfunction, hirsutism, obesity, and infertility) contribute 
significantly to the reduction of HRQoL and (2) that successful management of these symptoms 
improve HRQoL (Jones et al., 2007).  Given these findings, there would be an expectation to 
observe a direct relationship between clinical severity of PCOS and HRQoL.  However, Trent 
and colleagues (Trent et al., 2002) report that perception of PCOS severity, not actual severity, 
correlates directly with HRQoL.  This finding emphasizes the need for further investigations into 
the perceptual factors related to HRQoL.  Because illness perceptions of PCOS may be a 
promising determinant of HRQoL among WLW the syndrome, an exploration of the relationship 
between illness perceptions and HRQoL compliment the primary aim of this dissertation. 
Like other research studies, it is important to describe the sample of women recruited for 
the study.  However, because a clinical population of WLW PCOS is not accessible for the 
current dissertation, women were recruited from a social networking site (SNS).  As such, this 
dissertation makes a novel contribution to the literature by describing one of the first samples of 
WLW PCOS recruited through a SNS – a secondary aim of the study.   
To achieve research aims, a multi-phase, mixed-methods, cross-sectional study was 
conducted.  In Phase 1, an online survey was disseminated (1) to collect HRQoL data on women 
diagnosed with PCOS and (1) to recruit participants for Phase 2.  In Phase 2, qualitative  
 41 
 
Table 4. Research Methods Utilized to Meet Research Aims   
Specific Aims and sub-aims Research Questions Theoretical Constructs Measure 
1. To identify the illness 
perceptions of PCOS held by 
WLW the syndrome. 
 
 1. What illness perceptions do 
women hold about their 
PCOS? How do these relate 
to the CSM? How do they 
differ? 
 
Cognitive Representations of Illness 
 Identity 
 Timeline 
 Consequences 
 Cure/Control 
 Cause 
AND Emotional Representations of 
Illness 
 
Qualitative 
interviews 
 a. To explore the 
relationship between 
infertility and illness 
perceptions of PCOS held 
by WLW the syndrome 
 
2. Does the experience of 
infertility impact the illness 
perceptions that women hold 
about their PCOS? 
Cognitive Representations of Illness 
 Identity 
 Timeline 
 Consequences 
 Cure/Control 
 Cause 
AND Emotional Representations of 
Illness 
 
AND Contextual factor: Infertility 
 
Qualitative 
interviews 
 
AND 
 
Online survey: 
Medical history, 
Infertility 
 b. To explore the 
relationship between 
HRQoL and illness 
perceptions of PCOS held 
by WLW the syndrome 
 
 
 
 
 
 
3. Is there a relationship 
between women’s HRQoL 
and the illness perceptions 
they have about PCOS? 
Cognitive Representations of Illness 
 Identity 
 Timeline 
 Consequences 
 Cure/Control 
 Cause 
AND Emotional Representations of 
Illness  
 
AND Contextual factor: HRQoL 
Qualitative 
interviews 
 
AND 
 
Online survey: 
SF-36 
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Table 4 (Cont.)   
Specific Aims and sub-aims Research Questions Theoretical Constructs Measure 
2. To describe one of the first 
samples of WLW PCOS 
recruited through a SNS 
 
 4. What are the demographic 
characteristics of one of the 
first samples of WLW PCOS 
recruited through a SNS? 
 
Contextual Factors: 
 Age 
 Race/Ethnicity 
 Sexual Orientation 
 Marital Status 
 Education 
 Health insurance 
 Length of Diagnosis 
 BMI 
 Medical History 
 Childlessness 
 Trying To Conceive Status 
 
Online survey: 
Individual 
characteristics 
 a. To describe the HRQoL 
among one of the first 
samples of WLW PCOS 
recruited through a SNS 
 
5. What is the HRQoL of one of 
the first samples of WLW 
PCOS recruited through a 
SNS? 
HRQoL Online survey:  
SF-36 
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interviews were conducted with WLW PCOS to investigate their illness perceptions of the 
syndrome.  Specific aims and research questions are listed in Table 4 (pg. 40), as are the related 
theoretical constructs and methods used to collection data. 
Population  
The population for this research included women (1) who were 18 years or older, (2) who 
were able to read, speak, and comprehend English, (3) who were U.S. citizens, (4) who currently  
resided in the U.S., and (5) who had been told by a healthcare provider that they have PCOS.  
Citizenship and geographic criteria were set, because women’s illness perceptions may be 
shaped by the healthcare system itself and because healthcare systems are different in each 
country.  Although this conceptual population may include women diagnosed with PCOS by 
healthcare providers using different diagnostic criteria (Azziz et al., 2009), this differentiation is 
not important, because, the Common Sense Model (CSM) posits that all women receiving a 
PCOS diagnosis will form illness perceptions of the syndrome (Leventhal et al., 2003).   
Table 5. Inclusion and Exclusion Criteria of the Dissertation 
Inclusion Criteria Exclusion Criteria 
Women who are: 
1. 18 years or older 
2. Able to read, speak, and comprehend 
English 
3. U.S. citizens 
4. Currently  reside in the U.S 
 
AND  
 
5. Women who have been told by a healthcare 
provider that they have PCOS 
Women who are: 
1. 17 years or younger 
2. Unable to read, speak, and comprehend 
English 
3. Not U.S. citizens 
4. Currently  reside outside the U.S 
5. Currently trying to conceive (part 2 only) 
 
AND  
 
6.  Women who have NOT been told by a 
healthcare provider that they have PCOS 
 
 
While all women meeting inclusion criteria were able to participate in Part 1 of the study, 
women who reported that they were currently trying to conceive were excluded in Part 2.  As a 
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 reminder, a sub-aim of this dissertation is to explore the relationship between illness perceptions 
and infertility.  If a woman is trying to conceive, her current fertility status is unclear.  For 
clarity, the inclusion and exclusion criteria are listed in Table 5. 
Sampling and Recruitment Considerations.  Identifying and recruiting WLW PCOS is 
a challenge for any U.S. study, because a comprehensive sampling frame for WLW PCOS does 
not exist.  Therefore, a non-random sampling method is appropriate (Neuman, 2006).  In extant 
literature, most PCOS studies have recruited participants through private clinics to ensure 
consistency of diagnostic criteria.  However, this consideration is not important in the current 
study.  Instead, a woman’s understanding that she has received a PCOS diagnosed and, 
consequently, is living with PCOS is most important.   Also, access to a clinical population of 
WLW PCOS does not exist for the current dissertation, which eliminates this option for 
recruitment.   
Other sampling strategies for PCOS studies have included recruitment from face-to-face 
(Percy, Gibbs, Potter, & Boardman, 2009) and on-line (Benson et al., 2010) PCOS support 
groups.  Face-to-face PCOS support groups, however, are not geographically near, and are not as 
accessible as on-line support groups.  At the same time, the on-line PCOS support groups in the 
U.S., including PCOS Support (http://www.pcosupport.org/) and SoulCysters 
(http://soulcysters.net/), have not replied to numerous requests by the lead investigator to 
advertise the study on their websites.  For this reason, WLW PCOS were recruited through 
online support groups created on the SNS, facebook® (www.facebook.com).  This is one of the 
first studies to recruit WLW PCOS from SNS. 
As of December 2012, facebook© had more than one billion monthly active users, and, 
on average, 618 million daily active users ("facebook: key facts," 2013).  As a member, 
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individuals may create web pages for special interest groups, including social support groups, at 
no charge.  An initial search of “polycystic ovary syndrome” yields over 100 support groups 
established by facebook© users.  Most of these are open to the public and the largest of these has 
over 10,000 members.  Notably, the membership is this group is active, with multiple posts per 
day from its members.   
To assess the feasibility of recruiting WLW PCOS via facebook©, Baker (2012) 
conducted a study in February 2012.  In this study, posted a survey link was posted on the largest 
PCOS-related group on facebook®.  Those who clicked on the survey were redirected to the 
homepage of the survey, which included the study description and the consent form.  At the 
bottom of the webpage, readers were instructed to click on the “I Agree” button if they gave 
consent and wished to participate in the survey.  The first questions of the survey screened 
participants.  Those who met the inclusion criteria, which were the same as the current study’s 
criteria (see Table 4), gained access to the full survey, which collected additional demographic 
information of the participants (ex. race, marital status, insurance status).  At the end of the 
survey, participants were asked to provide their email addresses if they were interested in 
participating in future PCOS studies.  Fifty-seven out of 96 persons (1) met inclusion criteria and 
(2) completed the survey in full.  Over half of these provided their contact information.  Notably, 
most persons who did not meet the inclusion criteria lived outside of the U.S.  Also, the 
recruitment message was posted once and no incentives were offered.   Overall, this small study 
demonstrated the potential of using SNS to engage WLW PCOS in public health research.   
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Phase 1: Quantitative Survey 
Overview.  The purpose of Phase 1 was to (1) collect HRQoL data on women who meet 
inclusion criteria (see Table 5) and (2) recruit participants for Phase 2.  To accomplish these 
goals, data were collected using an online survey. 
Sampling and Recruitment.  Two strategies were used to recruit participants.  First, in 
August 2013, a facebook® page dedicated to the study, which included a description of the study 
and a link to the survey, was created.  This promoted the research in a number of ways.  Most 
importantly, if a person searched for PCOS-related pages on facebook®, this page appeared in 
their results.  Also, the lead investigator asked her facebook® “friends” to post the link to the 
study’s facebook® page with the message, “Please help a friend with her dissertation study on 
polycystic ovary syndrome (PCOS)!”  As such, a snowball sample of individuals was reached 
through the “Share” option on facebook®.  Second, a direct link to the survey was posted on the 
five largest PCOS-related facebook® pages with a brief message describing the study.  (Note: 
the direct link to the survey was posted, not the link to the study’s facebook® page, on the 
PCOS-related pages with the purpose of reducing the number of steps the target population went 
through to access the survey directly.)  After the initial posting, the link was reposted every two 
weeks until the end of December 2013, when (1) the recruitment goal was reached (see below) 
and (2) Phase 2 interviews were complete. 
These recruitment strategies built on the aforementioned pilot study (Baker, 2012) in the 
following ways: (1) an additional recruitment strategy was added - a facebook® page dedicated 
to the study; (2) a link to the survey on the five largest PCOS-related pages was provided, 
compared to only the largest PCOS-related page; and (3) the link was reposted every two weeks 
for four months to maximize the number of participants. 
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Because the primary purpose of Phase 1 was to recruit participants for Phase 2, the 
survey was kept open until Phase 2 interviews were completed.  In the pilot study, 56 women (1) 
met the inclusion criteria of this dissertation and (2) completed the online survey.  Over half of 
these expressed interests in a follow-up phone interview (n=31).  In this dissertation, the subset 
of phase 1 participants who expressed interests in a follow-up phone interview were stratified 
based on specific characteristics (see page 57).  For these reasons, the goal was to recruit 
approximately twice as many participants as the pilot study for Phase I of this dissertation (1) to 
reach phase 2 recruitment goals and (2) to account for Phase I participants who expressed 
interests in participating in a phone interview and who later declined an interview.  In short, the 
recruitment goal for Phase I of this study was 100 women. 
Procedure.  By clicking the link to the survey, potential participants were directed to its 
homepage, which acted as the consent form.  This page included a description of the study, an 
overview of the participant’s rights, and the investigator’s contact information.  At the bottom of 
the page, participants were informed that entering the survey signified their consent, after which 
participants had the option to click, “I agree to participate in the study” or “I do not agree to 
participate in the study.”  Those who clicked on the first option were directed to the survey that 
was hosted on a secure server at the University of South Florida; those who click the second 
option received a message thanking them for their time and encouraging them to share the study 
link with others who may be interested. 
Instrument.  The online survey was created using Qualtrics® and contained four parts.  
Part 1 of the survey was a screener.  Only individuals who indicated that they were women (1) 
who were 18 years or older, (2) who were able to read, speak, and comprehend English, (3) who 
were U.S. citizens, (4) who currently  resided in the U.S., and (5) who had been told by a 
 48 
 
healthcare provider that they had PCOS gained access to the full instrument.  Those who did not 
meet these criteria were informed and thanked for their time.  In addition, the automated message 
explained that other opportunities to participate in PCOS research may become available in the 
future, and women were asked to provide their preferred contact information to express interests. 
The next two parts of the survey captured more detailed information about the 
participants.  Part 2 included demographic information, such as race/ethnicity, sexual orientation, 
marital status, education, and health insurance status.  Part 3 included a brief medical history 
form.  Women were asked if they now or if they have ever experienced infertility and a number 
of additional symptoms typically listed on a medical history form (e.g. anemia, diabetes, high 
blood pressure, and urinary tract infections).  Although fertility status was the only item of 
interest, the additional items were included to avoid priming Phase 2 participants to discuss 
infertility. (Note:  Infertility status is important, because a sub-aim of the dissertation is to 
explore the relationship between illness perceptions and infertility).  Also, women were asked to 
enter their height and their weight, which were used to calculate BMI.  Women then were asked 
if they were currently trying to conceive.  If they were, they were excluded from Phase 2, as 
previously stated.  Next, women were asked if they have biological children.  This information 
was used to help stratify Phase 2 participants.  Lastly, women were asked at what age they 
received a PCOS diagnosis.  The latter is important, because the number of years a woman lives 
with a PCOS diagnosis may be proportionate to the amount of information she has about the 
diagnosis.  As previously stated, the CSM posits that individual’s construct illness perceptions 
according to the information available to them (Leventhal et al., 2003).   As such, women’s 
illness perceptions of PCOS may differ on length of diagnosis.  Parts 1, 2, and 3 of the survey are 
available in Appendix A. 
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Lastly, Part 4 of the survey captured women’s HRQoL.  In the PCOS literature, two 
measures have predominately been used to capture HRQoL: (1) the Quality-of-Life 
Questionnaire for Women with Polycystic Ovary Syndrome (PCOSQ) and (2) the Short Form- 
36 (SF-36).  The PCOSQ is currently the only validated PCOS-specific HRQoL measure (Guyatt 
et al., 2004; Jones et al., 2004).  It includes 26 items that divide into five HRQoL domains: body 
weight (5 items), emotions (7 items), hair growth (5 items), infertility (5 items), and 
menstruation (4 items) (see Appendix B). Each item has a seven-point scale, in which a score of 
7 denotes no problems or difficulties and a 1 indicates maximum HRQoL impairment.  The mean 
score of all items in a domain provides a domain score for each woman.   
The SF-36 is a well validated and widely used generic HRQoL measure (Ware & 
Sherbourne, 1992).  It includes 36 items that divide into eight HRQoL domains: bodily pain (2 
items), energy and vitality (4 items) general perception of health (5 items), physical functioning 
(10 items), mental health (5 items), role limitations due to emotional problems (3 items), role 
limitations due to physical problems (4 items), and social functioning (2 items).  Also, there is an 
unscaled single item on changes in respondent’s health (see Appendix C).  Scoring of the SF-36 
is more complex than the PCOSQ.  In short, summed data from the subscales are transformed 
into a 0- to 100-point scale, with a score of 100 denoting no problems or difficulties and a 0 
indicating maximum HRQoL impairment.  Also, the subscales are combined to yield physical 
function and emotional health as two summary health status measures.  (Note: More information 
on scoring the SF-36 is provided in Data Analysis, p. 57) 
Both the PCOSQ and the SF-36 have strengths and limitations.  On one hand, the 
PCOSQ more directly addresses the specific problems of WLW PCOS (e.g., body hair, weight, 
and infertility), which are not identified by the SF-36.  At the same time, the findings cannot be 
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compared with those of samples affected by other diseases and their healthy controls, which 
precludes an assessment of the relative impact of the specific problems.  To date, the SF-36 has 
been used to estimate disease burden in articles describing more than 200 diseases and 
conditions(Ware).  Also, PCOSQ studies agree that the measure has good reliability (Guyatt et 
al., 2004; Jones et al., 2004; McCook et al., 2005), but some question its content validity and 
suggests that it is weakened by the lack of an acne scale (Jones et al., 2004).  On the other hand, 
the SF-36 is reliable and well validated (Ware).  That is, with rare exception, published reliability 
statistics for the eight scales and the two summary health status measures have exceeded the 
minimum standard of 0.70 recommended for measures used in group comparisons.  Also, 
numerous studies have yielded content, concurrent, criterion, construct, and predictive evidence 
of validity. 
Considering the strengths and limitations of each instrument, Jones (2008) suggests that 
both the PCOSQ and the SF-36 be applied in the same study to measure HRQoL among WLW 
PCOS.  However, given (1) that the PCOSQ is an illness-specific measure that emphasizes the 
symptoms of PCOS, (2) that the primary aim of the dissertation is to identify the illness 
perception of WLW PCOS, and (3) that a domain of illness perceptions is identify (i.e. symptoms 
women associate with the syndrome), the PCOSQ was not used in this study to prevent priming 
of Phase 2 participants.  Instead, the SF-36 was the only measure used to assess HRQoL in this 
study. 
After completing the SF-36, participants received an automated message thanking them 
for their time.  The automated message also explained that there was an immediate opportunity 
to participate in a follow-up study, where they would be interviewed via phone or online video 
chat.  Participants were instructed to enter their desired contact information if they wished to 
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participate.  Also, participants were given the option to provide their information if they wished 
to participate in future PCOS research, but not the interviews.  On average, the survey took 12 
minutes for participants to complete.  Before the survey launched, the instrument was pilot tested 
with three women who live with a diagnosis of PCOS to uncover any technical or wording issues 
and to better estimate the time needed to complete the survey. Only minor, grammatical changes 
were suggested and addressed. 
Data Analysis.  The survey data was stored on a secure server at the University of South 
Florida. Data were downloaded from Qualtrics® into a text-based format and analyzed using 
SAS statistical software version 9.3 (SAS Institute, Cary, NC).  As this study is descriptive in 
nature, frequencies, measures of central tendency, standard deviations, and the distribution of 
variables were generated to describe the overall sample on demographic variables.   
Next, the average scores of the overall sample on each of the SF-36 domains were 
calculated: (1) bodily pain, (2) energy and vitality, (3) general perception of health, (4) physical 
functioning , (5) mental health, (6) role limitations due to emotional problems, (7) role 
limitations due to physical problems, and (8) social functioning.  Scores for each SF-36 item are 
reported in Appendix C.  To calculate domain scores, all items in a domain were summed and 
divided by the number of items summed.  A score for each domain was obtained by taking the 
average of scores within that domain. Domain scores could range from zero to 100, with a score 
of zero representing the lowest or worst possible level of functioning and a score of 100 
representing the highest or best possible level of functioning. 
Data Cleaning.  A total of 525 participants initiated the online Qualtrics survey.  Of 
these participants, some did not report being 18 years old or older (n=5), being U.S. citizens 
(n=93), currently residing in the U.S. (n=6), or being told by a healthcare provider that they have 
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PCOS (n=9).  Of the 412 participants remaining (i.e. the participants who met eligibility 
requirements), 29 participants (7%) had completely missing data or did not complete the SF-36, 
leaving 383 cases.  Upon further review of IP addresses, it became clear that a few respondents 
entered the survey multiple times, changing their answers to the screening questions until they 
had the opportunity to enter into the full survey.  To maintain the integrity of the data, all 
responses from these IP addresses were removed (n=7).  This left a final sample of 376 responses 
included in the analysis reported here (Note: 276 responses more than the recruitment goal of 
100 survey responses). 
Phase 2: Qualitative Interviews 
Overview. The purpose of Phase 2 was to investigate the illness perceptions of PCOS 
held by WLW the syndrome (Aim 1).  Rather than starting with a generic, existing quantitative 
measure, such as the IPQ-R, the distinct nature of the experience of PCOS indicates the 
importance of adopting a qualitative method to understand what kinds of illness perceptions are 
developed.  For this reason, this phase consisted of individual, semi-structured interviews.   
Sampling and Recruitment. All women who were eligible to participate in Phase 1 of 
the study were eligible to participate in Phase 2, with the exception of women who report that 
they were currently trying to conceive.  To identify participants for Phase 2, the survey data were 
monitored weekly and woman who expressed interest in participating in the interviews were 
contacted via email. 
Stratification.  Because exploring the relationship between infertility and illness 
perceptions was a sub-aim of the dissertation, Phase 2 participants were stratified into two 
groups: women (1) who reported and (2) who did not report current or past infertility (Note: 
These data were captured in Part 2 of the survey).  As a reminder, one reason infertility may be 
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important is that WLW PCOS have strong emotional responses to infertility (Jones et al., 2007; 
Y. Li et al., 2011; Shi et al., 2011) and that the CSM postulates that emotional responses to an 
illness (and its symptoms) are antecedents of illness perceptions.  To further explore the impact 
of infertility on illness perceptions, the two groups of women were divided into women (1) who 
did and (2) did not have biological children (see Table 6).  It was hypothesized that, among 
WLW PCOS who had no history of infertility, those who did not have biological children would 
have different illness perceptions than those who did, because their ability to become pregnant 
remained unclear.  Likewise, it was hypothesized that, among WLW PCOS who had a history of 
infertility, those who did not have biological children would have different illness perceptions 
than those who did, because their ability to become pregnant also remained unclear.  
Table 6. Phase 2 Sample Stratification 
In
fe
rt
il
it
y
  Biological Children 
 Yes No 
Yes Group 1 Group 2 
No Group 3 Group 4 
 
Given that the design focuses on qualitative description as opposed to grounded or 
phenomenological approaches, data from approximately 30 interviews should have been 
sufficient to achieve the first aim and sub-aims of the dissertation study (Guest, 2006; Mason, 
2010).  For this reason, the goal was to interview approximately 40 women, including 10 women 
in each stratum: (1) WLW PCOS with no history of infertility and no biological children, (2) 
WLW PCOS with no history of infertility and biological children, (3) WLW PCOS with history 
of infertility and no biological children, and (4) WLW PCOS with history of infertility and 
biological children. 
Procedure. As potential participants for Phase 2 were identified, they were emailed to 
confirm their willingness to participate in an interview, to explain its purpose, and to answer any 
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questions about the study.  She also confirmed that they still met inclusion criteria.  If so, she 
sent them an additional consent form for Phase 2 via email.  Based on participant preference, the 
interviews were conducted through telephone or video chat.  Interviews lasted between 15 and 
30 minutes.  Each interview began with an acknowledgment that the participant understood the 
consent document and agreed to be recorded (i.e. audio recording for telephone interviews and 
video and audio recording for video chat).   
Interviews. The aim of the interviews was to elicit illness perceptions of PCOS by WLW 
the syndrome.  Although the CSM was a guiding framework, the interviews were semi-
structured to allow women the opportunity to discuss their experiences from their own 
perspectives.  Following a method originally described by Lau, Bernard, and Hartman (1989), 
participants were asked to describe their experience with PCOS using the standard prompt, “Tell 
me about your experience with polycystic ovary syndrome.”  To prevent bias in the information 
produced by the participants, dialogue was encouraged through silence and prompts such as, 
“Can you tell me more about that?”  After the free response task, participants were asked 
questions regarding each of the dimensions of illness perceptions outlined in the CSM: identity, 
timeline, consequences, cause, and cure/control (LEVENTHAL ET AL., 2003).  These follow-up 
questions were modified from existing guides based on the CSM (Goodman, Morrissey, Graham, 
& Bossingham, 2005; Hurt, Burns, Brown, & Barrowclough, 2010; Nicholls, Glover, & Pistrang, 
2004).  Before data collection began, the interview guide was pilot tested with two WLW PCOS 
to check for content and face validity.  Following these discussions, changes were made to the 
format and content of the interview guide (Appendix D).   
 Data Analysis. All interviews were transcribed by graduate students trained in 
transcription service, and the data were analyzed two separate ways.   
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Analysis 1.  First, to test the ecological validity of the CSM in this population (i.e. 
women diagnosed with PCOS), a method of analysis described by Lau et al. (1989) and 
employed by a number of illness perception researchers, including Hurt (2010), Lobban (2005), 
and their colleagues, was used.  To begin, a graduate student who was unfamiliar with the CSM 
was recruited to assist in the beginning stages of data analysis.  This graduate student divided 
each transcript into distinct thoughts (usually separate sentences), which was verified by the lead 
investigator.  Each thought was then placed on a card. 
Next, the lead investigator, in addition to and independent from a second graduate 
student, grouped similar thoughts.  For example, the statements, “Like, I know that women with 
PCOS are more likely to get diabetes” and “It [PCOS] can also affect your um, it can also make 
you more prone to diabetes,” were placed in the same group.  Then, the lead investigator, 
together with the graduate student, settled any discrepancies in groupings, chose the most 
representative statement from each group, and removed the remaining statements in each group 
(i.e. the duplicates).  This activity resulted in 172 distinct thoughts or statements. 
Criterion Sorting.  The same graduate student, who assisted with the above grouping 
activity and was familiar with the CSM, was asked to assist with a sorting activity.  This student, 
in addition to and independent from the lead investigator, sorted the statements into the illness 
perception dimensions defined by Leventhal and colleagues (2003) (see Table 12).  In cases 
where disagreement existed about statement placement, both referenced to the definitions of the 
dimension and reached a decision.  When no consensus was possible, the statement was placed 
into a residual category.  Statements not represented by the CSM were also placed in the residual 
category. 
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 Naïve Sorting.  Then, five graduate students who were unfamiliar with the CSM were 
recruited to sort the statements.  These “naïve sorters” were all doctoral students in public health 
who had participated previously in qualitative research and who had been introduced to the topic 
of PCOS via a patient education handout printed by the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development (2008). 
The naïve sorters were given the pile of statements (in a shuffled order) and instructed to 
sort the statement into categories that “made sense” to them.  Before beginning the activity, 
naïve sorters were told that they could create as many categories as they liked and that categories 
did not have to be of equal sizes.  Once they had completed this task, they were asked to label the 
categories they created.  This activity was designed to test whether the dimensions were inherent 
in the data and if they logically emerged if a person was unaware of a model that hypothesized 
the existence of the dimensions.  This was different from the first sorting activity, where 
“criterion sorters” (i.e. the lead investigator and her colleague) were only testing whether it was 
possible to sort the statements into the dimensions with which they were familiar.  Results are 
reported in Tables 13 and 14. 
 Analysis 2 .To further explore the overall illness perceptions of WLW PCOS (Aim 1), 
transcripts were imported into NVivo 10.  Transcripts were subjected to content analysis with 
respect to each of the dimensions as originally defined by Leventhal and colleagues (1984) and 
expanded upon by Moss-Morris and colleagues (2002) .  These dimensions and their definitions 
are defined in Table 7.  A doctoral student in Public Health, the previous “criterion sorter,” was 
asked to independently code a number of transcripts.   
To determine inter-relater reliability, the lead investigator and the second coder first 
independently coded a transcript.  This NVivo file was then merged and compared.  Next, both 
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coders discussed and resolved any differences in coding, and then the coding of the transcript 
was revised.  This process was repeated two additional times.  Next, the lead investigator coded 
all of the remaining transcripts and the second coder coded every fifth transcript.  Inter-rater  
reliability was calculated through NVivo and based on these remaining transcripts (n=6).  Kappa 
results ranged between 0.71-.98, which represents substantial to almost perfect agreement 
(Landis & Koch, 1977). 
Table 7.  Definitions of Illness Perception Dimensions 
Illness Perception 
Dimensions 
Definition 
Symptoms Symptoms women identify as part of the PCOS experience 
Labels Label women give to PCOS 
Causes Perceived cause of PCOS 
Timeline, acute/chronic Expectations about the duration of PCOS and the persistence of its 
symptoms 
Timeline, episodic Beliefs about the cyclical nature of PCOS and its symptoms 
Consequences Impact of PCOS on women’s everyday lives and future well being 
Control, personal Beliefs in personal control of PCOS 
Control, treatment Beliefs in treatments for PCOS 
Cure Beliefs that PCOS is curable 
Illness coherence A sense of having a comprehensive understanding of PCOS 
Emotional representations Emotional responses generated by PCOS  
 
Next, frequencies, measures of central tendency, standard deviations, and the distribution 
of variables were generated to describe the demographic characteristics of the interviewees. 
Also, the average scores of the interviewees on each of the SF-36 domains were calculated.   
This allowed Phase 2 findings to be sorted by individual characteristics, including fertility status, 
childlessness, and HRQoL.  As such, the dissertations sub-aims (i.e. sub-aims 1a and 1b) were 
reached:  to explore the relationships between illness perceptions and (1) infertility status and (2) 
HRQoL.  
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Trustworthiness of the Data 
“Qualitative and quantitative criteria of excellence are equally important but inherently 
different” (P. Ulin, E. Robinson, & E. Tolley, 2005).  Each has their own appropriate and no less 
rigorous standards. To judge quantitative studies intended to describe, predict, and verify 
empirical relationships, criteria such as validity, reliability, and objectivity have been adopted.  
However, to judge qualitative studies intended to explore, discover, and understand 
phenomenon, criteria such as credibility, dependability, and confirmability have been adopted.  
When researchers evaluate the latter, they are evaluating the trustworthiness of the data.  When 
researchers say that data are trustworthy, they are saying that the findings are “worth paying 
attention to” (P. Ulin et al., 2005). 
Credibility. In quantitative studies, a measure is valid if it measures the concept it is 
intended to measure. Credibility is the corresponding criterion for qualitative research (Denzin, 
1978).  In this study, credibility was established by using an existing interview guide that has 
been utilized by a number of illness perceptions researchers and by pilot testing the interview 
guide specifically with WLW PCOS.   
Dependability. In quantitative studies, research is considered reliable if findings can be 
replicated in a different population (P. Ulin et al., 2005).  However, this goal is meaningless to 
qualitative researchers, who inquire into unique constellations of phenomena and meaning.  
Instead, the goal for qualitative research is to be dependable.  Research is dependable if the 
research process is executed with careful attention to the rules and conventions of qualitative 
methodology.  To increase dependability in the current study, the lead investigator documented 
her thoughts, decisions, and methods by taking notes or memos throughout the research process 
(i.e. an audit trail).   
 59 
 
Confirmability. Lastly, in quantitative research, objectivity is a traditional standard of 
quality.  Objectivity generally implies that the researcher will maintain distant from participants 
and take measures to reduce the amount of influence their values have on the process of inquiry 
(P. Ulin et al., 2005).  These strategies are often counterproductive in most qualitative studies.  
Instead, the goal of qualitative researchers is to confirm. Confirmability refers to a “way of 
knowing that, even as a coparticipant in the inquiry, the researcher has maintained the distinction 
between personal values and those of the study participant”  (P. Ulin et al., 2005). 
Applying reflexivity contributes to the confirmability of the results.  To ensure reflexivity 
during research activities, the lead investigator discussed her preconceived notions about illness 
perceptions of PCOS with her committee members. This process of becoming aware of 
assumptions was done to bring the lead investigator’s beliefs into the open so that she could be 
aware of them and could attempt to hold them in abeyance, referred to as bracketing assumptions 
(Husserl, 1970).  During data analysis, the committee members’ consultations provided a 
balanced perspective to any assumptions about the illness perceptions held by WLW PCOS.  
They also helped to question, refute, and clarify ideas and discussion points, reducing bias or 
assumptions as conclusions were made.  
Protection of Human Subjects 
Approval from the institutional review board (IRB) of the University of South Florida 
(USF) was obtained prior to the study’s initiation, and addressed a number of ethical issues 
including autonomy, privacy, anonymity, and confidentiality (Appendix F).  For example, in 
Phase I, individuals indicated their willingness to participate in the study by clicking on the 
survey link, which directed them to the homepage containing information about the study, 
informed consent information, and contact information of the lead investigator.  Because 
 60 
 
individuals’ survey answers were linked to their contact information, the lead investigator was 
the only person with access to this data. 
For the interviews in Phase 2, it was important that each participant felt comfortable 
enough to speak openly and honestly.  While the environment in which the participant chose to 
interview could not be controlled, participants were encouraged to select a quiet place to 
interview, free from distractions.  As such, it was confirmed, before each interview, that the 
scheduled time was acceptable to the participant and that the participant was in an environment 
where she could speak freely.  Also, before each interview, participants had the opportunity to 
ask questions and were asked for verbal consent.  During the interview, the respondents were 
given an opportunity to use an alias.  However, all participants chose to be referred to by their 
real names. 
The digital recordings and word files continue to be kept on a password protected 
computer of the lead investigator.  Transcripts and all other data are also kept on this computer.  
Likewise, the cognitions placed on note cards are stored in a locked cabinet in the study office.  
After finalizing all analysis and meeting all publication goals, all cognition cards from Phase 2 
were discarded by placing them in a security container provided by the university where shred 
materials are placed. 
The risks associated with this study were minimal.  However, it was plausible that some 
participants would have adverse reactions to answering questions about their experiences with 
PCOS.  For this reason, the nature of the interviews was fully described to participants prior to 
their participation, and participants had the option of stopping the interview at any time.  
However, no participants chose to stop the interview prematurely. 
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Other Methodological Considerations 
Interview Medium. Notably, there are a number of interview techniques including face-
to-face interviews, phone interviews, video chat interviews (ex., Skype), text/instant messaging, 
and emailing (P. Ulin et al., 2005).  The advantages and disadvantages of these techniques are 
outlined in Appendix D.  For this study, emailing and text/instant messaging were inappropriate, 
because they did not allow for the interview to remain fairly conversational, which is desired in a 
semi-structured interview (P. R. Ulin, E. T. Robinson, & E. E. Tolley, 2005).  Also, for this 
study, face-to-face interviews were not feasible, because participants were not centrally located.  
Thus, phone interviews and video chat interviews were the only appropriate, feasible interview 
techniques for this study.  The researcher, however, realizes that video chat interviews require 
the participants to have certain skill sets and technologies (ex., computer cameras and 
microphones).  Consequently, the researcher let participants decide how they would like to be 
interviewed, by phone or by video chat.  All but two participants chose phone interviews. 
Disclosure. In the study, the lead investigator decided to disclose her own diagnosis of 
PCOS to the participants.  This information was included in a short biography labeled “About the 
Researcher” on the facebook® study page.  The lead investigator also disclosed her diagnosis to 
the participant during the initial contact when she described the purpose of the study to the 
participants and scheduled the interviews.  This decision was made, in part, because the lead 
investigator was a member of many online support groups and realized that some participants 
would recognize her from those websites.  She also believed that self-disclosure would create an 
environment of trust and facilitate authentic dialogue. In previous qualitative studies, researches 
have stated that self-disclosure enhanced report, leveled the “playing field,” showed respect for 
the participants, and validated the participant’s stories (Dickson-Swift, James, Kippen, & 
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Puttong, 2007; Reinharz, 1992).  Lastly, disclosure was identified as an important feature of the 
research given that, in previous research studies, many WLW PCOS have reported that, to their 
knowledge, they have never met another woman with the syndrome. 
Specifically, the lead investigator’s diagnosis was disclosed during the first contact to 
provide the participants a time to ask any questions they had of her experiences.  At that time, 
she began by telling the participants that she was a woman living with PCOS and that she 
received her diagnosis at age 21 years during a routine check-up.  She then asked participants if 
they had any additional questions for her.  No participants initially asked questions, but some did 
after the interview was complete when the lead investigator again offered to answer any personal 
questions.  This strategy proved effective at keeping the focus of the interview on the participant.   
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Chapter 4: Results 
To collect health-related quality of life (HRQoL) data on women living with (WLW) 
polycystic ovary syndrome (PCOS), an online survey was administered.  Individual phone 
interviews and video chats were also conducted with a subset of these women to explore their 
illness perceptions. This section will provide the findings related to each research question.  
Sample characteristics are described and expanded upon where appropriate. 
What are the Demographic Characteristics of One of the First Samples of WLW PCOS 
Recruited Through a Social Networking Site (SNS)? 
Demographic characteristics of the study sample are described in Table 8.  The age of the 
sample ranged from 19 to 56 years with a mean age of 31.8 (SD=5.8).  Respondents were 
primarily non-Hispanic (92.5%), white (88.3%), straight (94.4%), and married (73.4%) with a 
college education (64.1%). 
The medical history of respondents is described in Table 9.  While the number of years 
women had lived with the syndrome ranged from less than one year to 47 years, they, on 
average, reported living with PCOS for 7.6 years (SD=6.1).  Approximately half of the sample 
reported having biological children (47.9%) and currently trying to conceive (42.1%), and most 
participants reported a history of infertility (70.7%).  The BMI of the sample ranged from 15.2 to 
65.4 with a mean of 35.1 (SD=8.9).  In fact, almost half of the total sample reported heights and 
weights that placed them in the morbidly obese category (BMI>35).  Also, a history of  
 
a Research questions are not presented in the order in which they were previously presented. 
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depression (63.6%) and anxiety (68.6%) was common among participants. 
Table 8. Demographic Characteristics of Study Sample (N=376) 
Characteristic No. (%) 
Age M=31.8 SD=5.8 
Hispanic   
 Yes 28 (7.5) 
 No 348 (92.5) 
Race   
 White or Caucasian 332 (88.3) 
 Black or African American 13 (3.5) 
 Other 31 (8.2) 
Sexual Orientation   
 Straight or heterosexual 355 (94.4) 
 Gay, lesbian, or homosexual 2 (0.5) 
 Bisexual 19 (5.1) 
Marital Status   
 Single 89 (23.7) 
 Married 276 (73.4) 
 Separated or divorced 10 (2.7) 
 Widowed 1 (0.3) 
Education   
 High school or less 26 (6.9) 
 Some college 109 (29.0) 
 College graduate 241 (64.1) 
Medical Insurance*   
 Private 281 (74.7) 
 Public  27 (7.2) 
 Military 19 (5.1) 
 Other 15 (4.0) 
 None 46 (12.2) 
*Numbers do not add to 100, because participants could select all that apply. 
 
What is the HRQoL of One of the First Samples of WLW PCOS Recruited Through a 
SNS? 
 As previously described, no overall score is calculated for the SF-36.  Instead, findings 
are reported on each of the eight domains: (1) bodily pain, (2) energy and vitality, (3) general 
perception of health, (4) physical functioning, (5) mental health, (6) role limitations due to  
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Table 9. Medical History of Study Sample (N=376) 
Characteristic No. (%) 
Years living with PCOS diagnosis (M =7.6)   
 < 1 years 63 (16.8) 
 > 1 years 313 (83.2) 
Biological Children   
 Yes 180 (47.9) 
 No 196 (52.1) 
Pregnant   
 Yes 29 (7.7) 
 No 347 (92.3) 
Trying to Conceive   
 Yes 146 (42.1) 
 No 201 (57.9) 
BMI (mean=35.1)   
 Underweight (BMI<18.5) 4 (1.0) 
 Normal (18.5-24.9) 45 (12.0) 
 Overweight (25-29.9) 61 (16.2) 
 Obese (30-34.9) 95 (25.3) 
 Morbidly obese (BMI>35) 171 (45.5) 
History of:   
 Diabetes 45 (12.0) 
 Hypertension 96 (25.5) 
 High cholesterol 101 (26.9) 
 Heart disease 9 (2.3) 
 Thyroid  63 (16.8) 
 Infertility 266 (70.7) 
 Endometriosis 31 (8.2) 
 Migraine 209 (55.6) 
 Anxiety 258 (68.6) 
 Depression 239 (63.6) 
 
emotional problems, (7) role limitations due to physical problems, and (8) social functioning.  
(see Table 10).  Domain scores can range from zero to 100, with a score of zero representing the 
lowest or worst possible level of functioning and a score of 100 representing the highest or best 
possible level of functioning.  Because the SF-36 measures HRQoL, which is personal to each 
individual, it is not appropriate to present normative values that define “good” or “bad” HRQoL 
(Sterling University, 2012).  Therefore, no normative values or cut-off scores are presented.   
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Table 10. SF-36 Domain Scores of Study Sample 
Domain Range 
of 
Sample
 
Mean 
(SD)  
of 
Sample 
Definition 
 Lowest Possible Score 
(0) 
Highest Possible Score 
(100) 
General Health 
Perceptions 
0-100 50.8 
(22.7) 
Evaluates personal 
health as poor or 
believes it is likely to 
get worse 
Evaluates personal health 
as excellent 
Vitality 0-85 34.4 
(18.1) 
Feels tired and worn out 
all of the time 
Feels full of pep and 
energy all of the time 
Physical 
Functioning 
10-100 81.2 
(22.9) 
Very limited in 
performing all physical 
activates, including 
bathing and dressing 
Performs all types of 
physical activities 
including the most 
vigorous without 
limitations due to health 
Role Limitations 
Due to Physical 
Health 
0-100 70.6 
(37.2) 
Problems with work or 
other daily activities as 
a result of physical 
health 
No problems with work 
other daily activities 
Bodily Pain 0-100 66.3 
(24.0) 
Very severe and 
extremely limiting pain 
No pain or limitations due 
to pain 
Social Functioning 0-100 67.4 
(26.8) 
Extreme and frequent 
interference with 
normal social activities 
due to physical and 
emotional problems 
Performs normal social 
activities without 
interference due to 
physical or emotional 
problems 
Role Limitations 
Due to Emotional 
Problems 
0-100 60.3 
(42.7) 
Problems with work or 
other daily activities as 
a result of emotional 
problems 
No problems with work or 
other daily activities 
resulting from emotional 
problems 
Emotional Well 
Being 
0-100 59.1 
(20.9) 
Feelings of nervousness 
and depression all of the 
time 
Feels peaceful, happy, and 
calm all of the time 
 
Overall, few women in the sample reported their general health as being excellent (2.6%) 
or very good (27.4%).  Similarly, women reported the lowest levels of functioning on the 
dimension of vitality, meaning that, in general, women reported feeling tired and being low in 
energy.  Conversely, women reported the highest scores on the dimensions of physical 
functioning and role limitations due to physical health, meaning that, in general, women did not 
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report that their health limited their physical abilities or caused problems with work or other 
daily activities. These findings are further explored by the last research question presented in this 
chapter: Is there a relationship between women’s HRQoL and the illness perceptions they have 
about PCOS? 
What Illness Perceptions do Women Hold About Their PCOS? How do These Relate to the 
CSM? How do They Differ? 
As previously described, transcripts were analyzed two different ways.  First, to test the 
ecological validity of the CSM in this population (e.g. women diagnosed with PCOS), a series of 
sorting activities were conducted (e.g. criterion and naïve sorting).  Then, to answer the research 
question, a content analysis of all transcripts was conducted.  The results of these activities are 
presented after a description of the interviewees’ demographic characteristics and medical 
history. 
Demographic Characteristics of Interviewees.  In total, 34 survey respondents were 
interviewed.  Of these, three chose to video chat via Skype®.  All others participated in phone 
interviews.  Demographic characteristics of interviewees were similar to the overall sample and 
are described in Table 11.  The age of the interviewees ranged from 22 to 46 years with a mean 
age of 33.6 (SD=5.1).  Respondents were primarily non-Hispanic (97.1%), white (94.1%), 
straight (85.3%), and married (64.7%) with a college education (82.4%). 
The medical history of interviewees is described in Table 12.  While the number of years 
interviewees had lived with the syndrome ranged from less than one year to 21 years, women, on 
average, reported living with PCOS for 10.9 years (SD=6.6).  The BMI of the sample ranged 
from 22.3 to 65.3 with a mean of 38.4 (SD=12.8).  In fact, almost half of the interviewees 
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reported heights and weights that placed them in the morbidly obese category (BMI>35).  Also, a 
history of depression (70.6%) and anxiety (64.7%) was common among this subset of women. 
Table 11.  Demographic Characteristics of Interviewees (n=34) 
Characteristic Total Sample (N=376) 
No. (%) 
Interviewees (n=34) 
No. (%) 
Age (M) 31.8 33.6 
Hispanic   
 Yes 28 (7.5) 1 (2.9) 
 No 348 (92.5) 33 (97.1) 
Race   
 White or Caucasian 332 (88.3) 32 (94.1) 
 Black or African American 13 (3.5) 2 (5.9) 
 Other 31 (8.2) 0 (0.0) 
Sexual Orientation   
 Straight or heterosexual 355 (94.4) 29 (85.3) 
 Gay, lesbian, or homosexual 2 (0.5) 1 (2.9) 
 Bisexual 19 (5.1) 4 (11.8) 
Marital Status   
 Single 89 (23.7) 8 (23.5) 
 Married 276 (73.4) 22 (64.7) 
 Separated or divorced 10 (2.7) 3 (8.9) 
 Widowed 1 (0.3) 1 (2.9) 
Education   
 High school or less 26 (6.9) 0 (0.0) 
 Some college 109 (29.0) 6 (17.6) 
 College graduate 241 (64.1) 28 (82.4) 
Medical Insurance*   
 Private 281 (74.7) 26 (76.3) 
 Public  27 (7.2) 3 (8.9) 
 Military 19 (5.1) 0 (0.0) 
 Other 15 (4.0) 2 (5.9) 
 None 46 (12.2) 3 (8.9) 
*Numbers may not add to 100, because participants could select all that apply. 
 
Criterion Sorting. Agreement between the criterion sorters was high (Kappa = 0.89). 
Overall, results suggest that it is possible to categorize the statements generated by WLW PCOS 
into the illness perception dimensions.  When there was disagreement between the criterion 
sorters, it was over whether the statement referred to identity (i.e.  a symptom women  identified 
as part of the PCOS experience) or a health consequence.  Distinguishing between these two  
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Table 12. Medical History of Interviewees (n=34)  
Characteristic Total Sample (N=376) 
No. (%) 
Interviewees (n=34) 
No. (%) 
Years living with PCOS diagnosis  Mean =7.6 Mean=10.9 
 < 1 years 63 (16.8) 5 (14.7) 
 > 1 years 313 (83.2) 29 (85.3) 
Biological Children*   
 Yes 180 (47.9) 19 (55.9) 
 No 196 (52.1) 15 (44.1) 
Pregnant   
 Yes 29 (7.7) 3 (8.8) 
 No 347 (92.3) 31 (91.2) 
BMI  Mean=35.1 Mean=38.4 
 Underweight (BMI<18.5) 4 (1.0) 0 (0.0) 
 Normal (18.5-24.9) 45 (12.0) 5 (14.7) 
 Overweight (25-29.9) 61 (16.2) 3 (8.8) 
 Obese (30-34.9) 95 (25.3) 8 (23.6) 
 Morbidly obese (BMI>35) 171 (45.5) 18 (52.9) 
History of:   
 Diabetes 45 (12.0) 4 (11.8) 
 Hypertension 96 (25.5) 10 (29.4) 
 High cholesterol 101 (26.9) 11 (32.3) 
 Heart disease 9 (2.3) 0 (0.0) 
 Thyroid  63 (16.8) 3 (8.8) 
 Infertility* 266 (70.7) 13 (38.2) 
 Endometriosis 31 (8.2) 2 (5.9) 
 Migraine 209 (55.6) 20 (58.8) 
 Anxiety 258 (68.6) 22 (64.7) 
 Depression 239 (63.6) 24 (70.6) 
*Interviewees recruited based on these characteristics. 
 
dimensions proved to be the biggest challenge in both the sorting activities and the content 
analysis.  For further guidance in sorting and coding, Dr. Howard Leventhal, who is credited for 
the development of the CSM and who has dedicated his life’s work to its advancement and 
application, was consulted.  Below is an excerpt from a personal communication with Dr. 
Leventhal in which he references an example the lead investigator provided, “Because I have 
PCOS, I have high insulin levels, and that makes me crave a lot of sugar” (2014): 
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I think it [cravings] is best coded as an experienced feature (a functional change) that 
identifies the underlying condition and not coded as a consequence…we need to 
recognize that the patient has an abstract concept of PCOS that subsumes elevation in 
insulin.  The conceptual elaboration of the syndrome integrates a wide range of specific 
experiences; concepts provide breadth that allows multiple experience to be linked to a 
common source; a developmental achievement.  Reasoning that way would argue to code 
as identity and expand the system and code both abstract and concrete features.  
 
Based on this communication, all symptoms women (1) experienced previously or currently or 
(2) identified in other women as part of their PCOS experience were sorted as identity and coded 
as symptoms (e.g. a subscale of identity defined by Moss-Morris).  Conversely, any references to 
anticipated health consequences were sorted and coded as consequence.   
The distribution of statements resulting from the criterion sorting activity is shown in 
Table 13.  Symptoms included the largest number of unique statements, followed by cure/control.  
Conversely, timeline contained the least number of unique statements.  In addition, two unique 
statements were placed in the residual category.  These statements represented a number of 
participants’ comments related to the prevalence of PCOS and their understanding of the 
syndrome.  These residual/other findings are expanded upon below under the heading, Cognitive 
Representations. 
Naïve Sorting.  Naïve sorters placed interviewees’ statements into between 5 and 12 
categories, with a mean of 8.8 categories.  The number of times that each of the illness 
perception dimensions were included as a category label by the naïve sorters was recorded and is 
shown in Table 14, labeled Time 1.   
After each naive sorter completed her sorting and labeling task, they were given the 
labels and definitions of each illness perception dimension and asked the naïve sorter whether 
she could (1) re-label any of her categories or (2) collapse categories into one of the dimensions 
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without rearranging any of the statements.  Results from this activity are reported in Table 14, 
labeled Time 2.  Examples of original labels are also provided in Table 15. 
Table 13.  Distribution of Criterion Sorting Statements 
Illness Perception 
Dimensions 
Examples of statement Number of 
statements 
% of total 
number of 
statements 
Identity  An endocrine disorder 
 Polycystic ovaries 
 Excess hair  
56 32.5 
Causes  Genes 
 Diet 
 Excess weight 
11 6.5 
Timeline  Forever 
 Until menopause 
 Until childbearing is complete 
3 3.5 
Consequences  Troubles dating 
 Future health risks 
 Financial strain 
30 15.6 
Cure/Control  Infertility treatments 
 Hair removal treatments 
 Hormonal supplements 
44 25.6 
Emotional 
representations 
 Frustration 
 Anger 
 Worry 
26 15.1 
Residual/Other  A common condition 
 Lack of understanding PCOS 
2 1.2 
Total  172 100 
 
Table 14.  Number of times illness perception dimensions were used as labels in sorting of 
statements by naïve sorters 
Illness Perception Dimensions Number of times label was 
used by naïve sorters:  
Time 1 
Number of times label 
was used by naïve sorters:  
Time 2 
Identity 0 5 
Causes 2 2 
Timeline 0 0 
Consequences 0 4 
Cure/Control 2 5 
Emotional representations 0 3 
Residual 3 3 
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The most commonly labeled categories by the sorters were Identity and Cure/Control.  
Conversely, Timeline was the only dimension not identified.  This is unsurprising, however, 
because only two statements referred to this dimension.  Notably, these statements were most 
commonly placed in the Identity dimension by naïve sorters under the original label Knowledge. 
Table 15.  Examples of original labels generated by naïve sorters 
Illness Perception Dimensions Examples of original labels 
Identity Symptoms 
Knowledge 
Causes* - 
Timeline** - 
Consequences Positive Outcomes 
Health Outcomes 
Cure/Control Lifestyle Management 
Medical Treatment 
Emotional representations Emotions 
Feelings 
* Because Causes was originally used by sorters, no alternative example of original label exists. 
**Because Timeline was not identified by naïve sorters, no example or original label exists. 
 
 
After learning the labels and definitions of each illness perception dimension, all naïve 
sorters agreed that statements could be categorized into each dimension proposed by Leventhal 
and colleagues (1984).  When asked why they could not (1) re-label or (2) collapse all original 
categories into the illness perception dimensions, naïve sorters usually replied one of the 
following ways:  
1. Emotional representations were scattered throughout the groupings.  Because they 
were instructed to re-label or collapse groupings without rearranging any of the 
statements, re-labeling and collapsing was not possible. 
2. Like the criterion sorters, naïve sorters struggled over placing certain statements into 
symptoms and physical consequences of PCOS.  After learning the definitions of 
each, all agreed that statements would need resorting. 
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Cognitive Representations of PCOS.  Interviewees’ responses to questions regarding 
the content of their cognitive illness representations highlighted areas of similarities between 
WLW PCOS.  However, they also highlighted areas in which WLW the syndrome had 
developed dramatically different cognitive illness representations despite having the same 
diagnosis.  This was expected, however, given the nature of PCOS (i.e. a spectrum disorder).  
These similarities and differences are described in the following paragraphs, with themes 
uncovered by the interview questions grouped around the illness perception domain to which it 
relates.  The first of these domains is illness coherence, followed by identity, cause, timeline, 
consequences, control, and cure. 
Illness coherence.  Although no question on the interview guide was specifically 
designed to illicit participant’s beliefs about the extent to which they felt they had a 
comprehensive understanding of their diagnosis, several discussed this topic.  In fact, some 
seemed compelled to preface their interview with a statement regarding their lack of knowledge 
about the syndrome. 
 I guess the first thing that I need to say is that I don’t really understand it, because I 
know that it’s called polycystic ovarian syndrome, but I don’t have ovarian cysts, so 
that’s not even like an easy answer…like, “Oh, it means you have cysts on your ovaries,” 
because it doesn’t even mean that. (A.H., age 35) 
 
Similarly, some concluded the interview by reflecting on the discussion and their overall 
experiences of PCOS. 
 Overall, I’m just a big enigma. I mean it’s hard to pinpoint PCOS – who I am, what it is - 
it’s like you spend your whole…you spend your whole life being your own mystery. (A.F., 
age 37) 
 
 Throughout the interviews, others focused more specifically on PCOS-related symptoms 
or conditions and the extent to which they understood them.  These reflections often led to 
further discussions about the participant’s clinical experiences, which most women described as 
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frustrating.  Specifically, women expressed frustration over the information provided to them at 
the time of diagnosis, which they described as confusing and/or insufficient.   
  
 I mean, even the day the doctor diagnosed me, I don’t think they told me anything. She 
printed something off for me about what it was, but I just don’t remember her explaining 
it. Umm, and even, you know, in talking to you, I’m realizing how confused I am by all of 
this. (E.S., age 34) 
 
Others made more general comments about their clinical experiences, often describing their 
providers as disinterested in their information needs.  Several also expressed a lack of confidence 
in their providers and identified gaps in their provider’s knowledge. 
 I mean, I’ll be the first one to tell you that I totally don’t understand terms like, “insulin 
resistance.”  All that stuff…it just goes right over my head, like, I totally don’t get it, and 
no one I’ve seen has cared to help me understand it. (A.H., age 35) 
 
 I wish I had more support and that my providers knew more about it [PCOS].  I know it  
 was a challenge for me when I knew more than, like, my provider. That's frustrating to  
 me. It’s frustrating when you go to a provider and they can’t answer your questions.  
 They’re supposed to be the experts. I shouldn’t be educating my doctor about the illness  
 they’re supposed to be treating  (E.A., age 29)  
 
 With questions left unanswered, many women reported searching for answers.  As 
expected from a sample recruited from a SNS, the internet was the medium of choice to obtain 
PCOS-related information.  While some searched for answers on common search engines (ex. 
Google), others sought informational support from other WLW PCOS via online PCOS support 
groups, including the groups from which they were recruited. 
 I feel like I get more information, like, more good, valid information from the internet 
and other women with it than I have from any doctor that I’ve ever talked to. Maybe I’m 
just going to the wrong doctor…(D.T., age 37) 
 
Identity.  Identity cognitions were most common and included the name used to refer to 
PCOS (e.g. label), its general description, and its symptoms.  Specifically, most participants 
responded to the initial interview prompt, “Tell me about your experience with polycystic ovary 
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syndrome,” by describing symptoms and spent most of their interview focused on the symptoms 
they had experienced, were currently experiencing, or had heard of others with the diagnosis 
experiencing.   
Label. While all women used the label PCOS to refer to their diagnosis, generic 
descriptions of the syndrome varied.  For example, many correctly identified PCOS as an 
endocrine disorder or a condition related to “hormone issues” or a “hormonal imbalance.”  While 
most did not specifically name the hormones that were imbalanced or describe how they were 
imbalanced, those that did gave mostly accurate descriptions - a combination of elevated 
androgen (i.e. hyperandrogenism) and insulin levels (i.e. hyperinsulinemia leading to insulin 
resistance) (Balen et al., 1995; Kiddy et al., 1990).    
 What it is is an imbalance of hormones where your estrogen and progestin levels are out  
 of balance and your testosterone is higher than it should be. (J.K., age 33) 
 
Likewise,  several accurately identified PCOS as a spectrum disorder (Balen et al., 1995), 
although none explicitly used this label.  Instead, interviewees described PCOS as “looking” 
different in every woman. 
 Well, PCOS is, as far as my understanding goes, is a very complicated condition. It can  
 cause very few symptoms for women or it can cause many symptoms for women that have  
 it. I recently learned that some women don’t have any symptoms at all. Whereas, for  
 myself, I have all of the lovely, I guess, signs of it. (J.S., age 33) 
 
Some also described PCOS as a condition that affected a number of body systems and identified 
a number of symptoms related to the syndrome (see Symptoms).  However, few used medical 
terms to describe these symptoms.  For example, none made reference to hypertension, 
anovulation, alopecia, or hirsutism.  Instead, women discussed having high blood pressure, not 
ovulating, balding or hair thinning, and growing excess hair, respectively.    
 I think it has affected every part of my body except for my ears [Laughter], and I’m just 
waiting for the day when it…when it does. (L.P., age 42) 
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 Now I mean, I’ve hear of like the thinning of the hair and those kinds of things.  As of  
 right now, I don’t have that and I really don’t want that…you know, the [thinning] hair  
 on your head. It can take all the hair off of my chin it wants [Laughter]. Leave the hair  
 on my head alone! (D.L., age 46) 
 
 Lastly, in their general descriptions of PCOS, a few participants emphasized that PCOS 
was not a reproductive disorder, and one participant specifically expressed dislike of the label. 
 I do not like the name “polycystic ovary syndrome,” because that implies that it’s just 
exclusively a reproductive issue, and it’s not! (L.P., age 42) 
 
Notably, renaming of the syndrome recently gained national attention, when a panel of PCOS 
experts met to assess the available scientific evidence on the syndrome (Neilson, 2013).  In this 
workshop, co-sponsored by the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD), experts agreed that the name polycystic ovary syndrome caused 
confusion and created a barrier to research progress and effective patient care.  According to the 
panel, the name PCOS focuses on one of many diagnostic criterion, polycystic ovaries, which are 
neither necessary nor sufficient for diagnosis (see Definition).  For this reason, in their final 
report, the panel recommended assigning a new name to PCOS that more accurately reflected the 
complex interactions that characterized the syndrome (National Institutes of Health, 2012).  
However, a new name was not suggested and no efforts have been made by since this workshop 
to address this recommendation. 
Symptoms.  All interviewees described symptoms related to PCOS.  In large, these 
symptoms could be categorized as follows: (1) reproductive, (2) dermatologic, (3) metabolic, or 
(4) psychological manifestations of the syndrome.  However, a few symptoms did not “fit” these 
categories and are described at the end of this section (see Other Manifestations).  To summarize 
findings, all symptoms women attributed to PCOS are listed in Table 16.  However, it should be 
noted that the relationships between PCOS and some of these symptoms are either inconsistent 
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with or unreported in the literature or remain unclear.  These specific symptoms are highlighted 
in Table 16 with asterisks (*). 
Table 16.  PCOS symptoms identified by interviewees 
Type of Manifestation Symptom  
Reproductive  
 
 Ovarian cysts or polycystic ovaries 
 Heavy menstrual bleeding (Menorrhagia) 
 Infrequent menstruation (Oliogomenorrhea) 
 Absence of menstruation (Amenorrhea) 
 Painful menstruation (Dysmenorrhea) 
 Infrequent ovulation  (Oligoovulation) 
 Absence of ovulation (Anovulation) 
 “Hyper” ovulation* 
 Painful ovulation (Mittelschmerz) 
 Infertility 
 Pregnancy complications, including miscarriage, pre-eclampsia, and 
gestational diabetes** 
 Low breast milk supply (Hypolactation)*** 
Dermatologic  Excess hair growth (Hirsutism) 
 Hair loss (Alopecia) 
 Oily skin 
 Severe, cystic acne 
 Discoloration of skin (Acanthosis nigricans) 
Metabolic  Weight gain, excess weight, or overweight 
 Difficulties losing weight 
 Insulin resistance 
 Diabetes 
 Uncontrollable food cravings 
 Exhaustion or feelings of tiredness 
 High cholesterol (Hypercholesterolemia) 
 High blood pressure (Hypertension) 
Psychological  Anxiety 
 Depression 
 Mood swings 
Other  Anemia 
 Vitamin D deficiency 
 Signs of virilization, including deepening of the voice and broadening of 
the shoulders 
 Insomnia*** 
 Hypothyroidism** 
 Low sex drive** 
 Migraines** 
*The relationship between this symptom and PCOS is inconsistent with the literature. 
**The relationship between this symptom and PCOS remains unclear. 
***The relationship between this symptom and PCOS is not reported in the literature. 
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Reproductive Manifestations of PCOS.  Of all the symptoms women described as part of 
the PCOS experience, reproductive manifestations were the most common.  In fact, almost all 
reported a history of menstrual irregularity.  This was expected, however, because menstrual 
irregularities are cited as the most common reproductive manifestations of PCOS (Teede et al., 
2010).   
Although menstrual irregularities were common among interviewees, their experiences 
varied considerably.  For example, many women reported infrequent periods and/or “skipping” 
periods (oliogomenorrhea) , which often resulted in long and/or heavy periods (i.e. menorrhagia).   
 I’ve never had regular periods in my entire life…you know, since I started 
menstruating…and, when I do have periods, they’re really, really, really, like, 
extraordinarily heavy. (C.Y., age 36) 
 
Others reported having a number of cycles per year, but reported that each cycle drastically 
differed in length. 
 Well, one [menstrual cycle]will be pretty normal, and then the next one will be 37 days, 
and then the next one will be 57 days, and then the one after, who knows? (B.A., age 27) 
 
On the other hand, some women reported spotting on a daily basis and never having a “real” 
period.  Still, others reported having all of these experiences at different times in their lives. 
Also, a few reported a total absence of menstruation (i.e. amenorrhea).  Lastly, one participant 
reported having regular periods but admitted that she had been on some form of birth control for 
most of her life and did not know her “natural” cycle.   
For WLW PCOS, menstrual irregularities such as oligo- and/or amenorrhea result from 
chronic oligo- and/or anovulation (defined as infrequent ovulation or absence of ovulation).  For 
this reason, it is not surprising that many interviewees also reported ovulatory dysfunction and 
described its connection to their menstrual irregularities.  However, a few women also expressed 
the belief that PCOS may result in “hyper” ovulation, which is inconsistent with the literature. 
 79 
 
I could go for, you know, six months without ovulating at all, or I could ovulate four  
times in a month.  That’s the way I understand it.  Umm, it seems to me [that], the time  
I’ve been off the pill, I don’t ovulate. I don’t over-ovulate.  I under-ovulate. (E.S., age 34) 
 
Also, most women reported having polycystic ovaries (PCO), which they identified as the 
underlying cause of their ovulatory dysfunction and/or menstrual irregularities.    
 PCOS is a hormone disorder that affects your ovaries…polycystic ovaries…you have 
ovarian cysts, and they affect your monthly cycle. (D.T., age 37) 
 
For about half of the women interviewed, ovulation and menstruation were a source of 
significant pain.  While many described their pains during ovulation (i.e. Mittelschmerz) as a 
temporary “pinching” sensation, a few reported visiting the emergency room one or more times 
for pain relief.   
 Oh boy, I mean, I would have the pain too, because it is, it is painful sometimes.  You get, 
like, pinching in your ovaries and you feel things bursting. (B.A., age 27) 
 
Similarly, a few reported that chronic pelvic pain limited their ability to engage in daily 
activities, and one participant reported regularly going on bed rest and “not being able to move” 
during painful menstruation (i.e. dysmenorrhea).   
 From the start, my periods, they were super painful. ..to the point of laying in bed…so 
painful that I would say to my mom “Do I have to live with this my whole life?”  
 (E.V., age 40) 
 
In fact, while most women reported that menstrual irregularities prompted them to make an 
appointment with their provider, which later led to a PCOS diagnosis, a few identified their pain 
as their primary motivation to seek help. 
 I was diagnosed with the PCOS when I was fourteen. I went in for abdominal pain in the 
ER, and they did an internal ultrasound the next morning and found that my left cyst 
looked like a whole bunch of grapes. So, I went to my first gynecologist visit that month, 
in February, and they diagnosed me with PCOS. (E.C., age 22) 
 
 Infertility was also commonly discussed by interviewees, regardless if they had 
experienced it themselves.  This was expected, however, because PCOS is recognized as the 
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most common cause of anovulatory infertility in women (Brassard et al., 2008) and because 
interviewees were partially recruited based on infertility status (see Phase 2, Sampling and 
Recruitment).  For most women, it “made sense” that anovulation prevented pregnancy.  
However, for a few women, reasons for PCOS-related infertility remained unclear. 
 It causes things like…fertility issues that don’t seem to necessarily have a reason. 
  (A.F., age 37) 
 
 Among women who reported a previous pregnancy, a few identified a number of 
pregnancy complications that they attributed to PCOS, including gestational diabetes and pre-
eclampsia.  Although emerging research supports the hypothesis that PCOS is an independent 
risk factor for these outcomes (Boomsma et al., 2006), most PCOS experts agree that further 
research is needed.  Likewise, some reported having had one or more miscarriages that they 
attributed to PCOS.  However, the association between PCOS and miscarriage remains 
controversial.  While some investigators report an increased risk of miscarriage in WLW PCOS 
(Balen, Tan, MacDougall, & Jacobs, 1993; Wang, Davies, & Norman, 2001), others do not 
(Nejad et al., 2011).  Laiu and colleagues  (2014) offer a few reasons for these conflicting results:  
First, WLW PCOS represent a heterogeneous population with several phenotypes, each with a 
possibly different risk of miscarriage.  Second, it remains unclear if miscarriage risk differs 
between WLW PCOS who have conceived spontaneously and those who have conceived 
following treatment.  In addition, WLW PCOS who do conceive following treatment may do so 
using different treatment modalities, each with a different risk of miscarriage. 
Among women who had successfully carried a pregnancy to term, half reported low 
breast milk production (i.e. hypolactation).  This topic, in particular, seemed difficult for women 
to discuss, as this was the only time women cried during interviews.   
 I know one of the most frustrating thing for me is that I have low milk supply and that I  
 feel like that was like the nail in the coffin for me.  Like, I feel like PCOS has stolen so  
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 many things from my life and that was really hard for me…[inaudible, cries]….  
 (E.A., age 29) 
 
In addition, many expressed frustration that their providers did not prepare them for possible 
breastfeeding difficulties. 
 I think I had one lactation consultant tell me that PCOS could cause low milk production.   
 But I mean, when I was pregnant, I had never heard anything about it.  Before getting  
 pregnant, I had never heard anything about it. I was, I was a wreck.  You know, and it  
 was, it was something that I felt very strongly about.  Like, I knew before ever getting  
 pregnant that I wanted to breastfeed my children.  And, I was ready to work through any  
latch issue, or, you know, any of the other problems that come up with, with 
breastfeeding.  But,  I never considered not producing enough milk. (J.F., age 33) 
 
However, this is not surprising, because few investigators have studied breast development and 
breastfeeding problems among WLW PCOS.  In short, this issue has received little attention in 
the medical community.   
Interestingly, Drs. Stein and Leventhal, the two American gynecologists that first clearly 
described PCOS, made reference to problems with breast development in their early studies.  In 
their seminal article describing PCOS, they described women as having “small, pale, firm" 
breasts, "large, flabby breasts," and "pendulous breasts"(1935).  In a later article, Stein (1945) 
also mentioned “retarded breast development” and “hypoplastic breasts.”  These descriptions are 
consistent with participants’ descriptions of their own breasts.  For example, most women who 
reported low breast milk supply reported having tubular (or tuberous) breasts or insufficient 
grandular tissue (IGT) and attributed this to PCOS.   
 And, with the insufficient glandular tissue, which goes along with PCOS, I don’t 
have…my breast tissue is not filled the same as somebody else’s.  I don’t have breast 
tissue hardly all on top. I have very tubular, long breasts with very, very, large areolas. I 
have little to no breast tissue underneath - on the underneath side of my breast - and it’s 
just caused a lot, a lot, A LOT of issues with milk production and breast feeding my child. 
Like, this is my biggest thing. I had no idea that it was this big of a deal until I had my 
baby. (E.C., age 22) 
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 Dermatologic Manifestations of PCOS.  Dermatologic  manifestations were the second 
most commonly described PCOS-related symptoms.  However, interviewees spent considerably 
less time discussing these symptoms compared to their reproductive issues, suggesting that the 
reproductive manifestations of PCOS  had a greater impact on their daily lives and/or overall 
experience of the syndrome. 
A majority of interviewees reported a history of hirsutism (i.e. the excessive growth of 
terminal hair).  This was expected, however, because hirsutism is the best marker of 
hyperandrogenism, a biochemical sign of PCOS that is commonly assessed during a diagnostic 
visit (The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 
2012).  Although hirsutism was common among interviewees, their experiences varied 
dramatically.  For example, some described having “a little peach fuzz” and commented that 
other WLW PCOS had it “way worse.”  On the other hand, some women reported significant 
hair growth, and one participant described her younger self in gym class as climbing ropes and 
looking like a “gorilla.” Although most women reported having hair on a number of androgen-
sensitive areas, including the chest, abdomen, and back, facial hair seemed to be the most 
distressing symptom. 
 The hair is irritating.  I mean, it's not fun to be 33 with a mustache.  And so, that’s one  
 more thing to deal with… you know, how you get rid of it.  And so, that kind of affects  
 the way I look at myself. And, it’s kind of like my body is broken...(J.K., age 33) 
 
About a third of interviewees also described other dermatologic symptoms, including hair 
loss (i.e. alopecia), oily skin, and cystic acne –all of which are clinical signs of 
hyperandrogenism (Teede et al., 2010).  While some participants only reported have one or two 
of the dermatologic manifestations of PCOS, some reported having all of the above. 
I started noticing, like, [Sigh] my face was super-duper oily, and I was having issues with  
really bad acne…and also like umm my hair is thinning on top of my head, which really  
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sucks.  Then, like, my [Sigh]…the lady that threaded my eyebrows was like, “You want  
your lip done?” I’m like, “Like are you serious?” And, then my friend is like, ‘Yeah you  
kind of do need it done.”  I’m like, “Seriously, why didn’t you tell me this, because that’s  
something you’re supposed to tell me” [Laughter]. Cause, I hadn’t noticed, and so…and  
then the guy who like does my pedicures was like, “Oh you got extra hairy feet.”  I’m  
like, “Yeah, I actually just found out I have a medical condition that causes that.   
Thanks”(S.R., age 30) 
 
Lastly, a few participants also described discoloration of their skin (i.e. acanthosis 
nigricans),  a symptom commonly associated with insulin resistance.  As previously stated, high 
insulin levels (i.e. hyperinsulinemia) underpin PCOS  and lead to insulin resistance (IR) (Balen 
et al., 1995; Kiddy et al., 1990).  Not surprisingly, the women who reported acanthosis nigricans 
also reported a history of IR (see Metabolic Manifestations).  In fact, one interviewee 
commented that her endocrinologists, without ordering any diagnostic tests, took “one look” at 
her skin, and said, “Yep, your insulin resistant.” (K.L, age 47) 
 Metabolic Manifestations of PCOS.  Metabolic  manifestations were also commonly 
described as part of the PCOS experience.  Symptoms included weight issues, IR, food cravings, 
diabetes, high cholesterol (i.e. hypercholesterolemia), and high blood pressure (i.e. 
hypertension).  This was not surprising, however, because the association between PCOS and 
these symptoms are identified in the literature (Essah et al., 2007; Tomlinson et al., 2010).   
Of all the symptoms described by interviewees, weight issues, including weight gain, obesity, 
and difficulties losing weight, were most often identified as women’s “biggest concern,” 
followed by infertility.   
 Well, I think that the weight issue is the hardest to deal with, because, I mean, I know, I 
KNOW that it’s harder for me. And, I feel like it’s just something that I struggle with 
everyday, and I know that it’s harder for me to lose weight than women that don’t have 
PCOS. (A.H., age 35)  
 
These results may be biased, however, given that over half of the interviewees had successfully 
carried to term by conceiving either spontaneously or following infertility treatment.  This 
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consideration is exemplified by an interviewee who had experienced infertility and had children 
following fertility treatments: 
 I’m almost 39.  It’s, it’s kinda like, for me it’s…like, my weight is the biggest way it 
impacts me at this point.  If you asked me 5 years ago - 4 years ago - I would have had to 
say...I would absolutely [have] told you my fertility. (J.T., age 38) 
 
Still, it is unsurprising that interviewees described weight issues as the “hardest part” of PCOS, 
because, similar to the overall sample, 85.3% of the interviewees (n=29) were overweight, obese, 
or morbidly obese.   
A majority of interviewees also reported a history of IR.  This was not surprising, 
however, because PCOS experts suggest that all women with the syndrome have IR  (DeUgarte, 
Bartolucci, & Azziz, 2005).  Likewise, because IR is a precursor to diabetes, it is also 
unsurprising that a few interviewees reported a history of diabetes (n=4, 11.8%) on the Phase 1 
survey and that others identified an association between PCOS and diabetes during their 
interview.  Several interviewees also reported “uncontrollable” food cravings, which are 
commonly reported among persons with uncontrolled insulin levels. 
 I think I have different cravings than other people, because of the insulin resistance. 
People are like, “Oh yeah, you just have to learn to control it, you know, you have to 
control what your, what you want and what you do.”  And it, it seems like other people 
have that drive...but, see, it’s a never ending cycle.  If I get off the bandwagon and start 
having cookies or brownies or something like that, then I have to get off of them for a 
while for the cravings to go away. (A.F., 37) 
 
On the other hand, a number of interviewees discussed general feelings of exhaustion or 
tiredness that limited their daily activities or interfered with their work.  Although some 
described these feelings as being cyclical in nature and being mostly related to their menstrual 
cycle, many associated these feelings with their IR. 
I know there are times, specifically, say, the week where I'm supposed to be 
premenstrual, or if I've gone a long time in between having periods where I know I 
should have had one, and I'll start feeling very, very run down.  I mean, to the point 
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where I'll be so fatigued. And, sometimes, it will be, like, difficult to even sort of drag 
myself up out of bed. (T.Z., age 34) 
 
While one-third of participants also reported a history of high cholesterol (i.e. 
hypercholesterolemia) and high blood pressure (i.e. hypertension) on the Phase 1 survey, only a 
few mentioned it during their interview.  Although these women all concluded that PCOS was 
the underlying cause of these issue, none discussed them at length, making statements in passing 
like, “My high cholesterol is a sign of my PCOS.”  For this reason, it remains unclear if women 
felt like these issues were serious or if they simply found other PCOS-related symptoms more 
troubling. 
Psychological Manifestations of PCOS.  The majority of interviewees also described 
psychological manifestations of the syndrome, including anxiety, depression, and mood swings.  
This was expected, however, because the majority of interviewees reported a history of anxiety 
(n=22, 64.7%) and depression (n=24, 70.6%) on their Phase 1 survey.  Likewise, previous 
studies suggests that a number of symptoms reported by interviewees, including hirsutism and 
obesity, are associated with anxiety and depression  (Himelein & Thatcher, 2006).  However, in 
this sample, many women attributed their moods to the hormone imbalance caused by PCOS 
and/or to their PCOS-related menstrual irregularities. 
I know that, as far as my moods [are concerned], if my hormones are out of whack, like, 
[Sigh]…when I actually would have my periods, like, I thought I had the premenstrual 
dysphoric disorder for the longest time, because of how much my moods swings would be 
so…awful.  And, so, I thought that I had that, but I think it’s really just the PCOS with the 
[Sigh]…irregularity of my hormones, meshing with my brain chemicals that are causing 
me to be an emotional wreck sometimes. (S.R., age 30) 
 
 I feel like I have, I mean, I have, like, anxiety and stuff like that, but I know that it’s…I 
feel like it’s very much, like, related to my cycle and stuff like that.  I have like a little bit 
of PMS symptoms.  But then, like, also, like, in the middle of my cycle, I, I do like natural 
family planning, so, I, like, chart my cycles and everything. And, in the middle, I like, 
um…like, I can tell, like, my body’s trying to ovulate, and it’s, like, failing and failing and 
failing, and I just feel like absolute crap, like, that entire…I don’t know, sometimes it 
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takes as long, you know, like, 20 days or something…and it just really affects my mood, 
and my energy, and stuff like that. And then… I just, like, cry, you know, these like mood 
swings, I guess. (M.W., age 25) 
 Other Manifestations of PCOS.  As previously stated, a majority of symptoms women 
described as being part of the PCOS experience could be classified as either reproductive, 
dermatologic, metabolic, or psychological manifestations of the syndrome.  However, a few did 
not fit neatly into these categories.  Although only a couple of interviewees described each of 
these “residual/other” symptoms, they are important to note.  For example, the association 
between PCOS and anemia, Vitamin D deficiency, and signs of virilization (e.g. deepening of 
voice and broadening of shoulders) were all described by one or two interviewees and are 
documented in the literature (Carmina & Lobo, 1999; Fraser & Kovacs, 2004; Li, Brerenton, 
Anderson, Wallace, & Ho, 2011).  On the other hand, the relationships between PCOS and sex 
drive, hypothyroidism, and migraines remain unclear (Archer, 2006; Benetti-Pinto, Piccolo, 
Garmes, & Juliato, 2013; Rellini et al., 2013).  Lastly, two participants also reported “suffering” 
from insomnia and attributed their sleep difficulties to PCOS.  Although a direct relationship 
between these two conditions is not reported in the literature, sleep disturbances have been 
associated with a number of PCOS-related conditions, including IR (Cauter, 2011) and anxiety 
and depression (Ohayon & Roth, 2003).  For this reason, it is possible that PCOS is an 
independent risk factor for insomnia, and future research should be conducted to explore this 
relationship. 
Consequences.  Interviewees’ responses to questions regarding the consequences of 
PCOS on their daily lives, the lives of significant others, and the future are reported here.  
Findings are organized by themes, which include the impact of PCOS on women’s self-image, 
work, social life, personal relationships, finances, and future health.  In addition, a few “positive 
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consequences” of PCOS were identified by interviewees and are summarized at the end of this 
section. 
Self-image.  Many women discussed the impact of PCOS on their self-image and  
described themselves as different from other women due to the various signs and symptoms of 
the syndrome.  Most commonly, women said they were “not like normal women” or discussed 
lack of normalcy.  In fact, over two-thirds of interviewees used the term normal at least once 
during their interview.   
When I finally was diagnosed with it [PCOS], it gave me a better understanding of why I 
wasn’t quite normal. Um, that’s the way I always felt. I felt not normal. (D.L., age 46) 
 
The signs and symptoms that women most commonly identified as making them feel different 
included menstrual irregularities, growth of unwanted body hair, loss of head hair, breast 
(under)development, mood swings, and higher than normal body weight or weight gain.  
Hirsutism, in particular, seemed to impact women’s feelings of themselves as female and many 
reported daily grooming routines. 
 In terms of my daily life...every morning I have to shave. Like I, I, have to. If I don’t, I 
have a five o’clock shadow.  I’m just always trying to make sure I look more feminine. 
(K.W., age 34) 
 
 Some also specifically stated that they lacked confidence and were insecure about their body. 
  I guess that’s the biggest thing is my, you know, confidence in myself.  Sometimes, like, I 
get all worried that something will happen, or my acne will come back, or I’m like OCD 
about tracking my cycles to make sure they’re all normal, and…I guess that’s, you know, 
the way it affects me…I just wish I could, like, lose weight and, you know, stay at the 
same weight without getting it back in a few months. (E.B., age 29) 
 
 I’m very insecure about my body in general.  I worry a lot about...I don’t know why, but I 
have this thing where I feel like my breast never…they never developed appropriately 
because of this stupid thing…(K.M., age 30) 
 
Also, one participant suggested that being different created a sense of isolation from others, 
while another said it created a “barrier” between her and her friends. 
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 I guess the best way to put it is something you go through where you feel isolate, ‘cause 
you’re not developing the same like everyone else. You know, when you go through your 
puberty and everything like that, you’re not developing the same. Then, once you start, 
you’re getting the male characteristics. (K.W., age 34) 
 
 My friends…I think, I think, it’s hard, because they don’t have…they have no idea what 
it’s like to not just have a healthy functioning, you know, reproductive system. And, and, 
that’s just not easy to deal with.  I don’t think.  And, I think it does create a little bit of a 
barrier between me and women in general, because I’ve always felt different, you know? 
And, I know it relates to this syndrome.  (K.M., age 30) 
 
Lastly, a few single participants remarked that their negative body image discouraged them from 
dating. 
 I didn’t want to date…my body was, honestly,… it was like a hearse. You know, I felt like 
I was stuck in this, you know, really dysfunctional and very inadequate body, and I still 
struggle with that at thirty.   I still see that… I know that I’m a, you know, norm- I’m a 
woman who deserves to be loved just like any other woman…[it’s just that] because of 
everything that’s, you know, I’ve gone through with this syndrome and everything, I still 
have to remind myself [of that].  Like, if I go out on a date with a guy, and he doesn’t call 
me, you know, it’s not because I have PCOS.  It’s not because I’m like a freak, you know?  
I still have to remind myself of that.  I’ve dated like…my serious boyfriends have made 
comments about the hair growth or have made comments about my breasts…and that’s 
horrifying, you know? You, you’re just horrified, and you just wanna like crawl up into a 
corner and you just don’t wanna date!  (K.M., age 30) 
 
Work.  Although problems with work were the least of the PCOS-related consequences 
discussed by interviewees,  they are important to note.  For example, a few women who reported 
being IR also reported difficulties fulfilling work responsibilities, mainly due to exhaustion. 
 I am tire a lot!  I have a really hard time with memory and concentration. Like, I, it 
interferes with my work, because, you know, my whole job is built around listening to 
people, and remembering what they said, and putting it to paper, or putting it in their 
computer - you know, their medical record.  And, I, I will find myself just spacing out and 
jus- and so tired…to the point where my boss will actually say to me, you know, “Go 
home!” ‘cause she sees it!  And, it’s gotten worse as I, you know, as I said.  It’s gotten 
worse over the past year. So, I definitely think those [insulin resistance and feelings of 
tiredness] are related. (K.M., age 30) 
 
Likewise, menstrual irregularities, particularly menstrual pain, resulted in some missing work 
days.  Also, one participant reported that excessive bleeding particularly interfered with her work 
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tasks.  As a trauma nurse, she described how difficult it was to fulfill her duties when she 
constantly had to run to the bathroom to change her feminine products. 
Social life.  Although most interviewees felt like PCOS had not interfered with their 
normal social activities, a few cited specific symptoms that discouraged them from going in 
public and/or being social, mainly hirsutism, alopecia, and weight. 
 [PCOS] alters whether I feel comfortable going in public, because I have to check my  
 face to see if I’ve cleaned [the]hair well enough to feel good.  If it’s a beach day or a  
 river day or something, then I have to make sure my, my, legs and arms and stuff feel,  
 feel, socially appropriate…I think that’s part of it.  I feel like society has such a  
 strong opinion about what’s appropriate for a woman that, that even if I didn’t care,  
 someone cares. (E.V., age 40) 
 
I avoid as many social gatherings as I can, so that I don’t have to deal with it…deal with 
having to pluck this or that in time to be there on that day or this event.  I have a scalp 
issue and I’m short, so everybody sees the top of my head.  So, when there’s something 
wrong with my scalp, I can’t hide it in anyway, and I have black hair, so it just kind of 
stands out.  I’m overweight, so I try to avoid, y’know, anything social, and I only go to 
the ones that I absolutely have to go to. (S.S., age 37) 
 
However, this was not surprising, because, as previously reported, several women identified 
hirsutism as their greatest concern. 
Personal Relationships.  While most interviewees described ways in which the 
experience of PCOS had positively affected their relationship with friends and family (see 
Positive Consequences), a few described circumstances in which their personal relationships had 
been affected.  For example, one interviewee, who was single, felt that her “masculine features” 
had interfered with her dating life. 
 Most guys say I’m too masculine. Usually, my features, like, just, just…some things like 
relations I’ve had…they’d be like, “Well, you just too dominant!” or “You just too 
manly!”... So, I mean, for some guys, it’s just like a turn off cause they don’t know what 
they’re dealing with. (K.W., age 34) 
 
Another participant, who was married and who reported problems with facial hair, described her 
insecurities when dating her now-husband. 
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 When I actually first started dating my husband, it wasn’t good, because I don’t like my  
 face to be touched [Laughter]…or my neck.  And, so, that was like an obstacle that we  
 had to overcome.  He was just like “Oh, you’re so cute.  I just want to touch your face.”  
 Then I kind of had a panic attack, because he touched my face. (S.K., age 32) 
 
For many women, however, their biggest personal struggle when dating was deciding when to 
disclose their diagnosis and when to explain its possible effects on fertility – a subject that many 
worried would be a “deal breaker.” 
 When my husband and I talked about getting married, I mean, that was obviously a big 
topic that we needed to cover…that, you know, I don’t, I’ve, I had never tried for 
children, but, according to the doctors, it would just never happen.  We had gone to see a 
gynecologist prior to getting married to talk about other options like the IVF and the 
drillings and all that, and, so, we, we…I wanted to make sure that, before we got 
married, that it was okay with him that we might not have our own kids. (C.Y., age 36) 
 
However, none reported that disclosing their diagnosis or possible infertility had ended their 
relationships. 
 While most women received a lot of support from their friends and family, a few felt like 
those closest to them did not understand their diagnosis and, consequently, made insensitive 
remarks and hurtful accusations. 
 Well, I find that the people around me don’t really understand what I’m going through,  
 because, they, they might see the symptoms, but they just…they don’t understand the  
 physical effects and how it makes you feel and why I’m gaining weight.  My husband  
 honestly sometimes thinks I’m a hypochondriac, but my doctor has flat out said that’s not  
 true, because of my lab results.  But, you know, that puts a strain [on you]…you know,  
 feeling like people look at me like I’m fat, you know, and, and I hate using that word.  I  
 do get that a lot. I actually didn’t talk to my sister for a year at one point, because, when  
 I was really struggling with my weight…she is super thin, herself, and she does not have  
 PCOS.  She can eat, you know, pizza and beer and run and work it off, and I have to eat,  
 you know, next to no carbs and still not lose weight. (L.P., age 42) 
 
 Lastly, of those women who reported issues with low breast milk supply, many expressed 
great sadness over not being able to bond with their child through breastfeeding. 
 It’s heart breaking.  I had no doubt in my mind that that was something that I wanted to  
 do, and, then, when they said, “I can’t,” I’m like, “That’s crazy,” you know?  I feel [like]  
 this  [is] something that has been taken away from me, you know.  And, no one took it  
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 away from me…you know what I mean?  My body just can’t do what it’s supposed to just  
 naturally do.  So I’m definitely trying to do what I can, but it’s still something that  
 definitely affects the relationship with my child. That’s definitely one of the tougher  
 PCOS things I experienced. (D.T., age 30) 
 
Finances.  When asked, “What would make living with the syndrome easier?” many 
participants answered having better health insurance coverage.  In particular, women in the study 
found it very troubling that a number of treatments needed to address PCOS symptoms were not 
covered by insurance.  These treatments included gastric bypass, IVF, laser hair removal, and 
alternative solutions, such as acupuncture.   
 For a while, I did try to buy creams and things that might remove hair temporarily better  
 than shaving or something, but, lately, I just…keep my face clean.  And, I feel like I’m not  
 in a position to spend [the] money that it would cost to, to make have a more permanent  
 type of solution. (E.V., age 40) 
 
One participant, in particular, reported that, because she had had a tubal ligation, her insurance 
would not pay for birth control pills, which she was prescribed to help regulate her hormones. 
Given the complex nature of the syndrome and the need for some to see a number of 
specialists, a few women also reported that their health insurance limited their ability to manage 
the syndrome by limiting their access to certain providers.  Similarly, others were troubled that 
they could not receive the care they needed, because they could not afford health insurance.  One 
exchange was particularly illustrative of the complexity of the problem.  This interviewee lived 
in Florida, a state that recently chose not to expand Medicaid (Ashtari, 2014). 
 Interviewee: Emotionally, it is, it’s really debilitating, because, you know, I’m married. I 
wanna do what a lot of women my age wanna do and have a family, but I can’t!  I can’t 
have children.  I mean, my husband and I have tried for…I don’t know, eight years.  It’s, 
it’s, apparently not going to happen without, you know, healthcare, which isn’t an option 
for me because I don’t qualify for Medicaid...and I need it…It’s pretty rough.  It makes, it 
makes me feel less than a woman, I guess…to not be able to reproduce is, is, is fairly 
devastating to me.  
 
 PI: So, it sounds like having better access to health care would make living with PCOS  
 easier for you? 
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 Interviewee: Well, yeah, yeah…That’d be great! Unfortunately, it doesn’t look like that’s 
gonna happen.  You know, the legislature and the state has decided not to expand 
Medicaid, and I don’t have...even though I qualify financially for Medicaid, in this state, 
if you do not have a child, you can’t have Medicaid.  That’s kind of ironic, you know? 
 (C.K., age 32) 
 
Lastly, some women expressed frustration with the “ups and down” of their weight, 
explaining that they had spent a significant amount of money to maintain a wardrobe that ranged 
in sizes.  One participant, for example, said that she had pants that ranged from size 0 to size 16.  
Others could not afford the clothes they needed to accommodate these weight fluctuations. 
 When I was in high school, we were poor.  So, when I would gain weight and then lose  
 weight, we’d get rid of one set of clothes and wouldn’t have enough money to buy more  
 clothes…so the weight gain and the hair, that was a big issue.  (E.C, age 22) 
 
 Future health.  When participants were asked how they thought PCOS would affect them 
in the future, some projected short- and long-term complications for themselves.  For example, 
of those who had not yet tried to conceive, the possibility of infertility was very concerning, and 
many worried about future pregnancy complications.  In large, these concerns emerged  from 
consultations with their provider. 
 I  mean, it didn’t really affect me until they told me that I would never have kids.  Their 
words were, that it would be…the chance of me having a child would be slim to none, and 
the chance of having a healthy baby would be pretty much nil.  (C.Y., age 36) 
 
Notably, like many others in the sample who had received such “matter-of-fact” information, this 
participant had no trouble conceiving or complications with her pregnancy. 
 On the other hand, those who were older and those who had successfully carried to term 
where more likely to express concern over long-term complications, including diabetes and heart 
disease.   A few of these participants also worried about developing cancers of the cervix, 
ovaries, and breasts.  Notably, while there is insufficient data to evaluate any association 
between PCOS and cervical cancers (Dumesic & Lobo, 2013), small studies do suggests an 
association between PCOS and cancers of the ovaries and breast (Eunice Kennedy Shriver 
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National Institute of Child Health and Human Development, 2012).  However, more research is 
needed to explore this relationship.  Surprisingly, endometrial cancer, which WLW PCOS have a 
2.7-fold increased risk for developing , was not identified as a health consequence of PCOS by 
any participant. 
Positive consequences.  As previously reported, some participants identified positive 
aspects of their experience with PCOS.  For example, a few participants felt that receiving the 
diagnosis had prepared them for possible infertility and  pregnancy complications. 
 I guess the positive is that I have not started trying to have children, and I know that I 
have this, so, I’m a little bit more prepared than some of the other women that find out 
[they have PCOS] when they’re trying to have kids.  Or, like, the fact that, they, they 
caught it at thirty, when I was not in a relationship, you know…At the time, I took it hard, 
but, in retrospect, it’s awesome that I already know that this is, this is the case, and I 
don’t have to waste a year wondering what’s wrong with me. (E.S., age 34) 
 
On the other hand, two women joked that having PCOS had probably prevented them from an 
unwanted pregnancy in their youth.  In the same vein, another suggested that she had not spent as 
much money on “period supplies,” because she had so few periods.   
 Several women also discussed how receiving the diagnosis had improved their 
relationships with their family and friends.  
 I feel like talking about it with my fiancé has kind of, like, helped our relationship, I 
guess.  Just like, as far as like, bonding [Laughter], and like, you know, seeing like, how 
much he cares about my health and stuff…(M.W., age 25) 
 
 I think it helped me and my mother’s relationship a little bit.  My mom adopted me, 
because my mom’s never been able to have children, and I was able to call her, and be 
emotional with her, and let her know that it could be very hard for me to get pregnant, 
and all these other things, and it was nice being able to have that support system there. 
(B.A., age 27) 
 
In fact, one participant expressed great happiness over helping her friend realize that her 
symptoms were characteristic of PCOS, which later led to her diagnosis and needed follow-up 
health care. 
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 Actually, through my process, this year, a friend of mine who I go to school with…I was 
just kinda talking to her, and telling her, you know, about my symptoms and stuff, and 
she’s like, “Oh, I have that same thing!”  And, I gave her my doctor’s number, she went 
to the doctor, had all the tests done, and she actually has it  too. So, if anything, me 
having it has helped someone else, because I was able to help her get on the right path, 
and, you know, get herself straightened out too. (C.A., age 31) 
 
Likewise, many reported that, by searching for answers online, they had identified and joined a 
number of social support groups, which they valued greatly.  This was not surprising, however, 
given that this sample was recruited from a SNS. 
 Lastly, a number of women reported that, because of their diagnosis, they were “more 
aware of their body.”  For some, this meant learning about the menstrual cycle and/or charting 
their own cycles to become pregnant successfully.  For others, it meant paying more attention to 
bodily cues and adopting a healthier lifestyle to improve PCOS manifestations. 
 I now know what’s going on with my body.  Like, I know if, you know, I get a pimple, like, 
“Ok, well…” [Laughs].   Or, you know, the gaining weight…like, I don’t wanna blame it 
on PCOS, but at least I know it’s a factor in it.  So, it’s like, I’m aware of it, and I know, 
like, I need to work twice as hard as like someone else to, you know, you know, stay 
healthy.  Also, I eat a lot better than I probably would normally, because I’m like, “Ok, 
this food’s not going to be great for me.” (E.B., age 29) 
 
Cause.  Although all participants expressed uncertainty about the cause of PCOS, most 
speculated that genetics contributed significantly to the development of the syndrome.  Some 
also believed that environmental factors contributed to its development. In particular, a few 
women felt like additives and hormones common in today’s foods had contributed to its 
development, and one participant suggested that more women lived with a PCOS diagnosis today 
due to dietary factors. 
 I really think that it's a combination between genetics and my environment.  I feel like  
 there’s a lot more PCOS in the population now than there was in other generations and I  
 feel like that supports [that] there's something in the environment. ..[like] growth  
 hormones that are in our food supply. (J.D., age 25) 
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Two participants also expressed the belief that BPA (e.g. bisphenol A), an industrial chemical 
that is used to make certain plastics and found in certain containers that store food and 
beverages, such as water bottles, contributed to the development of PCOS.  However, this 
association has not been reported in the literature.  Lastly, one participant expressed concern that 
WLW PCOS who breastfed their female children placed them at greater risk for developing 
PCOS. 
 It’s something that I asked, like, lactation consultants and stuff when I had my two girls. 
You know? Is there something, [Sigh] that I’m going to essentially be giving to them by 
breastfeeding them, because I know that there’s a crazy amount of hormones in breast 
milk.  So, if my hormones are screwed up, am I therefore, like, kind of transferring that to 
them by breastfeeding them? And, nobody could answer that question.  So I did decided 
to breast feed them, you know, because the other benefits kind of outweighed that risk, I 
guess, for me.  But, it was something that I did worry about, that I do worry about, 
because I don’t want them to be in this situation, y’know? (A.H., age 35) 
 
This finding, in particular, not only highlights the need for better PCOS-related patient 
information, but also the inclusion of specific PCOS-related content in lactation consultant’s 
training.  Unfortunately, little is known, in general, about the relationship between PCOS and 
breastfeeding issues, and these relationships need further attention in future investigations. 
Timeline.  Interviewees’ timeline beliefs related to their ideas about whether PCOS or its 
symptoms were acute, cyclical, or chronic.  These beliefs were assessed not only by asking 
participants about how long they believed they had lived with the syndrome, but also how long 
they believed it would affect them.   
Acute/Chronic.  While many women speculated that they had lived with PCOS “forever,” 
most believed that they experienced their first PCOS-related symptoms during puberty.  This is 
unsurprising, however, given that most reported a history of menstrual irregularities.  When 
asked how long they believed PCOS would affect their lives, about half of the participants, 
without hesitation, responded “forever” or “the rest of my life.” In contrast, others questioned 
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whether PCOS would affect them after menopause or a hysterectomy or if these circumstances 
would significantly change their experience with the syndrome.             
 It’s always felt like something was wrong, but I just...I don’t know.  I think it’s just a life-
long thing. Maybe when I go through menopause, right, then maybe it would…that, that 
everything would subside, you know...or maybe like a hysterectomy, maybe that would 
change it? (K.W., age 34) 
 
It also seemed that a few women, particularly those with a history of infertility, had not 
considered the possibility that PCOS would affect them in the long-term at all.  When asked, “Do 
you think PCOS will affect you in the future, and, if so, how?” one participant replied: 
I hope not.  We’re done having kids, so we’re not gonna have to do that again, y’know? 
(A. H., age 35) 
 
This finding most likely reflects this participant’s recent focus on fertility and need for infertility 
treatments.  However, it may also suggest that, during her clinical encounters, her provider did 
not discuss other implications of the syndrome or that she disregarded those messages.  For this 
reason, it is important that providers continue to discuss the larger implications of  PCOS, such 
as diabetes and heart disease, with their patients throughout their medical treatment, emphasizing 
any lifestyle modifications or treatments that will help prevent any future PCOS-related 
conditions. 
 Cyclical.  Lastly, when discussing symptoms, it was common for interviewees to 
described specific symptoms as being unpredictable or “coming and going” in cycles.  These 
symptoms included menstrual irregularities, painful menstruation and ovulation, mood swings, 
and acne.  This was expected, however,  because these symptoms center on women’s menstrual 
cycle.  Similarly, women also described cycles of weight gain and weight loss and issues related 
to IR, including exhaustion and cravings.  For example, one participant described the impact of 
her diet, which she adopted as a strategy to help manage her PCOS-related symptoms, had on her 
cravings: 
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 …it’s a never ending cycle.  If I get off the bandwagon and start having cookies or 
brownies or something like that, then I have to get off of them for a while for the cravings 
to go away. (A.F., 37) 
 
Control.  To access beliefs about the ability to control or manage PCOS, interviewees 
were asked what they did to manage thee syndrome and what strategies had and had not been 
helpful in the past.  In their responses, many also discussed the extent to which they felt they had 
control over PCOS and/or its symptoms (i.e. personal control).  These responses are summarized 
below. 
 Personal.   Overall, most interviewees felt like they had little to no control over their 
PCOS.  For many, these feelings seemed to arise from their inability to control one or more 
symptoms, including menstrual irregularities, alopecia, hirsutism, acne, weight issues, and mood 
swings. 
When I pluck the hairs off of my chin, I feel like I have absolutely no control…you’re 
never…I’m not ever allowed to forget what I have.  Whether I walk by a mirror and see 
that I’m overweight…you know? It’s very frustrating. (D.L., age 46) 
 
Breastfeeding problems, in particular, also seemed to affect women’s feelings of personal 
control.  
 [Low breast milk supply is] not in every woman with PCOS but you know…that’s what  
 hit me the most, because that’s something I can’t overcome, you know?  I can’t feed my  
 baby and that’s something I struggle with in my current pregnancy to accept, [inaudible,  
 cries]…I’m sorry.  (D.T., age 30) 
 
For others, the length of time they had lived with the diagnosis affected their sense of control.  
Understandably, those who were newly diagnosed felt less in control of their PCOS than those 
who had been living with the diagnosis longer.  
Right now, I don’t feel like I have much control over the syndrome, just for the simple 
fact that I’m still feeling new to the diagnosis, and they still haven’t gotten my 
medications regulated to the point where my body is working the way it’s supposed to, 
and I still haven’t lost the weight that I have that I need to lose and that I want to lose.  
 98 
 
I’d say it’s not completely out of control, but I definitely have a lot of work ahead of me. 
(S.R., age 30) 
 
In contrast, one participant reported that her physician led her to believe that there was nothing 
she could do to control or manage PCOS.  When asked, “How much control do you feel you 
have over your PCOS?” she responded: 
 Pretty much none.  Like, I… I guess I don’t think that it’s, you know…from what I was 
told by the doctors, you know, there’s nothing really to do for it, you know.  The only 
thing they were doing really for me was because I wanted to be pregnant…So, I, I guess, 
I just kinda felt, you know, it’s something that, you know, ever since, you know, at 13, 
when I got my first period, I’ve always been irregular.  So, it’s been, you know, 20 years 
that I’ve dealt with this. I, I, I just, I don’t think about it as…I just think about it as like 
part of, you know, my life…not really anything I can do anything about. (M.B., age 33) 
 
 At the same time, many interviewees reported modifying their lifestyle in order to gain 
control over PCOS or its symptoms. For most, their primary strategy was to lose weight through 
diet and/or exercise.  Although no participant identified a specific exercise regimen, participants 
named a number of diets they had adopted – all with varying success.  These included Weight 
Watchers™, Atkins™, Physicians’ Weight Loss™, the Paleo Diet™, the low glycemic index 
diet, and calorie restriction (defined as 1200 calories or less).   For many, slow or no weight loss 
discouraged them from continuing their diets and/or exercise regimens.   
 I started in February of last year.  I was like, okay, I’m gonna make some changes, you 
know?  I’m gonna eat better.  I’m gonna start, you know, exercising.  So, here, near 
home, we have this lake that’s three miles around, and everyone walks it, runs it, rides 
their bike, rollerblades, whatever. That’s like the spot to go to.  So, I started doing that 
AT LEAST three or four times a week.  I would go and either walk or, you know, jog, and 
I was eating better, and I started that in February.  By October/November, like, right 
before the holidays, I had not lost a single pound. (C.A., age 31) 
 
For others, uncontrollable food cravings made it difficult to follow a diet plan.  However, those 
on Metformin® reported greater success. 
 After I got on Metformin, I lost weight. So, I mean, I…before, diet and exercise really 
didn’t do a whole bunch for me, and, then, magically, I, you know, I had lost 10 pounds, 
and didn’t do anything different, quote unquote. But I lost some of my sugar cravings, so, 
it made life a lot easier. (A.F., age 37) 
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Overall, most participants, regardless of their weight loss strategy, reported little to moderate 
success. 
 For some, receiving their PCOS diagnosis helped them gain a small sense of control.   
 It's good to know what it is that I have.  All these weird things were happening to me, and  
 I didn’t know why, like, why I couldn’t control the acne or the hair that grows on me. It's  
 nice to have like…this is why and to use that info to be able to help myself more, I guess.  
 (J.S., age 33) 
 
Likewise, for one participant, finding the right healthcare provider made her feel more in control. 
 I don’t know that I’ve ever trusted another doctor as much as I trust my GP now, because 
she was really into women’s medicine, and she took the time to diagnose me with PCOS. 
Whereas, you know, my history with doctors before was kinda, okay, you’re fat, lose 
weight.  That’s pretty much it. And the lactation consultant, we’ve become lifelong 
friends.  She worked with me to use supplemental nursing systems - all sorts of fun stuff.  
I guess it’s because it’s, you meet, when you have to do things differently than other 
people, and you find a support system, it makes life nice. (A.F., age 37) 
 
Unfortunately, few participants described their clinical experiences positively and most 
expressed frustration with their provider(s) (see Emotional Representations, Frustration). 
 Lastly, to gain control, one participant reported adopting alternative therapies, including 
acupuncture and herbal remedies.  Although she did report great success with these alternative 
therapies, which she defined as spontaneous conception, she did admit that these therapies were 
costly.  
Treatment.  Almost all participants identified ways in which their PCOS had been 
medically managed.  These experiences were largely dictated by the interviewee’s symptoms and 
medical history and included one or more of the following: oral contraceptives, infertility 
treatments (see Table 19), hair removal treatments, acne treatments, Metformin®, and 
psychiatric drugs.  Among these, oral contraceptives and Metformin® were most commonly 
discussed.   
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Because almost all interviewees reported a history of menstrual irregularities, it was not 
surprising that almost all reported taking oral contraceptives.  Although most of these women 
reported that oral contraceptives had effectively treated their symptoms, by either eliminating 
them completely or lessening their impact, a few questioned if and how these medications 
“treated” PCOS. 
 I don’t feel like doctors even understand or are willing to take the time to figure out what 
is really wrong - to treat what’s really wrong versus just treating symptoms. Like the 
whole thing with, I mean, I’ve been to several different gynecologists who have told me 
that I’m “treating it” by being on birth control.  Well, I’m not treating anything by being 
on birth control.  I’m just making, you know, altering my hormones so I get my period 
every month.  I’m not treating whatever is causing my hormones to be out of whack to 
begin with, y’know? (A.H., age 35) 
 
 I wish the medical community was more aware of how to deal with it besides just giving  
 you a birth control pill, which I don’t think really helps the problem.  I think it just masks  
 some of the symptoms, you know? (D.H., age 37) 
 
While it remains unclear what type of “treatment” would be more acceptable to these women, it 
is seems that these beliefs were based, at least partially, on a misunderstanding of PCOS and its 
recommended treatments.  To avoid these misunderstanding and address patient concerns, 
providers should take time to explain the diagnosis and goals of treatments. 
 Many women reported medically managing their symptoms through a combination of 
oral contraceptives and Metformin®, an insulin sensitizer commonly prescribed to WLW PCOS 
with hirsutism, IR, metabolic syndrome, diabetes, and/or menstrual irregularities (Moll et al., 
2007).  Among those who reported taking Metformin®, quite a few reported that it “jump 
started” their weight loss and/or helped with their weight loss by helping control cravings. 
 After I got on Metformin, I lost weight.  So I mean, I, before, diet and exercise really 
didn’t do a whole bunch for me, and, then, magically, I, you know, I had lost 10 pounds 
and didn’t “do anything different.”  But, I lost some of my sugar cravings, so, it made life 
a lot easier.  (A.F., age 37) 
 
 101 
 
Also, several women reported that Metformin® helped regulate their cycles.  In fact, a few 
women, who had conceived spontaneously (i.e. without infertility treatments), credited 
Metformin® for their success. 
 Last year, they put me on Metformin, and, all of a sudden, a year later, we got 
pregnant…I mean, we just never thought that it was, you know, possible… I’ll always 
give Metformin a lot of credit - that’s really, that’s what helped me get pregnant. 
 (C.Y., age 36) 
 
Similarly, one participant with low breast milk supply believed that Metformin® had 
significantly helped her with her breast milk production. 
 I know the Metformin has helped greatly with the need for sugar, and, then, it also has 
helped, because Metformin is, I understand a diabetic medicine, but it’s also…the 
original form of Metformin was made from goat’s rue, and Goat’s Rue is a type of herbal 
supplement that helps grow breast tissue, and that has helped so much…especially my 
right breast - it’s about a size and a half smaller than my left.  [Taking Metformin] 
literally grew my right breast about a cup size from when I started taking it to the 
present, right now.  So, that’s helped me so much.  I’m so grateful for Metformin and 
Goat’s Rue.  And, Metformin’s free and Goat’s Rue is rather expensive. (E.C., age 22) 
 
Unfortunately, for some, the side effects of Metformin®, mainly nausea and diarrhea, were 
intolerable.  Consequently, they stopped taking the medication. 
 I had really bad, like, reactions to it. Like, I’d get sick really, really bad.  Like, eating, 
like, bland food, I’d get sick, so, I, I told my doc… I was up to two thousand milligrams 
and I’m like, “I cannot take this! Like, I get sooo sick,” and I’m like, “It’s not even worth 
it.” (E.B., age 29) 
 
Lastly, similar to the findings on oral contraceptives, a few participants questioned if and how 
Metformin® treated PCOS.  When asked, “What would make living with PCOS a little easier?” 
one participant replied: 
 I would say if…if there was a medicine that was geared specifically towards PCOS 
patients, ‘cause I feel like right now we have to kind of use diabetic medicine or use birth 
control, nothing that is recognized for PCOS sufferers and I would really like there to be 
something that could help with all the symptoms of PCOS… (L.P., age 42) 
 
Again, this response seems to reflect, in part, a misunderstanding of PCOS treatments. 
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To control their hirsutism, most women in the study invested time and money in 
treatments.  While some women bleached unwanted hairs, several reported shaving, waxing, 
plucking, and applying various creams.  In particular, a few women used Spironolactone® and 
reported satisfying results with this prescription medication.  Others also reported having more 
costly procedures, such as electrolysis and laser hair removal.  Unfortunately, women reported 
less success with these procedures and one participant described laser hair removal as a “waste 
of money.” 
 Oh, laser hair removal…I think that’s the biggest joke.  I mean, they do tell you when you  
 go and you sign the waiver, you know, for the risks and stuff, they do say it might not  
 work for some women.  I did not think it worked for me.  I think it grew back.  
 (J.S., age 33) 
 
Lastly, a few participants reported taking anti-depressants and/or anti-anxiety 
medications to address their mental health issues.  All reported that these partially or completely 
alleviated their symptoms.   
 I wish I wasn’t on Lexapro®, but, like, for people that do have problems with mood and 
stuff like that, I mean, SSRIs are really good, and, I was, I was amazed when I first 
started taking that.  I was like, “Wow!”  That worked for me, just, like, almost 
immediately. (M.W., age 25) 
 
 Cure.  To access beliefs about the cure of PCOS, interviewees were asked if they thought 
there would ever be a cure, and, if so, what that cure might be.  In response, approximately half 
of interviewees responded that there would never be a cure, but hoped for better management 
solutions.  Most often, these women emphasized that PCOS was a “syndrome,” not a “disease,” 
explaining that it could be managed, but not cured. When asked, “Do you ever think there will be 
a cure for PCOS?” one interviewee responded: 
 That would be great, but I don’t, because it’s pretty complicated, you know? I mean, it, 
it… there’s so many different aspects to it that I’m just not sure that it’s the kind of thing 
that you can necessarily cure or if it’s something that, umm, you just lessen the symptoms 
of or try to avoid by lifestyle changes, I guess. (K.C., age 32) 
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 In contrast, the other half expressed the belief that, one day, there would be a cure for 
PCOS but identified a number of barriers to its discovery.  For example, a few women felt like, 
because PCOS was a condition specific to women, it was unimportant to the medical community.  
One exchange was particularly illustrative of this belief: 
 PI: Do you think there will ever be a cure for PCOS? 
 
 Interviewee: I would hope, but I don’t think so…It’, a, I think small on the scale  
 compared to a lot of things that doctors really want, to, to, you know, investigate and try  
 to cure.  
 
 PI: And why do you think that is? 
 
 Interviewee: Because women are lesser? [Sigh] I don’t know… if it was prostate cancer  
 and, you know?  They’ve got a nice little pill for men that can’t get an erection, you  
 know?  I just, I don’t know that it’s, it’s a…on the grander scale, for a lot of doctors to  
 really worry about. ..I guess, maybe if it affected their daughters or their wives they  
 would maybe care little more.  But, it’s where…it’s not a male-focused thing.  I just don’t  
 think that it quite has as much importance in our world. (D.L., age 46) 
 
On the other hand, a few felt that PCOS had received less attention by the medical community, 
because PCOS was less important than other chronic conditions, particularly cancer. 
 I don’t know.  I’ve never had cancer or anything like that.  I would think that cancer 
would need a cure faster than PCOS, but, I mean, it’s, it’s hard to live with and 
sometimes it’s frustrating, but, I don’t think it’s on the same level as cancer. 
  (C.A., age 31) 
 
Still, other felt PCOS had not received sufficient attention, because awareness of PCOS was low 
among providers and the general public.  Lastly, a few felt that a cure for PCOS would be 
“discovered” accidentally. 
 Do I think there will be a cure?  Yeah, if there’s enough people complaining [Laughter].  
 Right?  There’s no, like, walks for PCOS or anything like that.   I think if there’s, like, 
  enough funding for research into it.  But, you know, there is always a chance that, like, 
  somebody will be researching some other problem, and then they will find, you know… a  
 solution will come up when they are looking for, you know, an answer to a different  
 problem. (S.G., age 39) 
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Residual/Other.  Lastly, a few interviewees described PCOS as a common condition 
among women.  By definition, this illness cognition, coded perceived prevalence, does not fit 
into any of the illness perception domain suggested by Leventhal (1984) , Moss-Morris (2002), 
or their colleagues.  The implications of this finding are further discussed in Chapter 5. 
Emotional Representations of PCOS.  The CSM posits that, when a person is 
confronted with an illness, he/she will develop emotional representations of illness in addition 
(and parallel) to cognitive representations of illness.  To assess interviewees’ emotional 
representations of PCOS, the following questions were asked: “What are your thoughts about 
having PCOS?” and “To what extent do you feel that your PCOS influences how you generally 
feel?”  In response to these questions, many women expressed their feelings and/or emotions 
related to their symptoms or anticipated symptoms.   While these responses provided invaluable 
information, unsolicited emotional expressions from participants were actually the most striking.  
For example, frustration was a dominant theme of this dissertation and was expressed most often 
when women described their experiences with their health care providers and clinical care – 
content that was also unsolicited.  All responses are summarized below. 
Response to PCOS and its Symptoms.   When asked, “What are your thoughts about 
having PCOS?” most interviewees responded that having PCOS was depressing, sad, and/or 
overwhelming.  Throughout the interviews, respondents also described “struggling” with one or 
more symptoms of PCOS and/or emphasized that PCOS was an “emotional struggle” in addition 
to a physical one.  In particular, women were annoyed, frustrated, and/or extremely embarrassed 
by PCOS-related symptom that affected their physical appearance.  These symptoms included 
menstrual irregularities, weight issues, acne, hirsutism, and alopecia. 
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 I’ve met lots of people with PCOS, and I think, generally, people get really frustrated  
 with the syndrome.  I know, for me, it’s the hair on my chin, dramatic weight gain before 
  I was diagnosed, and my hair falling out. (E.A., age 29) 
 
 It was annoying when my face would break out for no reason…other than that…I had no  
 idea when to expect my period.  That was the most annoying, because, you know, going  
 into school and you’re in the middle of class and your period starts, and it shouldn’t start  
 for another two weeks. That was annoying. (E.C., age 22) 
 
Likewise, among those who reported a history of infertility, women reported being frustrated, 
depressed, and/or devastated by the experience. 
 Well, with my son, I did have some trouble, because I wasn’t ovulating, and I tried to.   
 My doc put me on birth control to help control some of the symptoms of PCOS, but when  
 I came off birth control, I didn’t ovulate.  I mean, I never did before I was on birth  
 control, but it took me 6 months, and I didn’t ovulate the entire time, and they had to try  
 to induce my cycle with fertility drugs.  So, it was obviously frustrating when you so  
 adamantly wan to conceive and can’t. (D.T., age 30) 
 
Also, women with low breast milk supply often described their experience as being depressing, 
devastating, and/or heartbreaking. 
I was very, very depressed when I couldn’t feed my daughter…and then I ended up using 
a medication to bring up my supply…so, I gained like 15 pounds on that medication.  So, 
like, all of my baby weight that I lost, I put right back on.  And, so, I really hate pictures 
after my daughter is 6 months old.  And, that’s pretty…sad for someone who works so 
hard to lose weight and be healthy, and, for that to be, really just out of their control…I 
don’t know…definitely a lot of depression and really bad days during the time while I 
was still breastfeeding. (S.K., age 32) 
 
One participant, in particular, expressed guilt over having to feed her baby formula. 
 Well, and they tell you so much, “Oh, well, you should breastfeed your baby,” or, you  
 know, “You’re doing a horrible thing by feeding your baby formula.” You know what I  
 mean?  It’s just, like, they tell you that’s the one thing you definitely want to do, but I  
 can’t.  And, you get a lot of stigma, you know, in public, when your feeding your baby a  
 bottle, when everyone else around you is breastfeeding around you. You know?  So, it’s  
 just…it’s definitely a challenge… [cries] (D.T., age 30) 
 
 A number of interviewees also expressed concern and worry over PCOS-related 
symptoms that they had not yet experienced.  In particular, those with no history of infertility 
worried about their ability to conceive in the future. 
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 When I was first diagnosed, I was very, very upset.  I now don’t see it as a, you know, as, 
as the end all.  I know lots of women that have, you know, babies that have PCOS.  I 
guess, it’s just, it’s a little bit of a rollercoaster, you know?  I mean, some days I feel like 
I’m gonna be fine.  I’m gonna have a baby no problem, and, you know, other days, it’s 
like… I think about, on my honeymoon, I’m probably going to be on ovulation medication 
to make sure I ovulate.  You know? That’s, that’s upsetting.  (E.S., age 34) 
 
On the other hand, many were thankful for not experiencing all PCOS-related symptoms, but 
worried that they might in the future. 
 I have the hair issue.  I have like, the slight fuzz on my face, but it’s not noticeable, at all.   
 I wonder as I get older, if that’s gonna develop into the more masculine hair.  You know,  
 darker.  I don’t…I know someone who had, like, a thick treasure trail, for lack of a better  
 word, and I’ve never had to deal with that.  I’ve been thankful, but I wonder, as you grow  
 older…if I’ll end up with all the, uh, crazy hair stuff goin’ on. (A.F., age 37) 
 
 I, I’ve, I’m really lucky in that way and a lot of people have a lot of pain associated with  
 it, but I don’t, I never had that. (C.Y., age 36) 
 
One participant, in particular, was afraid of one day losing her hair. 
 The hair loss, I’m really worr- that probably sounds really vain, but I’m really worried  
 about the hair loss.  The acne…I have not had an issue with that.  I don’t think it would  
 be as bad as the hair loss though. That’s the one [symptom] I’m most afraid of.  
 (K.C., age 32) 
 
Response to Providers and Clinical Care.  As previously reported, frustration was a 
dominant theme of this dissertation, and one main area of frustration centered on interactions 
with health care providers, which often resulted in a lack of confidence or trust in providers.  
Overall, women described their care as incompetent and/or insensitive and attributed this 
experience to their providers (lack of) knowledge and/or training. 
For some, their frustrations started with their diagnosis.  For example, several participants 
reported reluctance from their providers to conclude that symptoms were abnormal and 
warranted further investigation. 
I was very frustrated early on, because I was, you know, I was just told that I was  
perfectly fine - that some women just have problems with their periods. (D.L., age 46) 
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In fact, a few women interviewed felt cheated by their delayed diagnosis, questioning whether 
they missed an opportunity to start treatments or adopt lifestyle changes that might have altered 
the course of their PCOS. 
  I wish I would have been diagnosed earlier.  I wish I would have been told earlier about 
it.  I wish I wouldn’t be 27 and just finding out about it.  I really feel that there were 
several opportunities when I was younger to have known about it, like, when I was 15/16, 
going in for my birth control for the first time, because my hormo-, because my periods 
were out of whack, and then again when I had an ectopic pregnancy.  I really think that 
they could have found it then and told me, and I could have made positive changes in my 
life back then, rather than waiting and getting heavy like I did.  I got, I, I, between the 
ages of 18 and 22, I got really, really heavy, um, and then lost a lot of weight.  So, I think 
I wouldn’t have done those things, and I wouldn’t have harmed my body in the way that I 
did, had I known about it before. (B.A., age 27) 
 
 Several women also voiced frustration over the (lack of) information and support they 
received at the time of their diagnosis and follow-up clinical encounters.  When asked, “What 
would make living with PCOS easier for you?” one interviewee responded: 
 I don't know…just more support and a better knowledge base for health care  
 professionals.  I know it was a challenge for me when I knew more than, like, my  
 lactation consultant about PCOS and milk production. I know, that, that was frustrating. 
  It’s frustrating if you go to a nutritionist and they have no idea. Just more awareness  
 and knowledge among health care professionals. (E.A., age 29) 
 
For others, it was the physician’s delivery of PCOS information that they found most frustrating. 
 I feel very frustrated with the treatments that we’re off-, that we have to…I mean like, I, I, 
I understand, I understand that there’s all this information out there, and there’s all these 
different tests you can do, and there’s all these different medications you can take, but, I, 
I still feel very confused about all of it.  And, I still struggle with finding what is wrong, 
you know? I, I, I just, I still wanna know, like, I wish they could say, “Okay, well, it’s 
your estrogen,” or “You’re, you’re…this is why you have hair growth.”  And, and, they 
don’t ever really do that, you know?  They just say, “Well, take this pill!” And, you just, 
you know, don’t…I mean, I literally had one doctor…I was twenty-one, and I had this - I 
was by myself, and this doctors like, “You have to take Metformin!” and “You have 
polycystic…”- this was when I was officially diagnosed.  He was like “You have 
polycystic ovarian syndrome, and you have to take this medication.  If you don’t, you’re 
gonna have diabetes, stroke,” you know, “heart attack,”…I don’t know.  He listed all 
these things, “heart disease, and this is the guide you have to follow.”  And, he literally 
gave me a piece of paper that said nuts and cheese and water.  I mean, it was a joke -  the 
list.  I mean, I’m not even ex- I’m not exaggerating!  I might be exaggerating, like, just a 
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very small amount, but that was literally the list of foods that I could eat.  And, when 
people give, you know, when doctors…and that’s how they treat us, you know, with the 
syndrome.  It’s like, it’s a joke!  It’s like, this is not treatment!  You know? (K.M., age 30) 
 
 Also, most women interviewed were frustrated by their provider’s inattentiveness to the 
symptoms they found most troubling.  For example, one participant, who worried about having a 
sufficient breast milk supply (because her breast were asymmetrical), was disappointed and upset 
by her prenatal consultation with her provider. 
 Even in my current pregnancy, when I went to my doctor, and he said he’d check for  
 asymmetry, and then he just went on through the exam, and I’m like “Really?! You didn’t  
 find the asymmetry you were looking for?”  But, I just, like, I don’t know.  I don’t think  
 doctors care.  They just say, “Oh well!  You can’t breastfeed.  That’s okay.  There’s  
 formula.”  But, there’s more to it than that.  It’s very upsetting, you know,  not being able  
 to do it. (D.T., age 30 ) 
 
In fact, one participant reported terminating treatment and her relationship with her provider after 
years of hormone therapy with no improvement. 
 I had lots of trouble with bleeding, and they put me on birth control, and I was just told,  
 “ Oh, its hormones, its hormones, its hormones.”   They kept me on birth control for a  
 year, and it was low dose, and I was fine, and then all of the sudden, it went hay-wire,  
 and I just bled and bled and bled and bled. So, finally, they got me stopped, and I got  
 frustrated with the doctors, and I quit going. (D.L., age 46) 
 
At the same time, it was the perception of most women interviewed that providers were 
“symptom-focused.”  When asked, “What would make living with the syndrome easier for you?” 
one participants replied: 
 Well, I guess, if the doctors had been more helpful with explaining what it is and what 
could be caused from and what I can do…I don’t even know.  I mean…like do you just 
treat the symptoms of the problem?  I don’t even know, like, ‘cause you, like, you go to 
the doctor complaining, like, “Oh, I don’t have a regular period” and then they fix that. 
Or, you go and complain about, you know, some other issue, and they just fix that issue.  
I don’t know. I feel like they’re not being overly helpful.  In terms of solving, sort of like, 
a diagnosis, of treating, like an overall problem.  They just wanna go symptom by 
symptom. (J.B., age 33) 
 
 109 
 
In particular, almost all felt that their providers were too focused on fertility.  Notably, this belief 
was prominent even among  women who were deeply concerned with their future ability to 
conceive. 
 Like I said, the concern with infertility-  I worried about it, you know?  ‘Cause, my doctor  
 at 17 said, you know, “We’ll worry about this when you wanna have kids.”  So, my  
 thought at 17 was, well, what if there was something they could be doing now to ensure  
 that I would be able to have kids? They’re seriously not gonna worry about it or do  
 anything for me over the next 10 years? (J.F., age 33) 
 
I was having very irregular cycles, and my mom took me to the doctor, and they did an  
ultrasound and saw the cysts, and said, “This is what you have.”  And, they put me on a  
birth control pill, and that was when I was 14 or 15 or something…yea, 14 or something  
like that.  So, they just told me right off the bat and didn’t really give me support for it.   
They just told me, “This is what you have, and you’re going to have fertility problems in  
the future.  I’m just like, “Thanks.”  I’m just, like, I don’t want to have kids, you know,  
because I’m 14.  I’m not really thinkin’ about that. (D.T., age 30 
 
One interviewee, in particular, was distressed and outraged by her providers’ disinterest in 
continued care after she successfully bore children. 
 I feel like…I mean, like, every doctor that I’ve ever talked to…I feel like has completely 
blown me off.  You know?  Like, “Oh, well, you had to do fertility treatment, but you still 
had your kids, so…” kinda like, “…well, what are you complainin’ about? You know?  
You have your period, because, you know, you’re on the pill.  So, what are you 
complaining about?”  Y’know?  “ You just need to try harder to lose weight.”   Like, it’s 
just not, right… I think that, for me, the focus when I try to talk to my doctors about 
PCOS, like, whatever my specific complaint is…“It’s not really an issue anymore, so why 
are you still talking to me about this?”  Y’know?  “Like, why are you still bringing up 
your PCOS when you successfully had kids, and, you know, you’ve gotten laser hair 
removal? You just need to try harder to lose weight.”   Not so much, like, “Let’s, you 
know, try some things to improve your overall quality of life.” (A.H., age 35) 
 
Is There a Relationship Between Women’s HRQoL and the Illness Perceptions They Have 
About PCOS? 
As previously described, the literature suggests that PCOS has a significant negative 
impact on HRQoL (Jones et al., 2007; Trent et al., 2002).  Yet, few factors that contribute to this 
reduction have been explored (Barnard et al., 2007).  In one study, however, Trent and 
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colleagues (2002) report that perception of PCOS severity, not actual severity, correlates directly 
with HRQoL.  This finding emphasizes the need for further investigations into the perceptual 
factors related to HRQoL.   
Because illness perceptions of PCOS may be a promising determinant of HRQoL among 
WLW the syndrome, the relationship between illness perceptions and HRQoL was explored 
using the following protocol: First, each interviewee’s score on each of the SF-36 domains was 
calculated.  Then, these scores were compared to the scores of the sample mean.  For each 
dimension, interviewees could fall either below the sample mean (i.e. Group “Below”) or above 
the sample mean (i.e. Group “Above”).  Lastly, for each domain, the responses of each group 
(“Above” vs. “Below”) were compared.  Differences among groups are summarized below by 
HRQoL domain.   
As previously stated, it is important to note that, because the SF-36 measures HRQoL and 
because HRQoL is personal to each individual, it is not appropriate to label scores as “good” or 
“bad” (Sterling University, 2012).  Instead, here, illness perceptions of those who report lower 
levels of functioning on each domain are compared with those who report higher levels of 
functioning on the same domain.  This analysis plan was discussed at length with one of the lead 
investigator’s co-major professors and was determined to be the best strategy to explore the 
relationships between HRQoL domains and illness perceptions. 
General Health Perceptions.  General Health Perception items measure each 
respondent’s (1) evaluation of her personal health and (2) belief that her health will either 
improve or worsen in the future.  In this study, the mean score of the total sample was 50.8 
(SD=22.7).  This means that, in general, about half of the sample agreed or mostly agreed with 
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the following statements and the other half disagreed or mostly disagreed with the following 
statements: 
 I seem to get sick a little easier than other people. 
 I am healthy as anybody I know. 
 I expect my health to get worse. 
 My health is excellent. 
These findings may easily be explained by the nature of PCOS.  As previously stated, the clinical 
spectrum of PCOS varies widely (Balen et al., 1995).  At one end of the spectrum are women 
who are largely asymptomatic, and, at the other, are women who present with most 
manifestations of the syndrome.  As such, it would be expected that, in general, some women 
would score higher and some women would score lower on general health perceptions, resulting 
in a mean score that fell roughly in the middle. 
 Given the above rationale, we would also expect that those who fell below the mean 
(n=13) and those who fell above the mean (n=21) would differ on the domain Symptoms, 
specifically on the number of symptoms reported.  However, when the similarities and 
differences between the groups were investigated, it was found that type of symptom, not number 
of symptoms, related to the General Health Perceptions score.   That is, those who fell above the 
mean spoke at length about the physical manifestations of PCOS, including weight issues, IR, 
hirsutism, and acne.  On the other hand, those who fell below the mean emphasized the impact of 
PCOS on their mental health.  Specifically, those who fell below the mean were more likely to 
report depression, feelings of worry, and constant stress.  In short, these findings highlight the (1) 
impact of mental health issues on General Health Perceptions and (2) importance of providers 
recognizing and addressing the mental health needs of their patients with PCOS. 
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 Those who fell above the mean also described better outcomes of PCOS treatments.  For 
example, women who fell above the mean reported that diet, exercise, medication, and laser hair 
removal treatments were effective at reducing PCOS symptoms.  On the other hand, women who 
fell below the mean were more likely to report no or little weight loss with changes in diet and 
increased physical activity.  Likewise, they were more likely to express the belief that 
medications “masked” the underlying causes of PCOS and that medications commonly 
prescribed to address PCOS-related symptoms, such as Metformin and birth control pills, were 
not “real” PCOS treatments.  While the reasons that lifestyle modifications and PCOS treatments 
failed more often in women falling below the mean remains unclear, the latter finding identifies 
the need for better patient information on available treatments – specifically, information that 
explains why certain medications are prescribed to address PCOS-related symptoms and how 
these medications work.  Also, those who fell below the mean were more likely to express 
frustration with their providers for being inattentive and symptom-focused.  Again, this finding 
may reflect providers’ own knowledge or PCOS or medical specialty.  It also may reflect a 
greater healthcare delivery systems issue.  Meaning that, in general,  women’s health services are 
currently separated into reproductive and non-reproductive services without provisions of 
coordinated care (Weisman, 1997).  Consequently, it is rare that women receive comprehensive 
care during one health care visit. 
 Lastly, while both groups shared the general belief that PCOS was a chronic condition, a 
few women who fell above the mean stated either (1) that they had not given much thought to 
how PCOS would affect their lives after they were done childbearing or (2) that they had stopped 
caring about how PCOS affected their lives once they completed childbearing.  For example, 
when asked how she thought PCOS might affect her in the future, one interviewee who fell 
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above the mean and who expressed a desire for more children responded, “I guess, I really, other 
than fertility, I don’t know how else it would affect me” (J.B., age 33). Another woman who fell 
above the mean and who stated that she was “done having children” responded: 
 Gee, I think, I figured, as long as I am a woman I would, I would…I haven’t treated it…I 
treated it with, with, birth control pills initially. But, once I started having kids, I just 
figured, what the heck!  I’m married, I can take ibuprofen when needed, and I could give 
a fuck about the hair on my chin [Laughs]. (E.V., age 40) 
 
On the other hand, an interviewee who fell below the mean was the only woman who expressed 
anticipation that her health would continue to deteriorate.  When asked how long she thought 
PCOS might affect her, she responded: 
 I think for the rest of my life…I see a gradual decline in my quality of health, and, so, I 
mean, I, I, think it’s gonna just keep on getting worse…(L.P., age 42) 
 
Taken together, these data suggests that infertility or fear of infertility have important 
implications in PCOS.  Note that the relationship between illness perceptions and fertility status 
is further explored under the next research question in this chapter, Does the experience of 
infertility impact the illness perceptions that women hold about their PCOS? 
Vitality.  This domain asks respondents to report energy levels and general feelings of 
tiredness during the past four weeks.   In this study, the mean score of the total sample was 34.4 
(SD=18.1).  Among interviewees, 14 and 20 interviewees fell below and above the mean, 
respectively.  To explore the differences between these groups, interviewees’ responses under the 
child code Exhaustion were first reviewed.  Surprisingly, both groups equally described low 
energy levels and feelings of tiredness during their interviews.  This prompted a review of the 
specific items that measured the sample’s Vitality.  In general, those who fell above the mean 
reported that, some of the time, they felt of pep and had lots of energy, but at other times, they 
equally felt worn out and tired.  On the other hand, those who fell below the mean generally  
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(1) felt worn out and tired a good bit of the time and (2) felt of pep and had lots of energy a little 
of the time.  In summary, few in the total sample report feeling of pep or having lots of energy a 
good bit of the time, most of the time, or all of the time.  In other words, both groups reported low 
levels of functioning on Vitality, explaining the similarities in interview responses.  One 
possibility for this finding, however, may be that specific manifestations of PCOS, such as 
depression and IR were common among the sample and may result in low energy and feelings of 
tiredness.   
Physical Functioning.  This domain asks respondents to report current limitations on ten 
mobility activities, such as walking specified distances, carrying groceries, and bathing, and 
dressing.  In this study, the mean score of the total sample was 81.2 (SD=22.9), meaning that, in 
general, most respondents did not feel like their mobility was limited by their physical health.  
For this reason, no major differences in illness perceptions between groups were expected.  
However, it is unsurprising that those who fell dramatically below the mean (n=3, scores ranging 
from 0 to 20) reported painful ovulation and/or menstruation.  For example, one of these 
participants described the pain as “debilitating” and reported often being bedridden during 
menstruation.  Whereas, those who fell above the mean (n=20), in general, either did not report 
pain or only reported minor “pinching” or cramping during ovulation and/or menstruation.  
Similarly, those who fell above the mean were more likely to report exercising as a strategy to 
alleviate PCOS-related symptoms, even though both groups equally reported weight issues.  
These findings highlight the importance of providers identifying and addressing any perceived or 
real physical limitations or WLW PCOS to promote physical activity among this population. 
Role Limitations Due to Physical Health.  This domain asks respondents to report 
problems with work or other daily activities they have experienced in the past four weeks as a 
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result of their physical health.  In this study, the mean score of the total sample was 70.6 
(SD=37.2), meaning that, in general, few respondents reported feeling like their daily activities 
were limited by their physical health.  However, it was puzzling that no major differences were 
found between the illness perceptions of the two groups.  To further explore these findings, each 
transcript was reread, with special attention paid to the six interviewees who scored a zero (0) on 
this domain, meaning that they answered Yes to all of the following questions: 
 During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health? 
o Cut down the amount of time you spent on work or other activities. 
o Accomplished less than you would like. 
o Were limited in the kind of work or other activities. 
o Had difficulty performing the work or other activities (for example, it took 
extra effort). 
Upon review, it was found that, among the interviewees who scored a zero (0) on this domain, all 
but one discussed a recent illness or medical complication that was unrelated to their experience 
of PCOS.  These included bronchitis, stomach ulcers, blood clots, and a serious antibiotic-
resistant infection.  The remaining interviewee who scored a zero (0) was 6 days post-partum.  In 
summary, domain scores reflected role limitations due to physical health issues that were not 
related to PCOS, highlighting a disadvantage of using a generic instrument to measure HRQoL.   
As a reminder, there are two measures that have predominately been used to capture the 
HRQoL among WLW PCOS: (1) the Quality-of-Life Questionnaire for Women with Polycystic 
Ovary Syndrome (PCOSQ) and (2) the Short Form- 36 (SF-36).  At first glance, it seems that it  
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would have been ideal to use a PCOS-specific instrument to measure the quality of life of WLW 
PCOS in this study.  However, given (1) that the PCOSQ is an illness-specific measure that 
emphasizes the symptoms of PCOS, (2) that the primary aim of the dissertation was to identify 
the illness perception of WLW PCOS, and (3) that a domain of illness perceptions is identity (i.e. 
symptoms women associate with the syndrome), the PCOSQ was not used in this study to 
prevent priming of interviewees.   
Bodily Pain.  This domain asks respondents to report (1) the amount of bodily pain and 
(2) the extent to which this pain has interfered with their work inside and outside of the home in 
the past four weeks.  In this study, the mean score of the total sample was 66.3 (SD=24.0), 
meaning that, in general, respondents reported that they had mild bodily pain in the past four 
weeks and that this pain had mildly interfered with their work and other activities.  As expected, 
those who fell below the mean (n=16) were more likely to report painful ovulation and 
menstruation than those who fell above the mean (n=19).  Notably, no other major differences in 
illness perceptions between groups were identified. 
Social Functioning.  This domain asks respondents to report the extent to which physical 
health or emotional problems have interfered with their normal social activities with family, 
friends, and other social groups in the past four weeks.  In this study, the mean score of the total 
sample was 67.4 (SD=26.8), meaning that, in general, most respondents reported that their 
physical health or emotional problems either moderately or slightly interfered with their social 
activities.  To first explore the differences between groups, the lead investigator searched for 
themes that explained how each groups’ physical health interfered with their normal social 
activities.  However, no major differences were found.  On the other hand, when the lead 
investigator searched for themes that explained how each groups’ emotional health interfered 
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with their normal social activities, it was found that those who fell below the mean (n=17) were 
more likely to report depressive symptoms and to report that these symptoms interfered with 
their relationships. 
 I think PCOS has affected, you know, every aspect of my mental health. So, for somebody 
who is as severely depressed as me and [who] has pulled away from people as much as I 
have…I mean, I sabotage relationships with friends and family members all the time - to 
the point where I think it’s pretty much just me and my husband now. So yeah, yeah, I 
think it’s, it affects, its affected relationships. (C.K., age 32) 
 
Again, these findings highlight (1) the impact of PCOS on mental health and (2) the need for 
mental health services among women with the syndrome. 
Role Limitations Due to Emotional Problems.  Sample scores on this domain also 
highlighted the impact of PCOS on mental health.   These items asked respondents to report 
problems with work or other daily activities they had experienced in the past four weeks as a 
result of their emotional health.  In this study, the mean score of the total sample was 60.3 
(SD=42.7).  Like those who scored below the mean on Social Functioning, those who scored 
below the mean on Role Limitations Due to Emotional Problems (n=16) were more likely to 
report depression and to report that this depression was either “chronic” or “debilitating.”   
Interestingly, these women were also more likely to report “visible” manifestations of PCOS, 
including alopecia, acne, acanthosis nigricans, and weight issues, suggesting that these 
symptoms in particular may have a greater impact on women’s emotional health than “non-
visible” symptoms. 
Emotional Well Being.  Lastly, this domain asks respondents to report how often they 
felt nervous, down in the dumps, calm and peaceful, downhearted, and happy in the past four 
weeks.  In this study, the mean score of the total sample was 59.1 (SD=20.9).  Like those who 
scored below the mean on Social Functioning and Role Limitations Due to Emotional Problems, 
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those who scored below the mean on Emotional Well Being  (n=17) were more likely to report 
depression and “visible” manifestations of the syndrome.  Also, this group was more likely to 
report mood swings, which they attributed to hormonal imbalances or menstrual irregularities 
caused by PCOS. 
Does the Experience of Infertility Impact the Illness Perceptions that Women Hold About 
Their PCOS? 
As previously described, a sub-aim of this dissertation was to explore the relationship 
between illness perceptions and infertility, a common symptom of the syndrome.  To achieve this 
sub-aim, interviewees were recruited based on two criteria: (1) history of infertility and (2) 
reported childlessness.  The latter recruitment strategy was employed to further stratify infertile 
and fertile WLW PCOS.  This decision was made, because it was hypothesized that, among 
WLW PCOS who had no history of infertility, those who did not have biological children would 
have different illness perceptions than those who did, because their ability to become pregnant 
remained unclear.  Likewise, it was hypothesized that, among WLW PCOS who had a history of 
infertility, those who did not have biological children would have different illness perceptions 
than those who did, because their ability to become pregnant also remained unclear.  In 
summary, interviewees were grouped in the following way: 
 Group 1: WLW PCOS with biological children and a history of infertility  
 Group 2: WLW PCOS with no biological children and a history of infertility 
 Group 3: WLW PCOS with biological children and no history of infertility 
 Group 4:  WLW PCOS with no biological children and no history of infertility 
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The demographic characteristics and the medical history of each group are described below.  The 
section following highlights major differences among groups’ illness perceptions.  This 
discussion is organized by illness perception dimension.   
Demographic Characteristics of Interviewees by Group.  The demographic 
characteristics and medical history of interviewees by group are summarized in Table 17 and 18.  
Although many similarities existed among samples and/or groups, a number of differences were 
observed.  For example, all groups except for Group 4 were older than the total sample.  This 
was expected, however, given that Group 4 did not have children and, to their knowledge, were 
fertile, meaning that they had not yet tried to conceive.  Given the older age of most of the 
interviewees, it was also not surprising that groups reported living with a PCOS diagnosis longer 
than the total sample. 
As a whole, Group 1 (n=10) was older than the others (M=35.3 years).  This was 
expected, however, given that Group 1 had a history of infertility but had biological children, 
meaning that they had (1) tried, unsuccessfully, to conceive spontaneously for at least 12 month, 
(2) pursued and been successful with follow-up infertility treatments, and (3) carried at least one 
pregnancy to term, which resulted in a live birth – all lengthy processes.  Table 19 lists the 
medications and procedures that each woman in Group 1 credited for her fertility success, the 
most common being Clomid®.  Also, Group 1 was more likely than others to report being 
married (90%), which was also expected, because infertility treatment-seeking is most common 
among married women (The Ethics Committee of the American Society of Reproductive 
Medicine, 2013).  Lastly, Group 1 was more likely to report having private insurance (90%) and 
less likely to report having no insurance (0%).   
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Noticeably, Group 2 is much smaller than the other groups (n=3).  As a reminder, this 
group consisted of women who had a history of infertility and who were childless.  Although 
many survey respondents reported these characteristics, most also reported currently trying to 
conceive (77%), which excluded them from Phase 2 of the dissertation, the interviews.  Overall, 
the mean age of Group 2 was highest of all groups.  Women in Group 2 were also more likely 
than others to report a history of hypertension and high cholesterol, which was unsurprising, 
because all women in Group 3 met the criteria for morbid obesity (BMI>35).  Unlike the other 
groups, no women in Group 2 were married – two were single and one was divorced.  When 
asked about their history of infertility, (1) all reported unsuccessfully trying to conceive 
spontaneously for at least 12 months (within the context of a long-term relationship or a previous 
marriage), and (2) none reported pursuing infertility treatments.  When asked about the latter 
finding, one Group 2 interviewee reported having a disabled partner with significant medical 
needs; the second reported receiving a tubal ligation out of fear of PCOS-related pregnancy 
complications and post-partum depression; and the third, the divorcee, reported being single with 
no current desire to have children.  
Lastly, Groups 3 and 4 were younger than Groups 1 and 2 and were more likely to report 
having no insurance.  These groups were also more likely to report depression, which is further 
explored below.  Women in Groups 4 (e.g. those who had no biological children and no history 
of infertility) were more likely than those in other groups to be single and to report a recent 
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Table 17. Demographic Characteristics of Interviewees by Group 
Characteristic Total Sample 
(N=376) 
No. (%) 
Interviewees 
(n=34) 
No. (%) 
Group 1** 
(n=10) 
No. (%) 
Group 2** 
(n=3) 
No. (%) 
Group 3** 
(n=9) 
No. (%) 
Group 4** 
(n=12) 
No. (%) 
Age (Mean) 31.8 33.6 35.3 39.7 32.4 31.3 
Hispanic       
 Yes 28 (7.5) 1 (2.9) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 No 348 (92.5) 33 (97.1) 9 (90.0) 3 (100.0) 9 (100.0) 12 (100.0) 
Race       
 White or Caucasian 332 (88.3) 32 (94.1) 9 (90.0) 3 (100.0) 9 (100.0) 11 (91.7) 
 Black or African American 13 (3.5) 2 (5.9) 1 (10.0) 0 (0.0) 0 (0.0) 1 (8.3) 
 Other 31 (8.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Sexual Orientation       
 Straight or heterosexual 355 (94.4) 29 (85.3) 10 (100.0) 3 (100.0) 8 (88.9) 8 (66.7) 
 Gay, lesbian, or homosexual 2 (0.5) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 
 Bisexual 19 (5.1) 4 (11.8) 0 (0.0) 0 (0.0) 1 (11.1) 3 (25.0) 
Marital Status       
 Single 89 (23.7) 8 (23.5) 1 (10.0) 2 (66.7) 0 (0.0) 5 (41.7) 
 Married 276 (73.4) 22 (64.7) 9 (90.0) 0 (0.0) 7 (77.8) 6 (50.0) 
 Separated or divorced 10 (2.7) 3 (8.9) 0 (0.0) 1 (33.3) 1 (11.1) 1 (8.3) 
 Widowed 1 (0.3) 1 (2.9) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 
Education       
 High school or less 26 (6.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Some college 109 (29.0) 6 (17.6) 2 (20.0) 1 (33.3) 2 (22.2) 1 (8.3) 
 College graduate 241 (64.1) 28 (82.4) 8 (80.0) 2 (66.7) 7 (77.8) 11 (91.7) 
Medical Insurance*       
 Private 281 (74.7) 26 (76.3) 9 (90.0) 2 (66.7) 6 (66.7) 9 (75.0) 
 Public  27 (7.2) 3 (8.9) 0 (0.0) 1 (33.3) 1 (11.1) 1 (8.3) 
 Military 19 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Other 15 (4.0) 2 (5.9) 1 (10.0) 0 (0.0) 1 (11.1) 0 (0.0) 
 None 46 (12.2) 3 (8.9) 0 (0.0) 0 (0.0) 1 (11.1) 2 (16.7) 
*Numbers may not add to 100, because participants could select all that apply. 
**Group 1 (Infertile with children), Group 2 (Infertile and childless),Group 3 (Fertile with children), Group 4 (Fertile and childless) 
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Table 18. Medical History of Interviewees by Group 
Characteristic Total Sample 
(N=376) 
No. (%) 
Interviewees 
(n=34) 
No. (%) 
Group 1* 
(n=10) 
No. (%) 
Group 2* 
(n=3) 
No. (%) 
Group 3* 
(n=9) 
No. (%) 
Group 4* 
(n=12) 
No. (%) 
Years living with PCOS diagnosis  M =7.6 M=10.9 M=11.8 M=16.0 M=11.8 M=8.3 
 < 1 years 63 (16.8) 5 (14.7) 0 (0.0) 0 (0.0) 1 (11.1) 4 (25.0) 
 > 1 years 313 (83.2) 29 (85.3) 10 (100.0) 3 (100.0) 8 (88.9) 9 (75.0) 
Pregnant       
 Yes 29 (7.7) 3 (8.8) 2 (20.0) 0 (0.0) 1 (11.1) 0 (0.0) 
 No 347 (92.3) 31 (91.2) 8 (80.0) 3 (100.0) 8 (88.9) 12 (100.0) 
BMI M=35.1 M=38.4 M= M= M= M= 
 Underweight (BMI<18.5) 4 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Normal (18.5-24.9) 45 (12.0) 5 (14.7) 1 (10.) 0 (0.0) 1 (11.1) 3 (25.1) 
 Overweight (25-29.9) 61 (16.2) 3 (8.8) 2 (20.0) 0 (0.0) 0 (0.0) 1 (8.3) 
 Obese (30-34.9) 95 (25.3) 8 (23.6) 2 (20.0) 0 (0.0) 5 (55.6) 1 (8.3) 
 Morbidly obese (BMI>35) 171 (45.5) 18 (52.9) 5 (50.0) 3 (100.0) 3 (33.3) 7 (58.3) 
History of:       
 Diabetes 45 (12.0) 4 (11.8) 2 (20.0) 0 (0.0) 1 (11.1) 1 (8.3) 
 Hypertension 96 (25.5) 10 (29.4) 3 (30.0) 2 (66.7) 3 (33.3) 2 (16.7) 
 High cholesterol 101 (26.9) 11 (32.3) 2 (20.0) 2 (66.7) 2 (22.2) 5 (41.7) 
 Heart disease 9 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Infertility 266 (70.7) 13 (38.2) 10 (100.0) 3 (100.0) 0 (0.0) 0 (0.0) 
 Thyroid  63 (16.8) 3 (8.8) 1 (10.0) 0 (0.0) 1 (1..1) 1 (8.3) 
 Endometriosis 31 (8.2) 2 (5.9) 1 (10.0) 1 (33.3) 0 (0.0) 0 (0.0) 
 Migraine 209 (55.6) 20 (58.8) 7 (70.0) 2 (66.7) 5 (55.6) 6 (50.0) 
 Anxiety 258 (68.6) 22 (64.7) 8 (80.0) 2 (66.7) 5 (55.6) 7 (58.3) 
 Depression 239 (63.6) 24 (70.6) 6 (60.0) 2 (66.7) 7 (77.8) 9 (75.0) 
*Group 1 (Infertile with children), Group 2 (Infertile and childless),Group 3 (Fertile with children), Group 4 (Fertile and childless) 
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Table 19. Group 1 Infertility Treatments 
Interviewee Treatment 
A.H., age 35  Ovidrel®, a prescription version of the hormone hCG 
 Follistim® AQ, a prescription version of the hormone FSH 
A.F., age 37  Clomid®, a selective estrogen receptor modulator (SERM) 
 Progesterone cream 
C.A., age 31  Clomid®, a selective estrogen receptor modulator (SERM) 
D.T, age 30  Fertility drugs, unspecified 
D. L., age 39  *Clomid®, a selective estrogen receptor modulator (SERM) 
 Provera®, a prescription version of the hormone progesterone 
 Metformin, an insulin-sensitizing agent 
J.W.,  age 39  Hormone injections, unspecified 
 Intrauterine insemination (IUI) 
J.T., age 28  Clomid®, a selective estrogen receptor modulator (SERM) 
 * Intrauterine insemination (IUI) 
L.P., age 42  Clomid®, a selective estrogen receptor modulator (SERM) 
 Provera®, a prescription version of the hormone progesterone 
 Prometrium®, a prescription version of the hormone progesterone 
M. B., age 33  Clomid®, a selective estrogen receptor modulator (SERM) 
S.G., age 39  Fertility drugs, unspecified 
*Interviewee reported that this treatment “did not work.” 
 
diagnosis.  This was unsurprising, however, given their younger age.  Also, Group 4 was more 
likely than other groups to be lesbian or bisexual and to be a college graduate. 
Cognitive Representations of PCOS by Group 
Illness Coherence.  No differences among groups were found on this dimension.  This was 
surprising considering the following: 
 The CSM suggests that individuals construct illness perceptions according to the 
information available to them (Leventhal et al., 2003). 
 WLW PCOS who experience infertility typically require additional medical 
interventions (Brassard et al., 2008). 
 Medical interventions, by nature, require more interactions with healthcare providers 
(who are potential sources of information). 
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Thus, it was expected that women with a history of infertility would express a greater 
understanding of PCOS than those with no history of infertility, especially women belonging to 
Group 4, who were more likely to be recently diagnosed.  Instead, all groups expressed a general 
lack of understanding about their diagnosis.  In fact, a woman in Group 1, who had reported 
taking a number of prescription drugs to conceive, stated that she had experienced infertility 
issues that did not “seem to have a reason.”  Not only do these findings again highlight the 
information needs of women living with PCOS, but also they bring into question whether 
consent to treatment of PCOS-related issues can be described as “informed.” Either way, these 
findings have important implications for patient-provider communication. 
Identity by Group. While members of each group labeled PCOS and its symptoms 
similarly, each discussed their symptoms differently.  For example, in each group, a few women 
identified the symptom(s) that gave them the greatest concern.  Among those in Group 1, a few 
still worried about infertility, because they had not decided if they wanted another pregnancy, 
while others expressed no desire for future pregnancies but did report weight issues as their most 
troubling symptom.  Like women in Group 1, those in Group 2 also reported weight issues as 
being there “greatest struggle.” Although few interviewees in Group 3 identified a “No. 1” 
concern, those who did were most troubled by their difficulties breastfeeding.  Lastly, women in 
Group 4 expressed greatest concern over menstrual irregularities and dermatologic issues, such 
as hirsutism and acne.  These findings suggests that, even though WLW PCOS may experience 
similar issues throughout the life course, the importance of those issues to each woman may 
depend on where she is in the life course.  For example, while younger, single women may be 
more immediately troubled by symptoms that affect their appearance, those who have started but 
have not yet completed childbearing may be more immediately concerned with fertility and 
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breastfeeding.  Because a major goal of PCOS management should be to improve HRQoL by 
alleviating symptoms women find distressing (Pfeifer & Kives, 2009), providers should pay 
careful attention to their patient’s presenting or primary complaint in addition to addressing any 
other medical needs. 
Surprisingly, women with children with no history of infertility (Groups 3) were more 
likely than women with children with a history of infertility (Groups 1) to discuss breast milk 
supply issues.   However, reasons for this difference remain unclear and highlight the need for 
additional research investigating the relationship between PCOS, breast development, and 
breastfeeding challenges.   
Lastly, women in Group 4 (e.g. women who were childless with no history of infertility) 
were more likely than any other group to discuss painful menstruation and/or ovulation, mood 
disturbances, depression, anxiety, hirsutism, alopecia, and acne during their interviews.  
Interestingly, these women were also more likely to report being non-compliant with their 
prescribed medication regime (usually birth control pills and/or Metformin®), which could 
easily explain their PCOS-related symptoms.  The most common reasons given for this non-
compliance were forgetfulness or “laziness.”  Likewise, those in Group 4 were also more likely 
than any other group to express worry and/or embarrassment over their cosmetic issues, which 
may have contributed to their feelings of depression or anxiety.  In fact, the only interviewee 
who specifically reported a history of suicidal thoughts was a woman in Group 4, who expressed 
significant distress over PCOS-related cosmetic issues. 
 I really suffered with it as a teenager when I had all the side-effects…with the hormones, 
with the, well, hair growth. I thought I was turning into a man, and I was, pretty much, 
suicidal.  I mean, I wanted to die. (K.M., age 30) 
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Again, these findings emphasize the need for providers to pay careful attention to their patient’s 
presenting or primary concerns and to explain treatment goals. 
Consequences.  While women in all groups identified a number of PCOS-related 
consequences related to their social lives, personal relationships, finances, and future health, 
many differences among groups were identified.   For example, women in Group 4 (e.g. women 
who were childless with no history of infertility) were more likely than those in other groups to 
report that the embarrassment, anxiety, and/or depression they felt over cosmetic symptoms 
discouraged them from being more social.  Likewise, Group 4 members also reported avoiding 
the dating scene due to lack of self-confidence.  In terms of personal relationships, few women 
reported major issues related to PCOS, but a couple of women in Group 2 (e.g. women who were 
childless with a history of infertility) did speak at length about the disappointment they felt over 
not being able to build their relationship with their babies through breastfeeding.   
When discussing future health consequences, those in Group 4 (e.g. women who were 
childless with no history of infertility) were more likely than others to express concerns over 
future infertility and pregnancy complications. In fact, some women in this group worried about 
finding a future spouse that would accept their uncertain fertility.  This was unsurprising, 
however, because many women in this group were single and had not yet tried to conceive.  On 
the other hand, those in Groups 1 and 2 (e.g. women with a history of infertility), the older 
groups, were more likely than those in Groups 3 and 4 (e.g. women with no history of infertility) 
to worry about future cancer and heart disease, which may have reflected their place in the life 
course. 
Lastly, those in Groups 3 and 4, the younger groups, were more likely to describe 
financial strain related to PCOS.  In particular, women in these groups reported being uninsured  
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or underinsured, which limited their access to care and ability to medically manage their PCOS 
as desired.  Similarly, women in these groups also reported stress over money to buy clothes as 
their weight fluctuated and to buy food that would allow them to stick to a healthier diet. 
Cause.  While most women, regardless of group, expressed uncertainty about the cause 
of PCOS, many believed that there was a genetic component.  Interestingly, those in Group 4 
(e.g. women who were childless with no history of infertility) were the only to suggest that 
weight “triggered” PCOS or exacerbated PCOS symptoms.  While it remains unclear why 
women in other groups did not explicitly identify this relationship, it is important that providers 
emphasize the role of obesity loss in PCOS severity and weight loss in PCOS management. 
Timeline.  In general, all groups identified PCOS as a chronic condition and believed that 
the syndrome would affect them throughout their life.  However, women in Group 3 (e.g. women 
with children with no history of infertility) were more likely to report that, because they had not 
struggled with fertility as expected, they were unsure of how the syndrome would affect them in 
the future.  This finding suggests that women in Group 3 may have been so focused on 
in/fertility, that they did not consider other consequences of the syndrome.  It also suggests that, 
during their clinical encounters, provider may have not discussed other implications of the 
syndrome or they themselves disregarded those messages.  For this reason, it is important that, in 
addition to providers addressing immediate concern of their patients, they also remind patients of 
the larger implications of the syndrome and discuss any lifestyle modifications or treatments that 
would help prevent any future PCOS-related conditions. 
Control.  Although most women in each group reported feeling like they had little control 
over the syndrome, most expressed the belief that PCOS could be managed.  Common 
management strategies identified by women in all groups included weight loss (through exercise 
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and/or diet), birth control pills, Metformin®, acne treatments, and hair removal treatments.  
Given group 4’s concerns over PCOS-related cosmetic issues, it was unsurprising that these 
women were more likely than others to discuss the latter, acne treatments - especially acne 
creams, and hair removal treatments, which included waxing, bleaching, shaving, and plucking – 
all short-term solutions.  On the other hand, women in Groups 1 and 2 (e.g. women with a 
history of infertility) were more likely than those in Groups 3 and 4 (e.g. women without a 
history of infertility) to report using long-term hair removal strategies, such as medications and 
laser hair removal.  This finding may be related to the age of the groups and their financial 
stability.  For example, a number of women in Groups 3 and 4, the two younger groups, 
specifically stated that laser hair removal was too expensive.  
Cure.  Lastly, most women in each group expressed the belief that PCOS could be 
managed but could not be “cured.”  The most common reasons given for this belief were that 
PCOS was (1) a chronic condition, resulting from a number of factors, including genes and 
environment or (2) a spectrum disorder, which, by definition, affected women differently, and, 
therefore, required different treatments for different women.  In contrast, there were only one or 
two women in each group who expressed the belief that a pill would be created, either 
purposively or accidently, to cure PCOS.  Interestingly, women in Group 4 (e.g. women who 
were childless with no history of infertility) seemed the most polarized on this domain.  While 
some women seemed very hopeful that, given enough research, a cure would be discovered, 
others expressed the belief that there was little awareness of PCOS and/or that there was little 
interest in the medical community to address and research the needs of WLW the syndrome.   
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 Emotional Representations of PCOS by Group.  Women in all groups reported that  
they felt the following when thinking about PCOS and its symptoms: frustration, depression, 
anxiety, and embarrassment. While Group1 (e.g. women with children with a history of 
infertility) was more likely than any other group to express feelings of frustration, which may be 
expected given their additional experience with infertility and follow-up treatments, Group 4 
participants were more likely to express feelings of depression.  As previously stated, the latter 
finding may be a result of (1) less hormone regulation and, consequently, more symptoms, as a 
result of non-compliance issues and (2) a concern over PCOS-related cosmetic issues, which this 
group reported being particularly depressing. 
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Chapter 5: Discussion 
 The aim of this chapter is to discuss the implications and limitations of the exploration 
reported in this dissertation.  The first part of this chapter will expand upon the overall findings 
of the dissertation in the context of current research in the field and identify implications for 
patient education, provider education, clinical practice, and policy improvements.  Overall, this 
summary will illustrate how this dissertation makes a valid contribution of advancing knowledge 
of the CSM and of PCOS.  The second part of this chapter will discuss the limitations of this 
dissertation along with suggestions for future research in this field.   
Major Findings of the Dissertation  
 The Common Sense Model.  In the field of health education and promotion, an 
important goal is to test health behavior theories iteratively in the real world (Rosenstock, 1990).  
While the CSM has been used as a guiding framework in studies of acute and chronic conditions, 
both physical and mental, no PCOS-related studies have adopted the CSM.  Thus, this 
dissertation was the first to test the ecological validity of the CSM in a population of women 
diagnosed with PCOS.  That is, this dissertation was the first to explore to what extent the 
dimensions of the CSM conformed to the illness perceptions of WLW PCOS.    
 Overall, it was found that WLW PCOS generally have illness perceptions of the 
syndrome that are consistent with the domains identified in the CSM (Leventhal et al., 2003).  In 
addition, it was found that, in relation to their illness cognitions, WLW PCOS described the 
extent to which they felt they had a comprehensive understanding of the syndrome, a 
phenomenon labeled illness coherence and identified as an additional dimension of illness 
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cognitions by Moss-Morris and colleagues (2002).  Similarly, participants identified PCOS as a 
common condition (i.e. labeled perceived prevalence).  Although this cognition does not “fit” 
into any previously defined dimensions of the CSM, it is arguable that this reflects a problem 
with the domain definitions, rather than the framework itself.  That is, it would be reasonable to 
include this cognition under Identity (defined as the label/name persons give to an illness and the 
symptoms they associate with that illness) if its definition were redefined or expanded 
(Leventhal et al., 2003).   
Whether perceived prevalence should be added to the model as its own domain or 
included under an existing domain of the CSM remains debatable.  However, this finding should 
not be ignored, because previous research (unrelated to the CSM) indicates that perceptions of 
illness prevalence are related to health behaviors, and, consequently, health outcomes.  For 
example, Chang, Klein, and Gorzalka (2013) recently reported that, among women,  higher 
perceived prevalence of male and female sexual dysfunctions was predictive of lower sexual 
functioning and poorer sexual satisfaction.  
Unmet Information Needs.  In this dissertation, the illness perceptions of WLW PCOS 
were identified, which included their beliefs regarding the symptoms, causes, consequences, 
cure/control, and timeline of the syndrome.  Although some of these beliefs were consistent with 
medical knowledge, others were not, suggesting that the CSM may be particularly useful in 
identifying knowledge deficits among WLW PCOS.  For example, a few participants identified 
“hyper” ovulation as a symptom of PCOS and/or cervical cancer as a health consequence of the 
syndrome, neither of which are consistent with the literature.  On the other hand, endometrial 
cancer, which WLW PCOS have a 2.7-fold increased risk for developing (Eunice Kennedy 
Shriver National Institute of Child Health and Human Development, 2012) , was not identified as 
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a health consequence of PCOS by any participant.   For this reason, PCOS informational 
materials, as well as providers, should make clear the risk factors for endometrial cancer, as well 
as cervical cancer.  More specifically, WLW PCOS should be made aware of their increased risk 
of endometrial cancer and the protective effect of intrauterine device (IUD) use on endometrial 
cancer risk (Benshushan, Paltiel, Rojansky, Brzezinski, & Laufer, 2002).  However, this caution 
should be accompanied by the disclaimer that information on endometrial cancer risk should be 
judged in the context of the relatively low incidence rate of endometrial cancer in the general 
population (National Cancer Institute, 2014).  In addition, PCOS information materials should 
(1) highlight that no studies report an association between cervical cancer and PCOS and (2) 
emphasize the fact that the human papillomavirus (HPV) is a necessary but insufficient cause of 
cervical cancer (American Cancer Society, 2009).  As a follow-up, information on HPV 
screening guidelines may also be provided to meet an additional information need of this 
population.  
 In addition, dissertation findings suggest that WLW PCOS do not understand the goals of 
clinical management of the syndrome. For example, almost all participants identified ways in 
which their PCOS had been medically managed.  These experiences were dependent on 
interviewee’s symptoms and medical history and included one or more of the following: oral 
contraceptives and Metformin®, which were the most commonly described, anti-depressants, 
and treatments for infertility, hair removal, and acne.  When asked about the effectiveness of 
these medications and/or treatments, most participants reported that they effectively alleviated 
symptoms.  However, many also expressed the belief that they were not really “treating” their 
PCOS with the medications and treatments, but, instead, were treating their PCOS symptoms.  
This thought, in particular, seemed very troubling to participants.  However, given that PCOS is 
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a chronic condition for which there is no cure; the goals of clinical management are to (1) 
address reproductive health concerns, (2) prevent PCOS-related chronic illness, and (3) improve 
HRQoL by alleviating symptoms women find distressing (Pfeifer & Kives, 2009).  As such, 
participants’ views mostly likely reflect (1) a misunderstanding of management goals and/or (2) 
cure beliefs, meanings that participants believe there is a medication or treatment that cures or 
treats PCOS, not just its symptoms.  For this reason, to minimize patient distress and to improve 
patient satisfaction with clinical care, providers should clarify management goals.  Likewise, 
providers and PCOS informational materials should emphasize the chronic nature of the 
condition and the long-term health implications of the syndrome. 
With this in mind, it is noteworthy that, in response to questions regarding the timeline of 
their PCOS, participants voiced drastically different views.  While some responded that it was a 
chronic condition that would affect them the remainder of their life, others questioned whether 
PCOS would affect them after menopause or a hysterectomy or if these circumstances would 
significantly change their experience with the syndrome.  Still, a few women, particularly those 
with a history of infertility, had not considered the possibility that PCOS would affect them after 
childbearing.  These findings provide further evidence that WLW PCOS not only need 
information on the long-term health implications of PCOS, but also the underlying hormonal 
imbalance that is characteristic of the syndrome.  That is, they need more information that will 
explain how menopause and/or a hysterectomy effects and does not effect this imbalance.   
Lastly, perhaps the most important findings highlighting the information needs of WLW 
PCOS were the unsolicited admissions by most participants that they did not understand their 
diagnosis.  Many explained that, prior to diagnosis, they had little knowledge of the syndrome, 
suggesting that they did not have an existing schema for this syndrome within which to make 
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sense of their symptoms.   To complicate matters, women felt that the information given to them 
at the time of their diagnosis was confusing and that not enough information was made readily 
available to them to answer their questions, which led to feelings of frustration.    In response, 
most participants reported searching for answers online, a behavior easily explained by the CSM 
and expected by a sample of women recruited through a social networking site (SNS).  Although 
this search proved helpful to many of the women interviewed, it also left some with more 
questions and feelings of uncertainty.  For this reason, it was suggested by a number participants 
that a follow-up visit soon after their diagnostic visit would have been particularly helpful.  
Notably, the frustration WLW PCOS felt over the information provided at diagnosis, as well as 
their search for answers, has been reported by other investigators over the past 12 years (Avery 
& Braunack-Mayer, 2007; Kitzinger & Willmont, 2002; Snyder, 2006; Weiss & Bulmer, 2011).  
Together with this dissertation, these studies provide overwhelming evidence that the 
information needs of WLW PCOS continue to be unmet.  Yet, few studies have explored 
preferences for information provision among WLW PCOS.  This knowledge gap is further 
addressed under Directions for Future Research. 
 Significant Psychological Morbidity & Unmet Mental Health Needs.  In this 
dissertation, a number of findings provide additional evidence that PCOS has a negative effect 
on women’s mental health and HRQoL, associations commonly reported in the PCOS literature 
(Barry et al., 2011; Jones et al., 2007).  For example, the majority of survey respondents reported 
a history of depression and/or anxiety.  Likewise, when comparing scores on health-related 
quality of life (HRQoL) domains, survey respondents, in general, reported lower levels of 
functioning on emotional well-being compared to physical functioning.  Similarly, respondents 
 135 
 
were more likely to report problems with work or other daily activities as a result of emotional 
problems rather than physical health problems.   
 Overall, few respondents reported their general health as being excellent or very good.  
Upon further investigation, it was found that type of symptom, not number of symptoms, related 
to this perception.   That is, those who reported higher levels of functioning were more likely to 
talk at length about the  physical manifestations of PCOS, including weight issues, insulin 
resistance (IR), hirsutism, and acne.  On the other hand, those who reported lower levels of 
functioning were more likely to emphasize the impact of PCOS symptoms on their mental health.  
Specifically, those who with lower levels of functioning  were more likely to report feeling 
depressed, worried, and /or stressed over current symptoms or the risk of PCOS-related health 
issues.  In summary, these findings highlight (1) the impact of PCOS and its symptoms on the 
mental health of WLW PCOS and (2) the importance of providers identifying and addressing the 
symptoms WLW the syndrome find most distressing.  Notably, from a clinical perspective, these 
symptoms may not be the most concerning.  However, because improving quality of life is a 
main goal of PCOS management (Pfeifer & Kives, 2009) and an overarching goal outlined in 
Healthy People 2020 (U.S. Department of Health and Human Services), these symptoms should 
not be ignored. 
To improve mental health, in general, the U.S. Preventative Task Force (USPSTF) also 
recommends “screening adults for depression when staff-assisted depression care supports are in 
place to assure accurate diagnosis, effective treatment, and follow-up. (U.S. Department of 
Health and Human Services).  At a minimum, this may include a screening nurse who screens 
patients for depression, reports positive findings to the resident physician, and follows a protocol 
to facilitate referral to mental health services.  Himelein and Thatcher (2006) identify two 
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appropriate depression screening tools: the Patient Health Questionnaire-9 (PHQ-9), a 9-item 
self-report measurement tool, or a shorter version of the instrument, known as the PHQ-2 
(Kroenke, Spitzer, & Williams, 2001, 2003; Löwe, Kroenke, & Gräfe, 2005; Lowe, Kroenke, 
Herzog, & Gräfe, 2004).  While the full measurement tool is brief and has the ability to assess 
severity and sensitivity to change, the shorter measure may be a more efficient alternative in 
busier clinics.  Again, if mental health issues are identified, providers should link women to 
appropriate, quality mental health services.  On the other hand, if no staff-assisted depression 
care supports are in place, providers should consider referring patients to a mental health 
provider, who may become part of a larger multidisciplinary team of providers to support his/her 
patient with PCOS. 
Breastfeeding Challenges and Need for Breastfeeding Support.  In this dissertation, a 
few women interviewed reported an issue with low breast milk supply.  Notably, this symptom 
proved to be the most difficult for participants to discuss, as these descriptions were often 
interrupted by tears and moments of silence during which participants took time to regain their 
composure.  Many of these women mourned the loss of their ability to bond with their children 
through breastfeeding and expressed frustration that their providers had not warned them that 
breastfeeding may be an issue. Similarly, most reported that the lactation consultants they sought 
advice from had little information on the effects of PCOS on breastfeeding, and one participant 
expressed concern that WLW PCOS who breastfed their female children placed them at greater 
risk for developing PCOS, which almost discouraged her from breastfeeding her children.  In 
short, breastfeeding challenges reported in this dissertation identified an unmet need not only for 
patient education, but also provider education and training.  However, it should be noted that, 
although there is overwhelming evidence that breastfeeding provides substantial health benefits 
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for mothers and babies (Office of Women's Health, 2011), no studies have been conducted to 
explore the impact of PCOS on breastfeeding.  This not only explains gaps in provider 
knowledge, but also highlights a knowledge gap in the literature, which is further addressed 
under Directions for Future Research. 
Poor Quality of Care and Low Patient Satisfaction.  As described in the results, 
frustration was a dominant theme of this dissertation, and participants’ frustration largely 
centered on their interactions with their health care providers.  In fact, some women interviewed 
in this dissertation became so frustrated with care that they switched providers or terminated care 
altogether, leaving their syndrome unmanaged and them at risk for developing PCOS-related 
conditions.  Specific sources of frustration are discussed below. 
Above all, women interviewed were most frustrated by perceived gaps in their providers’ 
knowledge, which they believed resulted in delayed diagnosis, lack of symptom improvement, 
and poor conveyance of information about the syndrome, its symptoms, and treatment options.  
Notably, many medical societies also believe that PCOS awareness is low among physicians, and 
PCOS experts have expressed concern that millions of WLW type 2 diabetes (T2D) and 
cardiovascular disease (CVD) may be receiving inadequate treatment, because their providers do 
not recognize these symptoms as indications of PCOS (Christopher, 2004).  It should be noted, 
however, that, no research provides supporting evidence for these beliefs.  That is, in the United 
States, no studies have explored PCOS content in current medical school curriculum, nor 
explored the beliefs, attitudes, knowledge, or practices of providers who treat WLW PCOS.  This 
knowledge gap is further discussed under Directions for Future Research. 
Moreover, women interviewed in this dissertation often expressed frustration that their 
providers focused on fertility, regardless of their concerns, and/or did not provide a 
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comprehensive treatment plan.  Although the reasons for these practices remain unclear, there 
are a few reasonable explanations for these findings.  First, because PCOS was originally 
described as a reproductive disorder (and not an endocrine disorder) and because clinical 
management of the syndrome initially centered on fertility restoration, providers, especially older 
providers, may have learned about the syndrome in this context.  Second, these practices may 
reflect lingering societal ideologies on gender, which define motherhood as women’s primary 
social purpose (Weisman, 1997).   Lastly, these practices may reflect a larger structural issue.  
That is, the fragmentation of healthcare (defined, in terms of women’s health, as the separate 
delivery of reproductive and non-reproductive services without provisions of coordinated care) 
(Weisman, 1997) presents a challenge to WLW the syndrome, because they may have 
dermatologic, reproductive, metabolic, and/or psychological concerns - all of which are currently 
addressed by different medical specialists.  Regardless of the reason, fertility-focused care is 
problematic, because women experiencing PCOS without fertility concerns remain largely 
undiagnosed and untreated, putting them at risk for PCOS-related conditions and subsequent 
reduced quality of life.  Again, no studies have explored the practices of providers who treat 
WLW PCOS, and this knowledge gap is addressed under Directions for Future Research. 
Lastly, some women also expressed frustration over being left out of the decision-making 
process, and a few who took  medications admitted to not know why that medication had been 
prescribed or what condition it was intended to treat, suggesting that their consent to treatment 
was uninformed.  As a consequence, some women reported stopping their medications altogether 
or taking their medications incorrectly, leading to little symptom reduction and greater risk for 
developing PCOS-related conditions.   Not only do these findings highlight an unmet 
information need of WLW the syndrome, specifically as it related to treatment options and goals, 
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but also a need for research exploring provider and patient factors related to shared decision 
making in the context of PCOS management.  This knowledge gap is also further discussed 
under Directions for Future Research. 
 Limited Access to Care.  Lastly, women interviewed in this study faced a number of 
barriers to PCOS management, particularly financial strain.  More specifically, participants were 
upset that a number of treatments needed to address PCOS symptoms, such as IVF and laser hair 
removal, were not covered by insurance.  Consequently, many women either went into debt 
paying out of pocket for these treatments or reported feeling depressed by their inability to 
control specific symptoms, particularly infertility and excess hair growth.   
 At this time, it is the position of most insurance companies within the US that treatments 
such as IVF and laser hair removal are not medically necessary (RESOLVE, 2014).  To date, this 
argument has made it easy for insurance companies to make a case for not covering these 
services.  However, this argument does not take into account the impact of the diseases they are 
meant to treat on health-related quality of life.  Because improving  health-related quality of life 
should be a main goal of clinical treatment (U.S. Department of Health and Human Services) and 
because these “medically unnecessary” treatments improve health-related quality of life, health 
insurance systems should revisit and revise their policies on these procedures.  
Study Strengths and Limitations 
Study Strengths.  In addition to testing the ecological validity of the CSM in a 
population of women diagnosed with PCOS, this dissertation study contributes to the literature 
and to the field of public health in a number of ways.  This is the first qualitative study to 
specifically focus the investigation on the illness perceptions of PCOS held by WLW the 
syndrome.  That is, previous qualitative research has focused primarily on the overall experience 
 140 
 
of living with the syndrome.  In these studies, researchers use phenomenological and grounded 
theory approaches to explore the meaning of PCOS to WLW the syndrome (Kitzinger & 
Willmont, 2002; Snyder, 2006; Weiss & Bulmer, 2011) and to describe the lived experience of 
WLW PCOS in the management of the syndrome (Crete & Adamshick, 2011).  As such this is 
the first qualitative study to capture any experiences of WLW PCOS using the CSM as a starting 
point. 
Unquestionably, the a priori use of a model in qualitative research can pose a threat to 
internal validity (Miles & Huberman, 1994).  However, several points support the authenticity, 
plausibility, and adequacy of the data obtained in this dissertation.  First, although the interview 
guide was framed around the constructs of the CSM, participants provided thick descriptions of 
their experiences of living with PCOS.  They were also asked, at the end of the interview, 
whether there was anything else they wanted to say regarding their experience with the 
syndrome.  No substantive information was obtained in response to this question.  Second, 
triangulation of data from this dissertation with both quantitative and qualitative data from other 
populations of WLW PCOS indicates converging conclusions between the groups.  Finally, the 
data reflect themes which emerged from previous qualitative research into the illness perceptions 
of those with PCOS-related illnesses, such as diabetes. 
In addition, this dissertation was the first to explore the relationship between illness 
perceptions of WLW PCOS and their HRQoL.  Because specific illness perceptions were 
associated with HRQoL, addressing these illness perceptions could be an effective strategy in 
increasing HRQoL among WLW the syndrome.  This is important, because HRQoL is identified 
as a national health standard (U.S. Department of Health and Human Services).  Lastly, this 
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study is the first to describe a sample of WLW PCOS recruited through a SNS, information that 
may be useful to other PCOS researchers. 
Study Limitations  
The dissertation has limitations related to disclosure, which was previously described, 
and to web-based surveys, mainly sample selection and recruitment. To date, researchers have 
recruited WLW PCOS primarily through healthcare settings or the internet.  In extant literature, 
researchers in medicine and nursing have mostly recruited women through large hospital 
networks and large healthcare practices, (Crete & Adamshick, 2011; Ekback, Wijma, & Benzein, 
2010; Jones, Hall, Lashen, Balen, & Ledger, 2011; Percy et al., 2009; Snyder, 2006)  and 
researchers from the social sciences have mostly recruited women through online support groups 
(Avery & Braunack-Mayer, 2007; Kitzinger & Willmont, 2002).  Unlike most studies, Weiss and 
Bulmer recruited women from a number of colleges by posting recruitment flyers around 
campuses (Weiss & Bulmer, 2011). 
The advantages and disadvantages of each recruitment strategy are clear. If recruiting 
through clinical populations, it can be confirmed that women meet inclusion and exclusion 
criteria.  However, this requires accessing patient’s medical records, and the “Privacy Rule,” a 
federal regulation under the Health Insurance Portability and Accountability Act (HIPAA), 
protects certain health information (National Institutes of Health).  Thus, healthcare personnel 
would have to have been relied upon to identify and to make first contacts with potential 
participants.  This process could have been time consuming and costly, and it could have been 
difficult to find healthcare personnel willing to assist in the study.  On the other hand, it took less 
time to identify participants via SNS.  Researchers using this recruitment strategy have gained 
the cooperation of groups such as Verity (http://www.verity-pcos.org.uk/), a United Kingdom 
organization, and the PCOS Association of Australia, Inc (http://main.posaa.asn.au/).   In these 
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studies, researchers were not able to clinically confirm participant’s PCOS diagnosis; rather, they 
asked women if a healthcare provider had ever told them they had PCOS (as was reported in the 
current dissertation study).   
In addition to a PCOS diagnosis, a number of inclusion and exclusion criteria were 
outlined.  Although participants were asked to complete a screening survey prior to their 
interview, it was impossible to verify that women were answering screening questions truthfully.  
This data collection issue, however, is not unique to this dissertation.  Getting honest answers to 
survey questions is a limitation of any research study collecting survey data (Neumen, 2006). 
Also, no data exists to determine how a number of PCOS populations differ including: 
(1) clinical populations and online populations, (2) populations that do and do not subscribe to 
facebook®, and (3) populations of facebook® subscribers who do and do not belong to PCOS-
related interests groups. The difference between the women who did and did not follow the link 
to the survey also could not be determined.  Thus, the representativeness of the sample could not 
be fully determined.  However, sample representativeness and generalizability were not relevant 
to the goals of this dissertation – to produce data that were conceptually representative, not 
statistically representative, of women’s illness perceptions of PCOS.   
Lastly, when a researcher advertises to a group with a specific experience, primary 
selection of a sample is said to have occurred (Bryant & Charmaz, 2007).  While those who 
contacted the lead investigator met “experience” criteria, it was unknown if they would be able 
to articulate and reflect – participant qualities important within a qualitative study (Morse, 1991).  
To account for this, secondary selection was employed (Bryant & Charmaz, 2007).  That is, 
when it became clear during an interview that the participant could not articulate her experience, 
the interview was politely completed, the digital recording was kept, but then the interview was 
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not transcribed, and the data was not incorporated into the study.  This procedure was followed 
for one interview.   
Directions for Future Research 
 Despite some limitations, the findings from this dissertation have several implications for 
future public health research.  These are summarized below. 
 Adapting the IPQ-R for WLW PCOS.  As previously described, there is a growing 
interest in Leventhal’s Common Sense Model (CSM) to explain the cognitive and emotional 
antecedents of health behaviors and illness outcomes in chronic illness (Hagger & Orbell, 
2003b).  This is largely credited to the development and subsequent revision of the Illness 
Perceptions Questionnaire (IPQ  and IPQ-R), a quantitative operationalization of the CSM, 
which has made it easier for researchers to utilize the general framework (Moss-Morris et al., 
2002; Weinmann et al., 1996).  The authors of both the IPQ and IPQ-R have encouraged 
researchers to adapt these measures to suit different health conditions and note that the 
applicability of the scales and sub-scales may vary depending on the unique characteristics of 
such groups.  Accordingly, researchers studying different health conditions have reported 
modifications to the instruments to improve model fit (see the IPQ website, 
http://www.uib.no/ipq), illustrating that a thorough evaluation of the instruments’ psychometric 
properties is necessary before it can be applied in research to different illness populations. 
 Given the aim of the current dissertation - to identify illness perceptions of WLW PCOS 
– the findings reported here lay the groundwork for developing and testing a modified version of 
the IPQ-R to study illness perceptions of WLW PCOS.  Notably, this instrument should include 
items assessing perceived prevalence. An IPQ-R measure for PCOS could be useful in clinical 
practice to identify whether women diagnosed with PCOS have an accurate or inaccurate 
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conception of the syndrome that may be contributing to inappropriate coping strategies and/or 
increased symptom burden.  An IPQ-R measure for PCOS may also by useful for identifying 
cognitive and emotional predictors of PCOS outcomes and self-care behaviors.  In addition, such 
a scale could help to capture how beliefs regarding PCOS (1) differ among women living with 
PCOS, based on symptoms and health status,  (2) change over time as women move from child-
bearing years to post-menopausal years, and relate to HRQoL.  This information would be 
critical to tailoring health promotion messages to WLW PCOS.   
 Addressing the Unmet Needs of WLW PCOS.  As in previous studies exploring the 
lived experiences of WLW PCOS (Crete & Adamshick, 2011; Kitzinger & Willmont, 2002; 
Snyder, 2006; Weiss & Bulmer, 2011), this dissertation reports an unmet information need in 
this population.  However, because the primary purpose of this dissertation or these studies was 
not to assess the information needs of WLW PCOS, the usefulness of findings is limited.   
The only study that has specifically explored the information needs of WLW PCOS was 
conducted in Australia in 2007.  Surprisingly, the authors did not report the types of information 
women were looking for, only that women preferred using the Internet when searching for 
information (Avery & Braunack-Mayer, 2007).  The study also had several limitations.  First, 
because women were recruited from a PCOS intervention program, these women already had 
high PCOS knowledge and were aware of the implications of PCOS on their future health.  
These women also represented an age group (28-38 years old) where fertility was likely a 
concern versus other PCOS symptoms.   
In the future, information needs of WLW PCOC should be assessed.  Qualitative and 
quantitative studies are needed to further explore the (1) PCOS knowledge of women with the  
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syndrome, which, to some extent, was captured in this dissertation, and (2) their preferences for 
information provision.  To date, no scales exist to measure the PCOS knowledge of women 
affected by the syndrome, nor their attitudes and beliefs about PCOS, such as their perceived 
severity and susceptibility to PCOS-sequelae.  A self-administered questionnaire measuring 
these constructs in women with PCOS could be developed and/or tested in future studies.  
Different types of PCOS media could also be developed and/or tested and the quality and 
helpfulness of existing PCOS information could be assessed.  Notably, these research activities 
are related to two Healthy People 2020 objectives: (1)  to “increase the proportion of health-
related websites that meet three or more evaluation criteria disclosing information that can be 
used to assess information reliability” and (2) to “increase the proportion of health-related 
websites that follow established usability principles” (U.S. Department of Health and Human 
Services). 
Because research suggests that women with the syndrome prefer using the internet to 
search for PCOS information (Avery & Braunack-Mayer, 2007), future studies could also 
explore how women access the internet to answer their PCOS questions and whether they 
retrieve accurate answers to their questions.  Research could also include secondary data 
analysis, where questions posted by WLW PCOS on PCOS support group websites and/or 
information pages would be analyzed.   
Most importantly, to advance the CSM, future studies should assess how PCOS 
information shapes women’s illness perceptions of PCOS and subsequent health behaviors and 
outcomes.  Notably, the social sciences literature has generally described information 
interventions as necessary but insufficient drivers of health behaviors (Glanz, Rimer, & Lewis, 
2002).  As such, future studies exploring individual-level determinants of health, such as illness 
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perceptions, can determine the role of information in motivating women to adopt health-
promoting behaviors such as weight reduction and management or screening behaviors.  Overall, 
findings from studies proposed in this section could be used to improve health communication 
strategies in WLW PCOS and potentially improve health outcomes among WLW PCOS.  
Exploring Relationships Between Breastfeeding and PCOS.  As previously reported, a 
few women interviewed in this study reported problems with breastfeeding and expressed 
frustration towards their providers for not advising them that they were at risk for low breast 
milk production.  However, this finding was not surprising, because no investigators have 
studied breast development and breastfeeding problems among WLW PCOS.  In short, this issue 
has received little attention in the literature.  To promote breastfeeding in the population and to 
improve provider training, more research is needed to explore the relationships between PCOS, 
breast development, and breastfeeding.  Medical school curriculum, as well as educational 
materials for lactations consultants, should also be reviewed for PCOS-related content. 
Improving Quality of Care and Patient Satisfaction.  To improve quality of care and 
patient satisfaction among WLW PCOS, more research is first needed to assess the breadth and 
depth of PCOS-related content in the medical school curriculum.  In addition, research is needed 
to assess the PCOS knowledge, diagnostic practices, and management strategies of providers.  
Arguably, the CSM would provide a useful framework in which to explore this phenomenon.  
That is, in this dissertation, the primary purpose was to identify illness perceptions of WLW 
PCOS to lay the groundwork for future research exploring how illness perceptions impact health 
behaviors, and, consequently, health outcomes.   However, the same program of study could be 
repeated with physicians to not only identify their illness perceptions of PCOS but also to 
explore how their perceptions impacted their diagnostic and clinical practices (i.e. their health 
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behaviors), and, consequently, the health outcomes of their patients.  In addition, an IPQ-R could 
be adapted for providers treating WLW PCOS, which would also require testing in future 
studies. 
Also, as previously described,  PCOS experts agree that awareness of PCOS among 
physicians remains low - a problem that medical associations, such as the American Association 
of Clinical Endocrinologists (AACE), the Androgen Excess Society (AES), and the American 
Society of Reproductive Endocrinologists (ARSE) have promised to address through position 
papers, workshops, trainings, and continuing medical education courses (CEUs) (Christopher, 
2004).  In future studies, researchers could partner with these organizations to develop, pilot, and 
evaluate these trainings and CEUs.  Before developing these trainings, however, researchers 
would need to explore the current clinical knowledge, attitudes, and beliefs about PCOS among 
providers – research which is described above.     
Given the clinical experiences regarding shared-decision making among those interviewed in 
the dissertation and the Healthy People objective to “increase the proportion of persons who 
report that their healthcare providers always involve them in decisions about their healthcare as 
much as they want” (U.S. Department of Health and Human Services), research is needed to 
explore physician and patient factors related to shared decision making.  First, studies should 
explore to what extent WLW PCOS want to participate in medical decision making related to 
their condition.  Previous research addressing this issue in other clinical populations has found 
mixed results and patient preferences appear to be condition specific (Frosch & Kaplan, 1999).  
This suggests that preferences may vary in different phenotypic groups of WLW PCOS, whose 
symptoms vary in severity.  Second, it should be determined if physicians treating WLW PCOS 
want to engage in shared decision making as a patient’s preferences will have little impact if the 
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physician is not open to the process.  Although studies consisting of large samples of physicians 
regarding their views on shared decision making have not been conducted, a number of variables 
are believed to impact their attitudes towards the process (Frosch & Kaplan, 1999).   For 
example, some physicians may feel threatened by patient empowerment, may engage in limited 
dialogue to avoid emotionally charged situations, may be reluctant to disclose information 
relevant to making uncertain choices, or may lack the necessary communication skills needed to 
engage patients in the shared decision making process (Frosch & Kaplan, 1999).  Kaplan and 
colleagues report that physicians who encourage shared decision making have lower patient 
volume in their practices, previous training in primary care or in interviewing skills, and more 
satisfaction with the extent of their personal autonomy (Kaplan, Greenfield, Gandek, Rogers, & 
Ware, 1996).  Future studies should explore these factors in provider treating WLW PCOS and 
determine if there are other factors unique to this condition, including illness perceptions, which 
facilitate or prevent providers from adopting a shared decision making paradigm.  Third, future 
studies should explore strategies to implement shared-decision making in PCOS care.  Decision 
aids are often utilized to prepare patients to participate in healthcare decisions (Stacey et al., 
2011).  To date, no decision aids have been developed for PCOS, which could be developed and 
tested in future studies. Lastly, future studies should identify health outcomes related to shared-
decision making in PCOS populations.  For example, in other clinical populations, shared 
decision making has been associated with lowered blood pressure and improved diabetes control 
- positive health outcomes relevant to WLW PCOS (Greenfield, Kaplan, Ware, Yano, & Frank, 
1988; Stewart, 1995).  Overall, findings from these studies could inform strategies to improve 
patient-provider communication and encourage shared decision making in PCOS care. 
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Improving Access to Care.  Assurance is one of the core public health function.  This 
function assures that services necessary to achieve agreed-upon goals (i.e. which are outlined in 
Healthy People 2020) are provided, either by encouraging actions by other entities (private or 
public), by requiring such action through regulation, or by providing services directly (Novick & 
Morrow, 2008b).  One major activity related to assurance is linking persons to needed services.  
To date, no studies have explored how WLW PCOS identify, access, utilize, and pay for PCOS-
related services.  Specifically, more research is needed to understand how WLW PCOS are 
linked to additional services after gaining entry into the healthcare system.  Given the numerous 
health implications of PCOS, most literature emphasizes the importance of a multidisciplinary 
healthcare team, consisting of medical providers, mental health providers, and dieticians, to 
improve PCOS treatment (Ahonen, 2010).   However, no studies have explored how providers 
perceive a team approach to PCOS care.  Research is needed to understand provider’s 
perceptions of their role in PCOS care and to understand referral practices of providers caring for 
WLW PCOS.  Again, future research studies could also specifically explore how referral 
practices (i.e. provider behaviors) are related to providers’ perceptions of PCOS. 
Conclusion 
It is now recognized that women’s health includes diseases and conditions that affect a 
woman’s health across the lifespan.  These conditions include the leading causes of death in 
women, such as CVD and type 2 DM – conditions which have also been identified as public 
health priorities by the Healthy People initiative (Centers for Disease Control and Prevention). 
The first step in reducing the disease burden of these conditions among women is recognizing 
the women at risk.  Previous public health efforts have targeted women with behavioral risk 
factors such as cigarette smoking, poor nutrition, and physical inactivity; and condition-specific 
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risk factors such as obesity, hypertension, high cholesterol, and metabolic syndrome (Mosca et 
al., 1997).  Although the latter are all characteristic of women with PCOS, the syndrome itself 
has yet to receive the same attention as other conditions (Corley, 2007).   Consequently, PCOS 
women may represent the largest underappreciated segment of the female population at risk for 
diabetes and cardiovascular disease.  Given the high prevalence of PCOS in the general 
population and the current obesity epidemic, which is an environmental risk factor for the 
syndrome, it is arguable that PCOS is not only a public health issue, but also is of increasing 
public health importance.   
Although some women who experience PCOS will not develop CVD and/or type 2 DM, 
it is likely that they will experience infertility, hirsutism, and/or obesity in their lifetime.  
Because these conditions reduce women’s HRQoL and because HRQoL has been identified as a 
new topic area in Healthy People 2020 (U.S. Department of Health and Human Services), it is 
further arguable that PCOS warrants increased public health attention.  Moreover, PCOS 
represents a huge financial burden to the U.S. healthcare system and this burden is only expected 
to worsen as obesity rates rise and, subsequently, more cases of PCOS are identified. 
 Although the specific aims of this dissertation were to explore the illness perceptions of 
WLW PCOS and their HRQoL, it is hoped that the findings reported here will inspire future 
investigations on the issues faced by WLW PCOS and spark a larger dialogue on the public 
health significance of PCOS.  It is also hoped that the findings reported in this dissertation will 
not only help WLW PCOS better understand their condition and the experiences of other WLW 
PCOS, but also contribute to provider’s understanding of how WLW PCOS experience their 
condition. 
  
 151 
 
 
 
 
 
 
References 
Acién, P., Quereda, F., Matallin, P., Villarroya, E., López-Fernández, J., Acién, M., . . . R., 
Alfayate. (1999). Insulin, androgens, and obesity in women with and without polcysytic 
ovary syndrome: a heterogeneous group of disorders. Fertility and Sterility, 72, 32-40.  
Allyn, D. (2000). Make Love, Not War. The Sexual Revolution: An Unfettered History New 
York, NY: Little, Brown and Company. 
American Cancer Society. (2009, May 13, 2009). Detailed Guide: Cervical Cancer.   Retrieved 
September 12, 2009, from 
http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_is_cervical_cancer_8.as
p 
Archer, D. (2006). Menstrual-cycle-related symptoms: a review of the rationale for continuous 
use of oral contraceptives. Contraception, 74, 359-366.  
Ashtari, Shadee. (2014, April 3, 2014). Charlie Crist hammers Rick Scott for failing to 'lift a 
finger' on Medicaid expansion, The Huffington Post.  
Atay, V., Cam, C., Muhcu, M., Cam, M., & Karateke, A. (2006). Comparison of letrozole and 
clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. 
Journal of Internal Medicine Research, 34(1), 73-76.  
Avery, J. C., & Braunack-Mayer, A. J. (2007). The information needs of women diagnosed with 
polycystic ovarian syndrome - implications for treatment and health outcomes. BMC 
Women's Health, 7(9).  
 152 
 
Azziz, R. (2003). The evaluation and management of hirsutism. Obstetrics & Gynecology, 101, 
995-1007.  
Azziz, R. (2004). PCOS: a diagnostic challenge. Reproductive Biomedicine Online, 8(6), 644-
648.  
Azziz, R. (2006). Controversy in clinical endocrinology: diagnosis of polycystic ovarian 
syndrome: the Rotterdam criteria are premature. Journal of Clinical Endocrinology & 
Metabolism, 91(3), 781-785.  
Azziz, R. (2007). Long-term morbidity of PCOS: estimating the economic burden of PCOS. In 
R. Azziz (Ed.), The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and 
Clinical Care (pp. 124). New York: Springer. 
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E, Escobar-Morreale, H. , 
Futterweit, W., . . . Task Force on the Phenotype of the Polycystic Ovary Syndrome of 
the Androgen Excess and PCOS Society. (2009). The Androgen Excess and PCOS 
Society criteria for the polycystic ovary syndrome: the complete task force report. 
Ferility and Sterility, 91(2), 456-488.  
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., 
Futterweit, W., . . . Witchel, S. F. (2006). Positions statement: criteria for defining 
polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen 
Excess Society guideline. Journal of Clinical Endocrinology & Metabolism, 91(11), 
4237-4245.  
 
 
 153 
 
Azziz, R., Ehrmann, D., Legro, R., Whitcomb, W., Hanley, R., Fereshetian, A., . . . Ghazzi, M. 
N. (2001). PCOS/Troglitazone Study Group. Troglitazone improves ovulation and 
hirsutism in the polycystic ovary syndome: a multicenter, double blind, placebo-
controlled trial. Journal of Clinical Endocrinology & Metabolism, 86, 1626-1632.  
Azziz, R., Marin, L. H., Badamgarav, E., & Song, P. (2005). Health care-related economic 
burden of the polycystic ovary syndrome during the reproductive life span. The Journal 
of Clinical Endocrinology & Metabolism, 90(8), 4650-4658.  
Azziz, R., Woods, K., Reyna, R., Key, T., Knochenhauer, E., & Yildiz, B. (2004). The 
prevalence and features of the polycystic ovary syndrome in an unselected population. 
Journal of Endocrinology & Metabolism, 89, 2745–2749.  
Baird, K. L. (2009). Protecting the Fetus: The NIH and FDA Medical Research Policies. In K. L. 
Baird (Ed.), Beyond Reproduction: Women's Health, Activisim, and Public Policy. 
Cranbury, NJ: Associated University Presses. 
Baker, E. (2012). Recruitment of an online sample of women living with polycystic ovary 
syndrome: a feasibility study. Department of Community and Family Health. University 
of South Florida.   
Balen, A, Tan, S., MacDougall, J., & Jacobs, H. (1993). Miscarriage rates following in-vitro 
fertilization are increased in women with polycystic ovaries and reduced by pituitary 
desensitization with busserlin. Human Reprodroduction, 8, 959-964.  
Balen, A., Conway, G., Kaltas, G., Techatrasak, K., Manning, P., West, C., & Jacobs, H. (1995). 
Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human 
Reproduction, 10, 2107-2111.  
 154 
 
Balen, A., & Michelmore, K. (2002). What is polycystic ovary syndrome? Are national views 
important? Human Reprodroduction, 17(9), 2219-2227.  
Barnard, L., Ferriday, D., Guenther, N., Strauss, B., Balen, A.H., & Dye, L. (2007). Quality of 
life and psychological well being in polycystic ovary syndrome. Human Reproduction, 
22(8), 2279-2286.  
Barry, J. A., Kuczmierczyk, A. R., & Hardiman, P. J. (2011). Anxiety and depression in 
polycystic ovary syndrome: a systematic review and meta-analysis. Human 
Reprodroduction, 26(9), 2442-2451.  
Barth, J. H., Yasmin, E., & Balen, A. H. (2007). The diagnosis of polycystic ovary syndrome: 
the criteria are insufficiently robust for clinical research. Clinical Endocrinology, 67(6), 
811-815.  
Benetti-Pinto, C., Piccolo, V., Garmes, H., & Juliato, C. (2013). Subclinical hypothyroidism in 
young women with polycystic ovary syndrome: an analysis of clinical, hormonal, and 
metabolic parameters. Fertility and Sterility, 99(2), 588-592.  
Benjamins, L.J., & Barratt, M.S. (2009). Evaluation and management of polycystic ovary 
syndrome. Journal of Pediatric Health Care, 23(5), 337-343.  
Benshushan, A., Paltiel, O., Rojansky, N., Brzezinski, A., & Laufer, N. (2002). IUD use and the 
risk of endometrial cancer. European Journal of Obestetrics, Gynaecology, and 
Reproductive Biology, 105(2), 166-169.  
Benson, S., Hahn, S., Tan, S., Janssen, O., Schedlowski, M., & Elsenbruch, S. (2010). 
Maladaptive coping with illness in women with polycystic ovary syndrome. Journal of 
Gynaecology and Neonatal Nursing, 39, 37-45.  
 155 
 
Berg, B. L. (2009). Qualitative Research Methods for the Social Sciences. Boston, MA: Allyn & 
Bacon. 
Boomsma, C., Eijkemans, M., Hughs, E., Visser, G., Fauser, B., & Macklon, N.S. (2006). A 
meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Human 
Reproduction Update, 12, 673-683.  
Brassard, M., AinMelk, Y., & Baillargeon, J. P. (2008). Basic infertility including polycystic 
ovary syndrome. The Medical Clinics of North America, 92(5), 1163-1192.  
Broadbent, E., Donkin, L., & Stroh, J. (2011). Illness and treatment perceptions are associated 
with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care, 
34(2), 338-340.  
Broadbent, E., Ellis, C., Thomas, J., Gamble, G., & Petrie, K. (2009). Further development of an 
illness perception intervention for myocardial infarction patients: a randomized control 
trial. Journal of Psychosomatic Research, 67, 17-23.  
Bryant, A., & Charmaz, K. (2007). The SAGE Handbook of Grounded Theory. London: Sage 
Publications. 
Carmina, E., Legro, R., Stamets, K., Lowell, J., & Lobo, R. (2003). Difference in body weight 
between American and Italian women with polycystic ovary syndrome: influence of the 
diet. Hum Reprod, 18(11), 2289-2293.  
Carmina, E., & Lobo, R.A. (1999). Polycystic ovary syndrome (PCOS): arguably the most 
common endocrinopathy is associated with significant morbidity in women. Journal of 
Clinical Endocrinology & Metabolism, 84(6), 1897-1899.  
Cauter, E. (2011). Sleep disturbances and insulin resistance. Diabetic Medicine, 28, 1455-1462.  
 156 
 
Centers for Disease Control and Prevention. (1999). Achievements in public health, 1900-1999: 
healthier mothers and babies. MMWR, 48(38), 849-858.  
Chang, S., Klein, C., & Gorzalka, B. (2013). Perceived prevalence and definitions of sexual 
dysfunction as predictors of sexual function and satisfaction. Journal of Sex Research, 
50(5), 502-512.  
Christian, R. C., Dumesic, D. A., Behrenbeck, T., Oberg, A. L., Sheedy, P. F., & Fitzpatrick, L. 
A. (2003). Prevalence and predictors of coronary artery calcification in women with 
polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 88, 2562-
2568.  
Christopher, A. (2004). Polycystic ovary syndome: common but unrecognized threat. DOC 
News, 1(2), 13-14.  
Clark, A., Ledger, W.L., Galletley, C., Tomlinson, L., Blaney, F., Wang, X., & Norman, R. 
(1995). Weight loss results in significant improvements in pregnancy and ovulation rates 
in anovulatory obese women. Human Reproduction, 10, 2705-2712.  
Clark, A., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. (1998). Weight loss in obese 
infertile women results in improvement in reproductive outcome for all forms of fertility 
treatment. Human Reproduction, 13, 1502-1505.  
Crete, J., & Adamshick, P. (2011). Managing polycystic ovary syndrome: what our patients are 
telling us. Journal of Holistic Nursing, 29(4), 256-266.  
Cronin, L., Guyatt, G., Griffith, L., Wong, E., Azziz, R., Futterweit, W., . . . Dunaif, A. (1998). 
Development of a health-related quality-of-life questionnaire (PCOSQ) for women with 
polycystic ovary syndrome (PCOS). Journal of Clinical Endocrinology & Metabolism, 
83, 1976-1987.  
 157 
 
Crosby, R. A., Kegler, M. C., & DiClemente, R. J. (2009). Theory in Health Promotion Practice 
and Research. In R. J. DiClemente, R. A. Crosby & M. C. Kegler (Eds.), Emerging 
Theories in Health Promotion Practice and Research (2nd ed.). San Francisco, CA: 
Jossey-Bass. 
Cussons, A. J., Stuckey, B. G., Walsh, J. P., Burke, V., & Norman, R. J. (2005). Polycystic 
ovarian syndrome: marked differences between endocrinologists and gynaecologists in 
diagnosis and management. Clinical Endocrinology, 62(3), 289-295.  
Dahlgren, E., Janson, P., Johansson, S., Lapidus, L., & Odén, A. (1992). Polycystic ovary 
syndrome and risk of myocardial infarction. Evaluated from a risk factor model based on 
a prospective population study of women. Acta obstetricia et gynecologica Scandinavica, 
71(8), 599-604.  
Dehbashi, S., Vafaei, H., Parsanezhad, M., & Alborzi, S. (2006). Time of initiation of 
clominphene citrate in women with polycystic ovaries undergoing ovarian stimulation. 
Journal of Gynaecology and Obstetrics, 93(1), 44-48.  
Denzin, N. K. (1978). The Research Act: A Theoretical Introduction to Sociological Methods. 
New York: McGraw-Hill. 
DeUgarte, C., Bartolucci, A., & Azziz, R. (2005). Prevalence or insulin resistance in the 
polycystic ovary syndrome using the homeostasis model assessment. Fertility and 
Sterility, 83, 1454-1460.  
Dhont, M., De Sutter, P., Ruyssinck, G., Martens, G., & Bekaert, A. (1999). Perinatal outcomes 
of pregnancies after assisted reproduction: a case-control study. American Journal of 
Obstetrics and Gynaecology, 181, 688-695.  
 158 
 
Dickson-Swift, V., James, E., Kippen, S., & Puttong, P. (2007). Doing sensitive research: what 
challenges do qualitative researchers face? Qualitative Research, 7(3), 327-353.  
Dumesic, D., & Lobo, R. (2013). Cancer risk and PCOS. Steroids, 78(8), 782-785.  
Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: mechanisms and 
implication for pathogenisis. Endocrine Review, 18, 774-800.  
Dunaif, A. (2003). Hyperandrogenemia is necessary but no sufficient for polycystic ovary 
syndrome. Fertility and Sterility, 80, 262-263.  
Ehrmann, D., Kasza, K., Azziz, R., Legro, R., & Ghazzi, M. N. (2005). Effects of race and 
family history of type 2 diabetes on metabolic status of women with polycystic ovary 
syndrome. Journal of Clinical Endocrinology & Metabolism(90), 66-71.  
Ekback, M., Wijma, K., & Benzein, E. (2010). "It is always on my mind":Women's experiences 
of their bodies when living with hirsutism. Health Care for Women International, 30(5), 
358-372.  
Elting, M., Korsen, T., Rekers-Mombarg, L., & Shoemaker, J. (2000). Women with polycystic 
ovary syndrome gain regular menstrual cycles when ageing. Human Reproduction, 
15(24-28).  
Essah, P., Wickham, E., & Nestler, J. (2007). The metabolic syndrome in polycystic ovary 
syndrome. Clinical Obstetrics and Gynecology, 50(1), 205-225.  
Esterberg, K. (2002). Qualitative Methods in Social Research. Boston, MA: McGraw-Hill 
Higher Education. 
 
 
 159 
 
Eunice Kennedy Shriver National Institute of Child Health and Human Development. (2008). 
Beyond infertility: polycystic ovary syndrome (PCOS).  Bethesda, MD: National 
Institutes of Health, Retrieved from http://www.farmacoecura.it/wp-
content/uploads/2009/03/pcos_booklet1.pdf. 
Eunice Kennedy Shriver National Institute of Child Health and Human Development. (2012). 
Can PCOS lead to cancer?   Retrieved April 15, 2014, from 
http://www.nichd.nih.gov/health/topics/pcos/conditioninfo/pages/cancer.aspx 
facebook: key facts. (2013).   Retrieved March 2, 2013, from http://newsroom.fb.com/Key-Facts 
Farquar, C. (2007). Introduction and history of polycystic ovary syndrome. In G. Kovacs & R. 
Norman (Eds.), Polycystic Ovary Syndrome (2nd ed.). United Kingdom: Cambridge 
University Press. 
Franks, S. (2006). Controversy in clinical endocrinology: diagnosis of polycystic ovarian 
syndrome: in defense of the Rotterdam criteria. Journal of Clinical Endocrinology & 
Metabolism, 91(3), 786-789.  
Fraser, I., & Kovacs, G. (2004). Current recommendations for the diagnostic evaluation and 
follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best 
Practice & Research Clinical Obstetrics and Gynaecology, 18(5), 813-823.  
French, D., Cooper, A., & Weinman, J. (2006). Illness perceptions predict attendance at cardiac 
rehabilitation following acute myocardial infarction: a systematic review with meta-
analysis. Journal of Psychosomatic Research, 61(6), 757-767.  
Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U., & Pasquail, R. (2002). Obesity and the 
polycystic ovary syndrome. International Journal of Obesity, 26(7), 883-896.  
 160 
 
Givens, J.R. (1988). Familial polycystic ovarian disease. Endorinology and Metabolism Clinics 
of North America, 17, 771-783.  
Glanz, K., Rimer, B., & Lewis, F. M. (2002). Theory, Research, and Practice in Health Behavior 
and Health Education. In K. Glanz, B. Rimer & F. M. Lewis (Eds.), Health Behavior and 
Health Education: Theory, Research, and Practice (3rd ed.). San Franscisco, CA: Jossey-
Bass. 
Glueck, C., Dharashivkar, S., Wang, P., Zhu, B., Gartside, P., Tracy, T., & Sieve, L. (2005). 
Obesity and extremem obesity, manifest by ages 20-24 years, continuing through 32-41 
years in women, should alert physicians to the diagnostic likelihood of polycystic ovary 
syndrome as a reversible underlying condition. European Journal of Obestetrics, 
Gynaecology, and Reproductive Biology, 122, 206-212.  
Goodman, D., Morrissey, S., Graham, D., & Bossingham, D. (2005). Illness representations of 
systemic lupus erythematosus. Qualitative Health Research, 15(5), 606-619.  
Goolsby, M. (2001). AACE hyperandrogemism guidelines. Journal of the American Academy of 
Nurse Practitioners, 13(11), 492-494.  
Govind, A., Obhrai, M., & Clayton, R. (1999). Polycystic ovaries are inherited as an autosomal 
dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. The 
Journal of Clinical Endocrinology & Metabolism, 84(1), 38-43.  
Graves, H., Scott, D., Lempp, H., & Weinman, J. (2009). Illness perceptions predict disability in 
rheumatoid arthritis. Journal of Psychosomatic Research, 67(5), 417-423.  
Guest, G. (2006). How many interviews are enough? An experiment with data saturation and 
variability. Field Methods, 18(1), 59-82.  
 161 
 
Guyatt, G., Weaver, B., Cronin, L., Dooley, J.A., & Azziz, R. (2004). Health-related quality of 
life in women with polycystic ovary syndrome, a self-administered questionnaire, was 
validated. Journal of Clinical Epidemiology, 57, 1279-1287.  
Guzick, D. S., Talbott, E. O., Sutton-Tyrrell, K., Herzog, H. Z., Kuller, L. H., & Wolfson, S. 
(1996). Carotid atherosclerosis in women with polycystic ovary syndrome: initial results 
from a case-control study. American Journal of Obstetrics and Gynaecology, 174, 1224-
1229.  
Hagger, M., & Orbell, S. (2003a). A meta-analytic review of the common-sense model of illness 
representations. Psychology & Health, 18(2), 141-184.  
Hagger, M., & Orbell, S. (2003b). A meta-analytic review of the common-sense model of illness 
representations. Psychology & Health, 18, 141-184.  
Himelein, M.J., & Thatcher, S.S. (2006). Polycystic ovary syndrome and mental health: a 
review. Obstetrical and Gynecological Survey, 723-732.  
Holte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995). Restored insulin sensitivity but 
persistently increased early insulin secretion after weight loss in obese women with 
polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 80, 2586-
2593.  
Hoving, J, van der Meer, M, Volkova, A, & Frings-Dresen, M. (2010). Illness perceptions and 
work participation: a systematic review. International Archives of Occupational and 
Environmental Health, 83(6), 595-605.  
Huber-Buchholz, M., Carey, D., & Norman, R. (1999). Restoration of reproductive potential by 
lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and 
leuteinizing hormone. Journal of Clinical Endocrinology & Metabolism, 84, 1470-1474.  
 162 
 
Hurt, C., Burns, A., Brown, R., & Barrowclough, C. (2010). Perceptions of subjective memory 
complaint in older adults: the Illness Perception Questionnaire-Memory (IPQ-M). 
International Psychogeriatrics, 22(5), 750-760.  
Husserl, E. (1970). Logical investigations. New York, NY: Humanities Press. 
Jones, G  , Hall, J  , Balen, A  , & Ledger, W  (2008). Health-related quality of life measurement 
in women with polycystic ovary syndrome: a systematic review. Human Reproduction 
Update, 14(1), 15-25.  
Jones, G. L., Benes, K., Clark, T. L., Denham, R., Holder, M. G., Haynes, T. J., . . . Ledger, W. 
L. (2004). The Polycystic Ovary Syndrome Health-Related Quality of Life Questionairre 
(PCOSQ): a validation. Human Reprodroduction, 19(2), 371-377.  
Jones, G. L., Hall, J.M., Lashen, H., Balen, A. H., & Ledger, W. L. (2011). Health-related 
quality of life among adolescents with polycystic ovary syndrome. JOGNN, 40, 577-588.  
Jones, G.L., Hall, J.M., Balen, A.H., & Ledger, W.L. (2007). Health-related quality of life 
measurement in women with polycystic ovary syndrome: a systematic review. Human 
Reproduction, 14(1), 15-25.  
Kaptein, A., Klok, T., Moss-Morris, R., & Brand, P. (2010). Illness perceptions: impact on self-
management and control in asthma. Current Opinion in Allergy and Clinical 
Immunology, 10(3), 194-199.  
Kaptein, A., Scharloo, M., Fischer, M., Snoei, L., Cameron, L., Sont, J., . . . Weinman, J. (2008). 
Illness perceptions and COPD: an emerging field for COPD patient management. The 
Journal of Asthma, 45(8), 625-629.  
 163 
 
Kashar-Miller, M., Nixon, C., Boots, L., Go, R., & Azziz, R. (2001). Prevalence of polycystic 
ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertility and 
Sterility, 75, 53-58.  
Kiddy, D., Hamilton-Fairly, D., Bush, A., Short, F., Anyaoku, V., Reed, M., & Franks, S. (1992). 
Improvement in endocrine and ovarian function during dietary treatment of obese women 
with polycystic ovary syndrome. Clinical Endocrinology, 36, 105-111.  
Kiddy, D., Sharp, P., White, D., Scanlon, M., Mason, H.D., Bray, C., . . . Franks, S. (1990). 
Differences in clinical and endocrine features between obese and no-obese subjects with 
polycystic ovary syndrome: an analysis of 263 consecutive cases. Clinical 
Endocrinology, 32, 213-220.  
Kiely, J. L. (1998). What is the population-based risk of preterm birth among twins and other 
multiples? Clinical Obstetrics and Gynecology, 41, 3-11.  
Kitzinger, C., & Willmont, J. (2002). 'The thief of womanhood': women's experience of 
polycystic ovarian syndrome. Social Science & Medicine, 54, 349-361.  
Knoop, H., Prins, J., Moss-Morris, R., & Bleijenberg, G. (2010). The central role of cognitive 
processes in the perpetuation of chronic fatigue syndrome. Journal of Psychosomatic 
Research, 68(11), 489-494.  
Knowles, S., Wilson, J., Connell, W., & Kamm, M. (2011). Preliminary examination of the 
relations between disease activity, illness perceptions, coping strategies, and 
psychological morbidity in Crohn's disease guided by the common sense model of illness. 
Inflammatory Bowl Diseasese, 17(12), 2551-2557.  
 164 
 
Kucukarslan, S. (2012). A review of published studies of patients' illness perceptions and 
medication adherence: lessons learned and future directions. Research in Social & 
Administrative Pharmacy, 8(5), 371-382.  
Kuh, D., & Hardy, R. Oxford University Press. (2003). A Life Course Approach to Women's 
Health. Oxford: Oxford University Press. 
Landis, J., & Koch, G. (1977). The measurement of observer agreement for categorical data. 
Biometrics, 33(1), 159-174.  
Lau, R., Bernard, J., & Hartman, K. (1989). Further exploration of common sense 
representations ofcommon illness. Health Psychology, 8, 195-219.  
Leventhal, E., Leventhal, H., & Robitaille, C. (1998). Enhancing self-care research: Exploring 
the theoreitcal underpinnings of self-care. In M. Ory & G. DeFriese (Eds.), Self-Care in 
Later Life: Research, Program, & Policy Issues (pp. 118-141). New York: Springer. 
Leventhal, H. (2014, March 20, 2014). [CSM Question]. 
Leventhal, H., Brisette, L., & Leventhal, E. (2003). The Common-Sense Model of Self-
Regulation of Health and Illness. In L. Cameron & H. Leventhal (Eds.), The Self-
Regulation of Health and Illness Behavior (pp. 42-65). New York: Routledge. 
Leventhal, H., Brown, D., Shacham, S., & Engquist, G. (1979). Effects of preparatory 
information about sensations, threat of pain, and attention on cold pressor distress. 
Journal of Personality and Social Psychology, 16(2), 143-163.  
Leventhal, H., Diefenbach, M., & Leventhal, E. (1992). Illness cognition: Using common sense 
to understand treatment adherence and affect cognition treatment. Cognitive Therapy and 
Research, 16(2), 143-163.  
 165 
 
Leventhal, H., Meyer, D., & Nerenz, D. (1980). The common sense model of illness danger. In 
S. Rachman (Ed.), Medical psychology (Vol. 2, pp. 7-30). New York: Pergamon. 
Leventhal, H., Nerenz, D., & Steele, D. (1984). Illness representations and coping with health 
threats. In A. Baum, S. Taylor & J. Singer (Eds.), Handbook of Psychology and Health 
(Vol. 4, pp. 219-252). Hillsdale, NJ: Erlbaum. 
Li, H., Brerenton, R., Anderson, R., Wallace, A., & Ho, C. (2011). Vitamin D deficiency is 
common and associated with metabolic risk factors in patients with polycystic ovary 
syndrome. Metabolism, 60, 1475-1481.  
Li, Y., Li, Y., Hung, E., Stener-Victorin, E., Hou, L., Wu, T., . . . Wu, X. (2011). Polycystic 
ovary syndrome is associated with negatively variable impacts on domains of health-
related quality of life: evidence from a meta-analysis. Fertility and Sterility, 96(2), 452-
458.  
Liu, L., Tong, X., Jiang, L., Li, T., Zhou, F., & Zhang, S. (2014). A comparison of the 
miscarriage rate between women with and without polycystic ovarian syndrome 
undergoing IVF treatment. European Journal of Obstetrics & Gynecology and 
Reproductive Biology(ahead of print).  
Lo, J., Feigenbaum, S. , Yang, J., Pressman, A., Selby, J., & Go, A. (2006). Epidemiology and 
adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. Journal of 
Endocrinology & Metabolism, 91(1357-1363).  
Lobban, F., Barrowclough, C., & Jones, S. (2005). Assessing cognitive representations of mental 
health problems. I: The Illness Perception Questionnaire for schizophrenia. British 
Journal of Clinical Psychology, 44, 147-162.  
 166 
 
Lord, J., & Norman, R. (2006). Obesity, polycystic ovary syndrome, infertility treatment: 
lifestyle modification is paramount. BMJ, 332(7541), 609.  
Lynch, J., Moore, M., Moss-Morris, R., & Kendrick, T. (2011). Are patients beliefs important in 
determining adherence to treatment and outcome for depression? Development of the 
beliefs about depression questionnaire. Journal of Affective Disorders, 133(1-2), 29-41.  
Macaluso, M., Wright-Schnapp, T. J., Chandra, A., Johnson, R., Satterwhite, C. L., Pulver, A., . . 
. Pollack, L. A. (2010). A public health focus on infertility prevention, detection, and 
management. Fertility and Sterility, 93(1), 16.e11–16.e10.  
Marx, T., & Metha, A. (2003). Polycystic ovary syndrome: pathogenisis and treatment over the 
short and long-term. Cleveland Journal of Medicine, 70(1), 31-45.  
Mason, M. (2010). Sample size and saturation in PhD studies using qualitative interviews. 
Forum: Qualitative Social Research 11(3).  
Mc Sharry, M., Moss-Morris, R., & Kendrick, T. (2011). Illness perceptions and glycaemic 
control in diabetes: a systematic review with meta-analysis. Diabetic Medicine, 28(11), 
1300-1310.  
McCook, J.G. (2002). The influence of hyperandrogenism, obesity and infertility on the 
psychosocial health and well-being of women with polycystic ovary syndrome 
[Dissertation]. Ann Arbor, MI: University of Michigan.  
McCook, J.G., Reame, N.E., & Thatcher, S.S. (2005). Health-related quality of life issues in 
women with polycystic ovarian syndrome. Journal of Obstetric, Gynecologic, and 
Neonatal Nursing, 34, 12-20.  
 167 
 
Michelmore, K.F., Balen, A.H., Dungar, D.B., & Vessey, M.P. (1999). Polycystic ovaries and 
associated clinical and biochemical features in young women. Clinical Endocrinology, 
51, 779-786.  
Miles, M., & Huberman, A. . (1994). Qualitative data analysis: An expanded sourcebook (2nd 
ed.). London: Sage Publications. 
Mitchinson, W. (1998). Chapter 6: Agency, Diversity, and Constraints: Women and Their 
Physicians, Canada, 1850-1950. In S. Sherwin (Ed.), The Politics of Women's Health: 
Exploring Agency and Autonomy. Philadelphia: Temple University Press. 
Moll, E., van der Veen, F., & van Wely, M. (2007). The role of Metformin in polycystic ovary 
syndrome: a systematic review. Human Reproduction Update, 13(6), 527-537.  
Moran, L., Misso, M., Wild, R., & Norman, R. (2010). Impaired glucose tolerance, type 2 
diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and 
meta-analysis. Human Reproduction Update, 16(4), 347-363.  
Moran, L., Noakes, M., Clifton, P., Tomlinson, L., & Norman, R. (2003). Dietary composition in 
restoring reporductive and metabolic physiology in overweight women with polycystic 
ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 88, 812-819.  
Morse, J. M. (1991). Strategies for Sampling. In J. M. Morse (Ed.), Qualitative Nursing 
Research: A Contemporary Dialogue. Newbury Park, CA: Sage Publications. 
Moss-Morris, R., Sharon, C., Tobin, R., & Baldi, J. (2005). A randomized controlled graded 
exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change. 
Journal of Health Psychology, 10, 245-259.  
Moss-Morris, R., Weinmann, J., Petrie, K., Horne, R., Cameron, L., & Deanna, B. (2002). The 
Revised Illness Perception Questionnaire (IPQ-R). Psychology & Health, 17(1), 1-16.  
 168 
 
National Cancer Institute. (2014). SEER Cancer Statistics Factsheets: Endometrial Cancer.   
Retrieved April 23, 2014, from http://seer.cancer.gov/statfacts/html/corp.html 
National Institutes of Health.). Protecting Personal Health Information in Research: 
Understanding the HIPPA Privacy Rule.   Retrieved March 8, 2012, from 
http://privacyruleandresearch.nih.gov/pr_02.asp 
National Institutes of Health. (2012). Evidence-based Methodology Workshop on Polcycystic 
Ovary Syndrome: Executive Summary.   Retrieved May 1, 2013, from 
http://prevention.nih.gov/workshops/2012/pcos/docs/PCOS_Final_Statement.pdf  
Neilson, E. (2013). Panel recommends changing name of common disorder in women.   
Retrieved April 9, 2014, from www.nih.gov/news/health/jan2013/od-23.htm 
Nejad, E., Saedi, T., Saedi, S., Rashidi, B., Nekoo, Z., & Jahangiri, N. (2011). Comparison of in 
vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. 
Gynecology & Endocrinology, 27, 117-120.  
Nestler, J., Clore, J., & Blackard, W. (1989). The central role of obesity (hyperinsulinemia) in 
the pathogenesis of polycystic ovary syndrome. American Journal of Obstetrics and 
Gynaecology, 161, 1095-1097.  
Nestler, J., Powers, L., Matt, D., Steingold, K., Plymate, S., Rittmaster, R., . . . Blackard, W. 
(1991). A direct effect of hyperinsulinemia on serum sex hormone-binding globulin 
levels in obese women with the polycystic ovary syndrome. Journal of Clinical 
Endocrinology & Metabolism, 72(1), 83-89.  
Neuman, W. L. (Ed.). (2006). Social research methods: Qualitative and quantitative approaches 
(Vol. 6th). Boston: Pearson Education, Inc. 
 169 
 
Neumen, W. L. (2006). Chapter 10: Survey Research Social Research Methods: Qualitative and 
Quantitative Approaches. Boston, MA: Allyn and Bacon. 
Nicholls, C., Glover, L., & Pistrang, N. (2004). The illness experiences of women with fibroids: 
an exploratory qualitative study. Journal of Psychosomatic Obstetrics & Gynecology, 25, 
295-304.  
Norman, R., Wu, R., & Stankiewicz, T. (2004). 4: Polycystic ovary syndrome. Medical Journal 
of Australia, 180, 132-137.  
Office of Women's Health, U.S. Department of Health and Human Services. (2011, September 
24, 2013). Why breastfeeding is important.   Retrieved April 23, 2014, from 
www.womenshealth.gov/breastfeeding/why-breastfeeding-is-important/ 
Ohayon, M., & Roth, T. (2003). Place of chronic insomnia in the course of depressive and 
anxiety disorders. Journal of Psychiatric Research, 37(1), 9-15.  
Opdenakker, Raymond. (2006). Advantages and disadvantages of four interview techniques in 
qualitative research.   Retrieved March 1, 2012, from http://www.qualitative-
research.net/index.php/fqs/article/view/175/391#g2 
Ory, M., & DeFriese, G. (1998). Self-Care in Later Life: Research, Program, & Policy Issues. 
New York: Springer. 
Panidis, D., Tziomalos, K., Papadakis, E., Vosnakis, C., Chatzis, P., & Katsikis, I. (2013). 
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact 
on metabolism and fertility. Endocrine(in press).  
Pasquail, R., Gambineri, A., & Pagotto, U. (2006). The impact of obesity on reproduction in 
women with polycystic ovary syndrome. British Journal of Obstetrics and Gynaecology, 
113, 1148.  
 170 
 
Percy, C.A., Gibbs, T., Potter, L., & Boardman, S. (2009). Nurse-led peer support group: 
experiences of women with polycystic ovary syndrome. Journal of Advanced Nursing, 
65(10), 2046-2055.  
Petrie, K., Jago, L., & Devcich, D. (2007). The role of illness perceptions in patients with 
medical conditions. Current Opinion in Psychiatry, 20, 63-167.  
Pfeifer, S.M., & Kives, S. (2009). Polycystic Ovary Sndrome in the Adolescent. Obstetrics & 
Gynecology Clinics of North America, 36, 129-152.  
Pharoah, P. O. (2006). Risk of cerbral palsy in multiple pregnancies. Clinical Perinatololgy, 33, 
301-313.  
Polson, D., Adams, J., Wadsworth, J., & Franks, S. (1988). Polycystic ovaries - a common 
finding in normal women. Lancet, i, 870-872.  
Prapas, N., Karkanaki, A., Prapas, I., Kalogiannidis, I., Katsikis, I., & Panidis, D. (2009). 
Genetics of polycystic ovary syndrome. Hippokratia, 13(4), 216-223.  
Public Health Service Task Force on Women's Health Issues. (1985). Women's health. Public 
Health Reports, 100(1), 73-106.  
Rachon, D., & Teede, H. (2010). Ovarian function and obesity - interrelationship, impact on 
women's reproductive lifespan and treatment options. Molecular and Cellular 
Endocrinology, 316, 172-179.  
Radosh, L. (2009). Drug treatments for polycystic ovary syndrome. American Family 
Physicians, 79(8), 671-676.  
Reinharz, S. (1992). Feminist Methods in Social Research. London: Oxford University Press. 
 171 
 
Rellini, A., Stratton, N., Tonani, S., Santamaria, V., Brambilla, E., & Nappi, R. (2013). 
Differences in sexual desire between women with clinical versus biochemical signs of 
hyperandrogenism in polycystic ovary syndrome. 63(65-71).  
RESOLVE. (2014). The Affordable Care Act and Infertility.   Retrieved April 23, 2014, 2014, 
from http://www.resolve.org/get-involved/the-affordable-care-act-and-infertility.html 
Rosenstock, I. (1990). The Past, Present, and Furture of Health Education. In K. Glanz, F. Lewis 
& B. Rimer (Eds.), Health Behavior and Health Education: Theory, Research, and 
Practice. San Francisco: Jossey-Bass. 
Schieve, L. A., Ferre, C., Peterson, H. B., Macaluso, M., Reynolds, M., & Wright, C. (2004). 
Perinatal outcome among singleton infants conceived through assisted reproductive 
technology in the United States. Obstetrics & Gynecology, 103, 1144-1153.  
Schieve, L. A., Meikle, S. F., Ferre, C., Peterson, H. B., Jeng, G., & Wilcox, L. S. (2002). Low 
and very low birth weight in infants conceived with use of assisted reporductive 
technology. New England Journal of Medicine, 346, 731-737.  
Searle, A., Norman, P., Thompson, R., & Vedhara, K. (2007). Illness representations among 
patients with type 2 diabetes and their partners: relationships with self-management 
behaviors. Journal of Psychosomatic Research, 63(2), 175-184.  
Sen, G., & Ostlin, P. (2008). Gender Inequality in Health: Why it exists and how we can change 
it. Global Public Health, 3(1), 1-12.  
Senat, M. V., Ancel, P. Y., Bouvier-Colle, M. H., & Breart, G. (1998). How does multiple 
pregnancy affect maternal mortality and morbidity? Clinical Obstetrics and Gynecology, 
41, 78-83.  
 172 
 
Seow, K., Juan, C., Hwang, J., & Ho, L. (2008). Laparoscopic surgery in polycystic ovary 
syndrome: reproductive and metabolic effects. Seminars in Reproductive Medicine, 
26(1), 101-110.  
Shi, X., Zhang, L., Fu, S., & Li, N. (2011). Co-involvement of psychological and neurological 
abnormalities in infertility with polycystic ovary syndrome. Archives of Gynecology and 
Obstetrics, 284(3), 773-778.  
Skelton, J., & Croyle, R. (1991). Mental Representation in Health and Illness. New York: 
Springer-Veriag. 
Snyder, B.S. (2006). The lived experience of women diagnosed with polycystic ovary syndrome. 
Journal of Obstetric, Gynecologic, and Neonatal Nursing, 35(3), 385-392.  
Speroff, L., & Fritz, M. (2005). Clinical gynecologic endocrinology and infertility (7th ed.). 
Philadelphia, PA: Lippincott Williams and Wilkins. 
Stankiewicz, M., & Norman, R. (2006). Diagnosis and management of polycystic ovary 
syndrome: a practical guide. Drugs, 66(7), 903-912.  
Stein, I. (1945). Bilateral polycystic ovaries. American Journal of Obstetrics & Gynecology, 
50(385).  
Stein, I.F., & Leventhal, M.L. (1935). Amenorrhea associated with bilateral polycystic ovaries. 
American Journal of Obstetrics and Gynaecology, 29, 181-186.  
Sterling University. (2012). Framework for Measuring Impact: SF-36.   Retrieved April 1, 2014, 
from http://www.measuringimpact.org/s4-sf-36 
Sullivan, H., Rutten, L., Hesse, B., Moser, R., Rothman, A., & McCaul, K. (2010). Lay 
representations of cancer prevention and early detection: associations with prevention 
behaviors. Preventing chronic diseases, 7(1), A14.  
 173 
 
Talbott, E. O., Guzick, D. S., Sutton-Tyrrell, K., McHugh-Pemu, K. P., Zborowski, J. V., 
Remsberg, K. E., & Kuller, L. H. (2000). Evidence for association between polycystic 
ovary syndrome and premature carotid atherosclerosis in middle-aged women. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 20(11), 2414-2421.  
Teede, H., Deeks, A., & Moran, C. (2010). Polycystic ovarian syndrome: a complex condition 
with psychological, reproductive and metabolic manifestations that impacts on health 
across the lifespan. British Medical Journal, 8(41), 1741-7015.  
Teede, H., Misso, M., Deeks, A., Moran, L., Stuckey, B., Wong, J., . . . Groups, Guideline 
Development. (2011). Assessment and management of polycystic ovary syndrome: 
summary of an evidence-based guideline. The Medical Journal of Austaila, 195(6), S65-
112.  
The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. (2012). 
Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Fertility 
and Sterility, 97(1), 28-38.  
The Boston Women's Health Book Collective. (1998). Our Bodies, Ourselves: For the New 
Century. New York: Touchstone. 
The Boston Women's Health Book Collective. (2005). Our Bodies, Ourselves (35th ed.). New 
York: Simon & Schuster. 
The ESHRE Capri Workshop Group. (2000). Multiple gestation pregnancy. Human 
Reprodroduction, 15, 1856-1864.  
The Ethics Committee of the American Society of Reproductive Medicine. (2013). Access to 
fertility treatment by gays, lesbians, and unmarried persons: a committee opinion. Ferility 
and Sterility, 100, 1524-1527.  
 174 
 
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. (2004a). Revised 
2003 consensus on diagnostic criteria and long-term health risks related to polycystic 
ovary syndrome. Ferility and Sterility, 81(1), 19-25. doi: S001502820302853X [pii] 
The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004b). Revised 
2003 consensus on diagnostic criteria and long-term health risks related to polycystic 
ovary syndrome (PCOS). Human Reproduction, 18, 41-47.  
Thomson, R., Buckley, J., Lim, S., Noakes, M., Clifton, P., Norman, R., & Brinkworth, G. 
(2010). Lifestyle management improves quality of life and depression in overweight and 
obese women with polycystic ovary syndrome. Fertility and Sterility, 94(5), 1812-1816.  
Thomson, R. L., Buckley, J. D., & Brinkworth, G. D. (2010). Exercise for the treatment and 
management of overweight women with polycystic ovary syndrome: a review of the 
literature. Obesity Reviews, 12, e202-e210.  
Tomlinson, J., Millward, A., Stenhouse, E., & Pinkney, J. (2010). Type 2 diabetes and 
cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be 
reduced? Diabetic Medicine, 27(498-515).  
Trent, M.E., Rich, M., Austin, S.B., & Gordon, C.M. (2002). Quality of life in adolescent girls 
with polycystic ovary syndrome. Archives of Pediatric and Adolescent Medicine, 156, 
556-560.  
Trivax, B., & Azziz, R. (2007). Diagnosis of polycystic ovarian syndrome. Clinical Obstetrics 
and Gynecology, 50(1), 168-177.  
Tweedy, A. (2000). Polycystic ovary syndrome. Journal of the American Academy of Nurse 
Practitioners, 12(3), 101-105.  
 175 
 
U.S. Department of Health and Human Services. March 3, 2013). HealthyPeople.gov.   Retrieved 
May 1, 2013, from http://www.healthypeople.gov/2020/default.aspx 
Ulin, P. R., Robinson, E. T., & Tolley, E. E. (2005). Qualitative Methods in Public Health. San 
Francisco, CA: Jossey-Bass. 
Ulin, P., Robinson, E., & Tolley, E. (2005). Qualitative Methods in Public Health. San 
Francisco: Jossey-Bass. 
United States General Acounting Office. (2000). Women's Health. NIH Has Increased Its Efforts 
to Include Women in Research Report to Congressional Requesters. Washington, DC. 
Vural, B., Caliskan, E., Turkoz, E., Kilic, T., & Demirci, A. (2005). Evaluation of metabolic 
syndrome frequency and premature carotid atherosclerosis in young women with 
polycystic ovary syndrome. Human Reprodroduction, 20, 2409–2413.  
Wang, J., Davies, M., & Norman, R. (2001). Polycystic ovarian syndrome and the risk of 
spontaneous abortion following assisted reproductive technology treatment. Human 
Reprodroduction, 16, 2606-2609.  
Ware, J.). SF-36® Health Survey Update.   Retrieved May 13, 2013, from http://www.sf-
36.org/tools/sf36.shtml#LIT 
Ware, J., & Sherbourne, C. (1992). The MOS 36-Item Short-Form Health Survey (SF-36): I. 
Conceptual framework and item selection. Medical Care, 30, 473-483.  
Wei, A.Y., & Pritts, E.A. (2003). Therapy for polycystic ovarian syndrome. Current Opinion in 
Pharmacology, 3, 678-682.  
Weinmann, J., Petrie, K., Moss-Morris, R., & Horne, R. (1996). The Illness Perception 
Questionnaire: A new method for assessing the cognitive representation of illness. 
Psychology & Health, 11(3), 431-445.  
 176 
 
Weisman, C. S. (1997). Changing definitions of women's health: implications for health care and 
policy. Maternal and Child Health Journal, 1(3), 179-189.  
Weiss, R., & Bulmer, S. M. (2011). Young women's experiences living with polycystic ovary 
syndrome. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 40, 709-718.  
Wilroy, R. S., Givens, J.R., Wiser, W. L., Coleman, S. A., Anderson, J., & Summitt, R. L. 
(1975). Hyperthecosis: an inheritable form of polycystic ovarian disease. Birth Defects: 
Original Article Series, 11, 81-85.  
World Health Organization. (1983). Health Education in Self-Care: Possibilities and Limitations. 
Report of a Scientific Consultation. Geneva, Switzerland. 
 
 
  
 177 
 
 
 
 
 
 
Appendices 
  
 178 
 
Appendix A. Parts 1-3 of the Online Survey 
Part 1 
 
1. Sex 
 
What is your biological sex? 
a. Male (exclude) 
b. Female 
 
2. Age 
 
How old are you? (Enter age in years) (>18 years, exclude) 
 
3. Citizenship 
 
Which statement best describes you? 
a. I am a United States citizen, and I currently live in the United States. 
b. I am a United States citizen, but I do not currently live in the United States. 
(exclude) 
c. I am not a United States citizen. (exclude) 
 
4. PCOS 
 
Has a medical provider ever told you that you have polycystic ovary syndrome (PCOS)? 
a. Yes 
b.  No (exclude) 
c. Unsure (exclude) 
 
Part 2 
 
5. Ethnicity 
 
Are you Hispanic or Latina, or of Spanish origin? 
a. Yes 
b. No 
c. Unsure (code as No) 
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6. Race 
 
Which of the following groups describes your racial background? (Check all that apply.) 
a. American Indian or Alaska Native 
b. Asian 
c. Native Hawaiian or Other Pacific Islander 
d. Black or African American  
e. White 
f. Other (fill in the blank) 
 
7. Sexual Orientation 
 
How would you describe your sexual orientation? 
a. Heterosexual or straight 
b. Homosexual, gay, or lesbian 
c. Bisexual 
d. Not sure/questioning 
 
8. Marital Status 
 
What is your current marital status? 
a. Married to a male 
b. Married to a female 
c. Not married, but living together with a male partner 
d. Not married, but living together with a female partner 
e. Widowed 
f. Divorced 
g. Separated, because you and your partner are not getting along 
h. Never been married  
 
9. Education 
 
What is the highest level of education you have completed? 
a. Less than high school 
b. High school/GED 
c. Some college 
d. 2-year college degree 
e. 4-year college degree 
f. Master’s degree 
g. Doctoral Degree  
h. Professional Degree (JD, MD) 
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10. Health Insurance 
 
Which type of health insurance do you have? (Check all that apply.) 
a. No insurance (self-pay for all healthcare costs) 
b. Private insurance (ex. Blue Cross, Aetna, United Health Care, etc.) 
c. Public insurance (ex. Medicaid, Medicare, etc.) 
d. Military or Veterans Administration 
e. Student Health Insurance 
f. Other (fill in the blank) 
g. Unsure 
 
Part 3 
 
11. Weight 
 
What is your weight (in pounds)? (Enter numeric value.) 
 
12. Height 
 
What is your height in feet and inches? (Enter numeric value.) 
 
13. Medical History 
 
Below is a list of common medical conditions. Have you EVER had any of the conditions 
listed below? Choose yes or no. 
 
1. Diabetes? Yes/No 
2. High blood pressure or hypertension? Yes/No 
3. High cholesterol? Yes/No 
4. Heart disease? Yes/No 
5. Thyroid problems? Yes/No 
6. Infertility? Yes/No 
7. Endometriosis? Yes/No 
8. Migraines? Yes/No 
9. Depression? Yes/No 
10. Anxiety? Yes/No 
 
14. Children 
Do you have biological children? 
a. Yes 
b. No 
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Are you currently trying to conceive? 
a. Yes 
b. No 
 
15. Length of PCOS  Diagnosis 
 
You previously indicated that a medical provider diagnosed you with PCOS. How old 
were you at the time of diagnosis? (Enter age in years) 
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Appendix B. The Polycystic Ovary Syndrome Questionnaire (PCOSQ) 
To what extent have you felt that growth of visible hair on your chin has been a problem 
for you during the last two weeks: 
 A severe 
problem 
A major 
problem 
A 
moderat
e 
problem 
Some 
Problem 
A Little 
problem 
Hardly 
any 
problem 
No 
problem 
1. Growth of 
visible hair on 
chin? 
       
During the past two weeks, how much of the time have you felt: 
 All of 
the time 
Most of 
the time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
Hardly 
any of 
the time 
None of 
the time 
2. Depressed as a 
result of having 
PCOS? 
       
3. Concerned 
about being 
overweight? 
       
4. Easily tired?        
5. Concerned 
with infertility 
problems? 
       
6. Moody as a 
result of having 
PCOS? 
       
In relation to your last menstruation, how much were the following issues a problem for 
you: 
 A severe 
problem 
A major 
problem 
A 
moderat
e 
problem 
Some 
Problem 
A Little 
problem 
Hardly 
any 
problem 
No 
problem 
7. Headache?        
8. Irregular 
menstrual 
periods? 
       
To what extent has growth of visible hair on your upper lip been a problem for you during 
the last two weeks? 
 A severe 
problem 
A major 
problem 
A 
moderat
e 
problem 
Some 
Problem 
A Little 
problem 
Hardly 
any 
problem 
No 
problem 
9. Growth of 
visible hair on 
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upper lip?  
 
 
 
 
 
 
 
During the past two weeks, how much of the time have you: 
 All of 
the time 
Most of 
the time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
Hardly 
any of 
the time 
None of 
the time 
10. Had trouble 
dealing with 
your weight? 
       
11. Had low self-
esteem as a 
result of your 
having PCOS? 
       
12. Felt frustration 
in trying to 
lose weight? 
       
13. Felt afraid of 
not being able 
to have 
children? 
       
14.  Felt frightened 
of getting 
cancer? 
       
Over the last two weeks, to what extent have the following issues been a problem for you: 
 A severe 
problem 
A major 
problem 
A 
moderat
e 
problem 
Some 
Problem 
A Little 
problem 
Hardly 
any 
problem 
No 
problem 
15. Growth of 
visible hair on 
your face? 
       
16. Embarrassment 
about excess 
body hair? 
       
During the past two weeks, how much of the time have you been: 
 All of 
the time 
Most of 
the time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
Hardly 
any of 
the time 
None of 
the time 
17. Worried about 
having PCOS? 
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18. Self-conscious 
as a result of 
having PCOS? 
       
In relation to your last menstruation, how much were the following issues a problem for 
you? 
 A severe 
problem 
A major 
problem 
A 
moderat
e 
problem 
Some 
Problem 
A Little 
problem 
Hardly 
any 
problem 
No 
problem 
19. Abdominal 
pain? 
       
20. Late menstrual 
period? 
       
21. Menstrual 
cramps? 
 
       
How much of the time during the last two weeks did you: 
 All of 
the time 
Most of 
the time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
Hardly 
any of 
the time 
None of 
the time 
22. Feel like you 
are not sexy 
because of 
being 
overweight? 
       
23. Feel a lack of 
control over 
the situation 
with PCOS? 
       
24. Have 
difficulties 
staying at your 
ideal weight? 
       
25. Feel sad 
because of 
infertility 
problems? 
       
To what extent has growth of visible body hair been a problem for you during the last two 
weeks: 
 A severe 
problem 
A major 
problem 
A 
moderat
e 
problem 
Some 
Problem 
A Little 
problem 
Hardly 
any 
problem 
No 
problem 
26. Growth of 
visible body 
hair? 
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(Guyatt et al., 2004) 
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Appendix C. The Short Form-36 (SF-36) 
Survey Question Answer Choices (Item Score) HRQoL 
Domain 
Summary 
Measure 
 
1. In general, would you 
say your health is: 
 
1. Excellent (100) 
2. Very good (75) 
3. Good (50) 
4. Fair (25) 
5. Poor (0) 
General 
Health 
(GH) 
Physical Health 
2. Compared to one year 
ago, how would you rate 
your health in general 
now? 
1. Much better now than one year 
ago (100) 
2. Somewhat better now than one 
year ago (75) 
3. About the same (50) 
4. Somewhat worse now than one 
year ago (25) 
5. Much worse now than one year 
ago (0) 
N/A N/A 
 
The following items are about activities you might do during a typical day.  Does your health now 
limit you in these activities? If so, how much? 
3. Vigorous activities, such 
as running, lifting heavy 
objects, participating in 
strenuous sports 
1. Yes, limited a lot (0) 
2. Yes, limited a little (50) 
3. No, not limited at all (100) 
Physical 
Functioning 
(FP) 
Physical Health 
 
 
 
 4. Moderate activities, such 
as moving a table, 
pushing a vacuum 
cleaner, bowling, or 
playing golf 
5. Lifting or carrying 
groceries 
6. Climbing several flights 
of stairs 
7. Climbing one flight of 
stairs 
8. Bending, kneeling, or 
stopping 
9. Walking more than a 
mile 
10. Walking several blocks 
 
11. Walking one block 
12. Bathing or dressing 
yourself 
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During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of your physical health? 
13. Cut down the amount of 
time you spent on work 
or other activities 
1. Yes (0) 
2. No (100) 
Role-
Physical 
(RP) 
Physical Health 
14. Accomplished less than 
you would like 
15. Were limited in the kind 
of work or other 
activities  
 
16. Had difficulty 
performing the work or 
other activities (for 
example, it took extra 
effort) 
During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of any emotional problems (such as feeling depressed or anxious)? 
17. Cut down the amount of 
time you spent on work 
or other activities 
1. Yes (0) 
2. No (100) 
Role-
Emotional 
(RE) 
Mental Health 
18. Accomplished less than 
you would like 
19. Didn’t do work or other 
activities as carefully as 
usual 
20. During the past 4 weeks, 
to what extent has your 
physical health or 
emotional problems 
interfered with your 
normal social activities 
with family, friends, 
neighbors, or groups? 
1. Not at all (100) 
2. Slightly (75) 
3. Moderately (50) 
4. Quite a bit (25) 
5. Extremely (0) 
Social 
Functioning 
(SF) 
Mental Health 
21. How much bodily pain 
have you had during the 
past 4 weeks? 
 
1. None (100) 
2. Very mild (80) 
3. Mild (60) 
4. Moderate (40) 
5. Severe (20) 
6. Very severe (0) 
Bodily Pain 
(BP) 
Physical Health 
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22.  During the past 4 
weeks, how much did 
pain interfere with your 
normal work (including 
both work outside the 
home and housework)? 
 
 
 
 
 
1. Not at all (100) 
2. A little bit (75) 
3. Moderately (50) 
4. Quite a bit (25) 
5. Extremely (0) 
Bodily Pain 
(BP) 
Physical Health 
These questions are about how you feel and how things have been with you during the past 4 weeks. 
For each question, please give one answer that comes closest to the way you have been feeling. 
 
How much of the time during the past 4 weeks… 
23. Did you feel of pep? 1. All of the time (100) 
2. Most of the time (80) 
3. A good bit of the time (60) 
4. Some of the time (40) 
5. A little of the time (20) 
6. None of the time (0) 
Vitality 
(VT) 
Mental Health 
24. Have you been a very nervous 
person? 
1. All of the time (0) 
2. Most of the time (20) 
3. A good bit of the time (40) 
4. Some of the time (60) 
5. A little of the time (80) 
6. None of the time (100) 
Mental 
health 
(MH) 
Mental Health 
25. Have you felt so down in the 
dumps that nothing could 
cheer you up? 
26. Have you felt calm and 
peaceful? 
(reverse score) 
27. Did you have a lot of energy? 1. All of the time (100) 
2. Most of the time (80) 
3. A good bit of the time (60) 
4. Some of the time (40) 
5. A little of the time (20) 
6. None of the time (0) 
Vitality 
(VT) 
Mental Health 
28. Have you felt downhearted 
and blue? 
1. All of the time (0) 
2. Most of the time (20) 
3. A good bit of the time (40) 
4. Some of the time (60) 
5. A little of the time (80) 
6. None of the time (100) 
Mental 
health 
(MH) 
Mental Health 
29. Did you feel worn out? 1. All of the time (0) 
2. Most of the time (20) 
3. A good bit of the time (40) 
4. Some of the time (60) 
Vitality 
(VT) 
Mental Health 
 189 
 
5. A little of the time (80) 
6. None of the time (100) 
30. Have you been a happy 
person? 
1. All of the time (100) 
2. Most of the time (80) 
3. A good bit of the time (60) 
4. Some of the time (40) 
5. A little of the time (20) 
6. None of the time (0) 
Mental 
health 
(MH) 
Mental Health 
31. Did you feel tired? 1. All of the time (0) 
2. Most of the time (20) 
3. A good bit of the time (40) 
4. Some of the time (60) 
5. A little of the time (80) 
6. None of the time (100) 
 
 
 
Vitality 
(VT) 
Mental Health 
32. During the past 4 weeks, how 
much of the time has your 
physical health or emotional 
problems interfered with 
your social activities (like 
visiting your friends, 
relatives, etc.)? 
1. All of the time (0) 
2. Most of the time (25) 
3. Some of the time (50) 
4. A little of the time (75) 
5. None of the time (100) 
Social 
Functioning 
(SF) 
Mental health 
How true or false is each of the following statements to you: 
33. I seem to get sick a little 
easier than other people 
1. Definitely true (0) 
2. Mostly true (25) 
3. Don’t know (50) 
4. Mostly false (75) 
5. Definitely false (100) 
General 
Health 
(GH) 
Physical Health 
34. I am healthy as anybody I 
know 
(reverse scoring) 
35. I expect my health to get 
worse 
36. My health is excellent 
(reverse scoring) 
(Ware & Sherbourne, 1992) 
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Appendix D. Sample Interview Guide Based on the Common-Sense Model (CSM) of Self-
Regulation of Health & Illness 
Hi! Thank you for taking the time to talk to me today.  My name is Elizabeth Baker, and I am a 
PhD student at the University of South Florida.  Right now, I am conducting my dissertation 
research where I’m asking women who have been diagnosed with polycystic ovary syndrome or 
PCOS to tell me about their experience with the syndrome.  Although I am a woman living with 
PCOS, I understand that everyone’s experience is different, and I need other women like you to 
tell me about their experiences. 
 
As a reminder, I will be recording this interview, but all the information you provide will be kept 
confidential.  Is this still ok with you? 
You can also skip any question you don’t want to answer or stop the interview by letting me 
know that that’s what you would like to do.  I will never use your name or any identifying 
information when reporting the results of the interview, so no one will ever know your 
responses.  In fact, if you’d like to use another name during the interview, we can do that.  What 
would you like for me to call you while I am recording? 
Do you have any questions before we begin? 
Ok, then let’s get started. 
Tell me about polycystic ovary syndrome. How would you describe the syndrome to 
someone who had not heard of it? 
Probes: Cognitive Representations 
1. Identity  
a. Could you describe any symptoms you have that are related to your PCOS? 
 
2. Timeline 
a. How long do you believe you have had PCOS? 
b. How long do you think PCOS will affect you? 
i. How do you think PCOS will affect you in the future? (Consequences) 
 
3. Consequences 
a. How do you think PCOS has affected your life? 
b. What are the effects on your everyday life? 
i. Prompts: work, socializing, everyday activities, relationships, family, 
friends, finances 
4. Causes 
a. What do you understand about the cause of your condition? 
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5. Control/Cure 
a. How much control do you feel you have over PCOS? 
b. What things do you do to deal with your PCOS symptoms? 
i. What strategies have been successful?  
ii. What strategies have failed? 
c. What would make living with syndrome easier for you? 
d. Do you think there will ever be a cure for PCOS? If yes, do you have any 
ideas what the cure might be? 
Probes: Emotional Representations 
6. What are your thoughts about having PCOS? 
 
7. To what extent do you feel that your PCOS influences how you generally feel? 
Probes: If woman reports history of infertility  
8. On your survey, you indicated that you had a history of infertility. Tell me about that. 
a. When were you diagnosed? 
b. How were you diagnosed? 
Probes: If woman reports history of infertility and having biological children 
9. How have you addressed your fertility concerns? 
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Appendix E: Advantages and Disadvantages of Interview Techniques 
Type of 
Interview 
Characteristics Strengths Weaknesses 
In-person Interviewer and participant 
are in the same place at the 
same time (e.g. office) 
Interviewer can record nonverbal 
cues that may indicate the 
importance of particular questions 
or topics to respondents;(Berg, 
2009; Esterberg, 2002)  Interviewer 
has more control over environment; 
Does not require participant to 
have a particular skill set which 
may be required for phone or 
internet interviewing; 
Travel time and costs for participant 
or interviewer may be too long or 
too high, respectively, especially if 
both are not in the same 
geographical location; (Opdenakker, 
2006) Participant may be less 
willing to discuss sensitive 
topics;(Opdenakker, 2006) 
Phone    
    Audio-only Interviewer and participant 
communicate via phone and 
cannot see each other 
Participant and interviewer do not 
accrue travel expenses; Time 
commitment is reduced without 
travel; Enables interviewer to 
interview populations that might be 
difficult to access; Does not require 
participant to have a particular skill 
set which may be required using 
other interview techniques; 
Participant may be more willing to 
discuss sensitive 
topics;(Opdenakker, 2006) 
 
Interviewer cannot record nonverbal 
cues that may indicate the 
importance of particular questions or 
topics to respondents; Participant 
and interviewer must have phone; 
Phone connection may not be 
reliable; Participant may accrue 
additional costs based on their 
individual phone plan; Interviewer 
cannot control the environment in 
which the participant chooses to 
interview; Participant may be less 
willing to discuss sensitive topics; 
 
    Face-to-face Interviewer and participant 
communicate via phone but 
are able to look at each other 
using video chat program 
(e.g. FaceTime or Skype) 
Interviewer can record facial 
expression that may indicate the 
importance of particular questions 
or topics to respondents;  
Participant and interviewer do not 
accrue travel expenses; Time 
commitment is reduced without 
travel; Enables interviewer to 
interview populations that might be 
difficult to access; May allow 
interviewer to establish addition 
rapport with participants that may 
not be possible with traditional 
phone interviews; 
 
Interviewer may not be able to 
observe all non-verbal cues; 
Participant and interviewer must 
have phone with video chat 
capabilities and both must know 
how to use such technologies; 
Technologies may not be reliable; 
Participant may accrue additional 
costs based on their individual 
phone plan; Interviewer cannot 
control the environment in which the 
participant chooses to interview;  
 
 
    Text messaging Instantaneous transmission 
of text-based messages from 
sender to receiver 
Participant and interviewer do not 
accrue travel expenses; Time 
commitment is reduced without 
travel; Enables interviewer to 
interview populations that might be 
difficult to access; May be 
appealing to younger participants 
who use text messaging as a 
primarily way of communicating; 
Participant must know how to read 
and write; Participant must have a 
phone with texting capabilities and 
must know how to use such 
technologies; Technologies may not 
be reliable; Participant may accrue 
additional costs based on their 
individual phone plan; Interviewer 
cannot record nonverbal cues that 
may indicate the importance of 
particular questions or topics to 
respondents; Interviewer and 
participant cannot clue in to verbal 
cues such as tone which may lead to 
a misunderstanding between parties;  
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May be significant time delay 
between question and 
answer;(Opdenakker, 2006)  
Concentration of the interviewer and 
the participant may be decreased;  
Internet    
    Face-to-face Interviewer and participant 
communicate via internet but 
are able to look at each other 
using video chat program 
(e.g. FaceTime or Skype) 
 
Interviewer can record facial 
expression that may indicate the 
importance of particular questions 
or topics to respondents;(Berg, 
2009; Esterberg, 2002)  Participant 
and interviewer do not accrue 
travel expenses; Time commitment 
is reduced without travel; Enables 
interviewer to interview 
populations that might be difficult 
to access; May allow interviewer to 
establish addition rapport with 
participants that may not be 
possible otherwise; 
 
Interviewer may not be able to 
observe all non-verbal cues; 
Participant and interviewer must 
have internet access and video chat 
capabilities and both must know 
how to use such technologies; 
Technologies may not be reliable; 
Interviewer cannot control the 
environment in which the participant 
chooses to interview;  
 
    Instant   
    Messaging 
Instantaneous transmission 
of text-based messages from 
sender to receiver (e.g. 
Facebook messenger) 
Participant and interviewer do not 
accrue travel expenses; Time 
commitment is reduced without 
travel; Enables interviewer to 
interview populations that might be 
difficult to access;  
 
Interviewer cannot record nonverbal 
cues that may indicate the 
importance of particular questions or 
topics to respondents; May be 
significant time delay between 
question and answer;(Opdenakker, 
2006) Participant must know how to 
read and write; Participant must 
have internet access and instant 
messaging software and know how 
to use such software; Technologies 
may not be reliable; Interviewer 
cannot record nonverbal cues that 
may indicate the importance of 
particular questions or topics to 
respondents; Interviewer and 
participant cannot clue in to verbal 
cues such as tone which may lead to 
a misunderstanding between parties; 
May be significant time delay 
between question and 
answer;(Opdenakker, 2006) 
Concentration of the interviewer and 
the participant may be decreased; 
Note: Only synchronous communication activities in time and/or space are outlined above.  Specifically, emailing as an 
interview technique has been omitted as it does not allow for the interview to remain fairly conversational, which is desired in a 
semi-structured interview.(P. R. Ulin et al., 2005) 
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